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EDITORIAL
THE

TRIALS

TO

BE

FACED

By Carla Garcia & Aaron M . Glickman, Editors-In-Chief

f all the diagno es that a person can be labeled
with, cancer has alwa ys been one of the mo t
feared, and certainly the mo t varied in what it
means to both the patient and hi health care provider .
Some of the most aggre ive, lethal di ea e proce e fall
under the heading of ' cancer'- diagno es that usually
carry life expectancies of week or month . And yet, other
neoplasm carry very little morbidity and mortality, and
have cure rates of over 90%. One name, but thousands of
di ea e , each with its own treatment, progno is, and
high-risk population. In thi en e, at lea t, not much ha
changed ince the times in which people died inexplicably
of illne e vaguely referred to as ' consumption' or
'wasting sickne '.
De pite thi , the field of oncology it elf-the treatment
of the one di ea e that is really many different one -has
become one of the most dynamic and rapidly changing
a re as of medical re earch today . Over the last three
decade , we have gone from a time in which the Qnly
treatment available wa urgery to a ituation in which a
new ly diagno ed patient and hi phy ician are often faced
w ith a menu of options in treatment protocol . 1 The
arrival of radiotherapy, followed by the still ever-growing
pharmacopoeia of chemotherapy, have been followed
more recentl y b y immunological, histological, and
molecular genetic discoverie into the treatment of cell
which have lo t the delicate and e sential control required
to function normally.2 Each new step in each field ha
repercu sion that usually extend throughout all of
oncology, and not just the specific cancer for which it wa
developed .
The ocial and public health aspect of cancer are a
dramatic a the recent technological advance . It i the
econd most common killer in both men and women after
heart disease in orth America. More alarmingly, the
w orld burden of cancer seems to be increasing at a
co n siderable rate: in 1985, 7.6 million cancer were
diagno ed world wide, and 5 million people died of their
cancer . In 1990, the number of deaths rose to about 5.7
million, and the predicted number of deaths for the year
2000 is 7.1 million, and a projected 10.6 million ne w
diagnose will be made.3 Much re earch and speculation
ha s revolved around the e climbing numbers, and
every thing from the depleted ozone layer to extended
life pans have been irnplicated.3•4
The social repercus ions of the demographics will
hopefully be lessened by technological advances in
oncology treatment. It i clear from the number of
submissions for this volume of the University of Western

O

Ontario Medical Journal that oncology is an area of active
re earch and inve tigation in our medical community. It
is, however, also clear from the number of submis ions for
this volume that oncology impact ignificantly on most, if
not all, branche of medicine. This makes it a problem
that will require immense re ources into and likely
beyond the next millennium.
REFERE CES
1. Sou/rami, Robert & Tobia , Jeffrey. Caucer & its Mauagemeut. Blackwell
Scieuce Press, London. 1998. pp. 2-22.
2. Bishop, James. Cancer Facts: A coucise oncology text. Harwood Academic
Pub., Syduey. 1999. ppB-12.
3. Audreoli, T., Carpenter, C., Bennet, f., & Plum, F. General Cousiderations
in Oncology. I : Cecil Essentials of Medicine. W .B. Saunders Co.,
Philade/plria. 1997. pp. 425-437.
4. Kitclreu , Kirk. Carcinogenicity: testing, predictiug, aud iuterpreting
chemical effects. Marcel Denker luc. , ew York. 1999. pp. 1-11.
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PROFILES
EDITOR: HELE

LEWANDOWSKI

INTERVIEW WITH DR. VENKATESAN
By Helen Lewandowski, MEDS 2001

r.
Varagur
M.
Venkatesan i
a
R a diation
Oncologis t at the London
Re gi onal Cancer C ntr e
(LRC C) who ha a pecial
intere t in brach y ther a p y.
Brachy therapy i a form of
radiotherap y wherein the
radioacti ve ub tance i
placed near or in contact
with the tumor. Treatment in
thi
way
i
called
brachytherapy which means
" hort di tance therapy" a
oppo ed to teletherapy or long di tance therapy. Although
brachytherapy ha b en available to cancer patient for a
few decade , it i currently performed in only elected
centre aero Canada. One of the e centr is the London
Regional Cancer Centre.
Dr. Venkate an received hi under-gradua te m dical
education in India, following which he moved to England
to pur ue training in Ear, o e and Throat Surgery. He
completed an E T fellow hip in Edinburgh, and received
po t-fe llow hip training at the Univer ity of Wale ,
Cardiff, U.K. He emigrated to Canada in 19 3 and trained
in radiation oncology at the London Regional Cancer
Centre. Six year later, he joined the London Regional
Cancer Centre a a taff radiation oncologi t, a po ition he
has held ince that time. In 1993, Dr. Venkate an had the
opportunit to tra ve l on abbatical to ancy, France
where he received advanced training in head and neck
brach ytherap . He al o received training in pro tate
brachytherapy in SeattJ , Wa hington. He i an A ciate
Profe or in the Department of Oncology at the Uni er ity
of We tern Ontario, and i involved in clinical re earch
pertaining head and neck and pro tate cancer. He i
married and ha a on who i at the Univ r ity of Windsor
doing a bu ine degree. His favorite activitie include
cricket, golf and traveling with hi family.

D

Could you talk about head and neck brachytherapy?
Head and neck brachytherapy is widely practiced in
Europe, e pecially in France and Italy . Howe er in
Canada it is till in it infancy. The radioactive source that
is u ed in head and neck brachytherapy i iridium 192
who e half-life is 74 days. It is a temporary implant (i.e.
the radiation ource i left in the area of interest for a few
day and then removed). In orne tumor of the head and
8

neck, brachytherapy i u d as the primary modality of
treatment, however in other it is u ed as the final pha e
of treatment (boo t), that i , after an initial cour e of
external beam radiation . The obviou advantage of
brach y therapy in treating any malignancy i that the
radioactive ource i plac d either in the tumor or very
do e to the tumor and hence receive a relatively high er
do e of radiation. However, a you move away from the
ource, the radioactivity fall precipitously, and the
urrounding normal ti ue receives a relatively le s
amount of radiation. Henc , if brachytherapy procedure is
carri d out properly, (i.e. the ources are placed in
appropriate locations and at appropriate interval ) we are
able to achieve very good tumor control with acceptable
treatment complication . One of the major ide effect of
e temal beam radiotherap in head and neck cancer i
xero tomia (dry mouth) w hich occur a a re ult of
irradiation of alivary gland . In brachytherapy, ince the
major alivary gland do not receive ignificant amount of
radiation, the incidence of xero tomia is minimal. Thi i a
major advantage. Brachytherapy in general i not only a
cience but al o an art. It i le forgiving compared to
external beam radiotherapy, meaning that if the procedure
i not carried out properly, and the implant i uboptimal,
the outcome i bound to b poor. There i major empha is
in the quality control a p ct of brachytherapy when you
obtain training in brachytherapy. If the radioactive ource
are too do e or too far apart, you may end up with not
enough radiation, which means tumor control is poor, or
too much radiation in which ca e the complication are
bound to be severe and unacceptable. Adequate training is
e enti a ! before one contemplate carry ing out
brachyth rapy.
Since I have had formal training in ear, no e a nd
throat urgery, I felt I could u e my experti e to trea t
patient with head and neck cancer. My previous surgical
training has certainly help d me in learning the technique
of head and neck brachytherapy. I started the head and
neck brachytherapy program at th e Lo ndo n Regional
Cancer Centre a few year ago. Since then I have been able
to do 19 lr implant in highly elected patient with tumor
involving the tongue, floor of mouth and lip .
You are also using brachytherapy to treat patients with
prostate cancer. Can you describe the principles of this
treatment?
Dr. Glenn Bauman and I have started a pro tate
brachytherapy program at the London Regional Cancer
Centre . It i done in a multidi ciplinary etting in
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Profiles
conj unction with the urolog y department and the
radiology department. Dr. Joe Chin i the urologi t
involved, and we are al o collaborating with Dr. Downey,
a radiologi tat the niver ity Ho pita) and Dr. A. Fenster,
a cienti t at the Robart Re earch In titute who ha a
pedal intere tin 3D transrectal ultra ound.
Pro tate brachythera y involves implantation of
radioacti e iodine eed (1 1 ) into the pro tate and seminal
ve icle under transrectal ultra ound guidance (TRUS)
utilizing a template to guide the needle. Radioactive I 125
ed are permanently implanted in the pro tate and they
relea e the radiation over a period of time. The large t
e perience of tran rectal ultra ound guided pro tate
brach therapy i from Seattle, Wa hington, where over
1500 patient have been treated over the Ia t 10 to 12 year .
In a elected group of prostate cancer patient , extremely
good re ult have been reported by them. The e include
patient with mall, low grade pro tate cancer with PSA
<10. The grade of the tumor i determined b y th e
pathologi t, who as ign a core to the tumor ba ed on the
hi topathological feature and thi i referred to a the
Glea on score. In the tudie reported to date, they have
found that the patients with a Glea on core of 6 or le
tend to do very well. Serum pro tate pecific antigen
(PSA) level i a ve r y u eful prognostic indicator in
pro tate cancer. PSA i a glycoprotei n that can be
mea ured in the erum of patient . Higher value indicate
wor e progno i . The number of radioactive iodine eed
that are inserted under transrectal ultrasound guidance i
determined b the ize and shape of the pro tate gland,
w hich i again determined by the tran rectal ultra ound .
The procedure i carried out by a team con i ting of the
urologi t, radiation oncologi t, and the radiologi t. The
procedure can be done either under general anae the ia or
pinal anae the ia and take appro imately an hour or
two.
Currently, the modalitie of treatment which are
con idered to be tandard for organ confined pro tate
cancer are urgery a nd external beam radiotherapy .
Pro tate brachytherapy i till con idered omewhat
experimen tal. It has been around for appro imately 10 to
15 yea rs, and hence, long term re ult of thi treatment
modality are not available. It i hoped that in 5 to 10 year ,
it will be con idered a one of the acceptable treatment
option for organ confined pro tate cancer. Brachytherapy
i now offered to a highly elected group of patient who
have mall organ confined tumor with Glea on core 6 or
le a nd a PSA le than 10. We feel that the e patient
b nefit the mo t. We have already treated everal patient
u ing this modality and the program i expanding to the
point that in the near future, we will be doing at lea t one
or two implant per week . We are in the proce of
commencing a tran -Canada randomized trial w hi ch
compare radical pro tatectomy with brachy therapy for
early tage low grade organ confined pro tate cancer with
PSA le than 10.
H ow does brachy therapy compare to more conventional
treatment modalities for prostate cancer?
If the patient are elected properly for pro tate
brachytherapy u ing the criteria outlined above, th e
outcome i thought to be comparable to urgery a nd

e ternal beam radiotherapy. There are no prospecti ve
randomized trial which compare brachytherapy with
other modalities. The re ult are mainly from retro pective
serie . One of the main advantage of brachytherapy is the
convenience to the patient. The patient i discharged home
on the day of the procedure or the very next day and ince
the po t-operative recovery is quick, he returns to hi life
routine within a hart period of time after the I 125 implant.
Brachytherapy doe have ide effects, including urinary
frequency, nocturia, dy uria and urgency. There i a mall
ri k of perineal hematom a. A mall proportion of patients,
le than 3%, develop comple te urinary retention for
w hich an indwelling urinary catheter is required for a
period of time. The incidence of impotence i thought to
be relatively le s compared to urgery and external beam
radiothera p y. Most of the ide effects from pro tate
brachytherapy are u ually minimal and temporary . If
properly selected, the incidence of incontinence with
brachy therap y i ve r y lo w compared to radi cal
pro tatectomy. The duration of hospitalization a tated
above is less compared to urgery. One of the major
advantage of brachytherapy over external beam radiation
therapy is the duration of treatment is short and hence it i
very convenient to the patient. As stated before, pro tate
brachytherapy is an art a well a a cience and there i a
learning curve for the team which carries out the implant.
It ha been recentl y reported that it take s the team
approximately 4 to 5 year to perfect this technique. The
re ult of pro tate implant i only a good as the geometry
of the implant and there i le s room for error compared to
external beam radiotherapy. It i less forgiving compared
to external beam radiation. If the radioactive eed are not
in erted in appropriate place , you may end up with the
eed too far apart re ulting in under-dosage and hence
poor tumor control or the eed may be crowding in one
area re ulting in a hot pot a nd , hence, increa ed
complication rate uch a urinary incontinence due to
urethral damage. Thi i very much a technique oriented
modality and the experti e of people concerned i very
important in term of outcome.
Is there a difference in survival between prostate cancer
patients treated with b rachytherapy and those treated
with surgery and external beam radiation?
Currently we have -year re ults on the tumor control
and complication rate for pro tate brachy therapy from
the Seattle group. In patients who are carefully elected for
brachy therapy there ult are very comparable to urgery
and external beam radiation therapy. However, ince we
do not have long term follow-up, (i.e. 10 to 15 year
follow- up ) we cannot claim that the re ult of
brachy therap y are a good a tho e of urgery and
radio therap y. To orne ex tent, brachytherap y ha
with toad the te t of time. The Seattle group ha ve
demon trated that the biochemical progression free and
clinical di ea e free survival curve have reached a plateau
a t 8 years.
In your opinion, w hat are important issues in prostate
can cer research at the p resent time?
i. Conf ormal Exte rn a l B ea m Ra dio t he rapy using
Computerized Tomography (CT)
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Profiles
A practical i ue in external beam radiotherapy i how
be t to deli er the radiation do e, to the pro tate gland
without giving excessive radiation to the urrounding
normal ti ue . We are now u ing a new technique
called "conformal external beam radiation thera py"
which refer to treating the pro tate with a margin.
Computerized tomography (CT) ha improved our
ability to localize and recon truct the tumor and the
anatomy of the urrounding tructures in order to
accurately de ign the radiotherapy treatment field .
Many tudies are currently underway to a e the
efficacy and toxicity of conformal external beam
radiation therapy in pro tate cancer. In imple term ,
the patient i immobilized, the location and ext nt of
the pro tate gland i delineated using a CT can and
then with ophi ticated computerized technology, the
radiation do e is delivered to the prostate gland with a
margin in an acc ura te manner. With thi unique
technique, we have now proved that it is po ible to
give a relatively higher dose of radiation to th e
pro tate gland with acceptable ide effect . In patient
with omewhat bulky pro tate cancers, we hop that
by giving higher do e of radiation than before, we
might be able to achieve better control of the tumor.
We ultimately hope that thi will tran late to a better
urvival. There are many cancer centre wherein
re earch pertaining to thi area are being carried out
including our . Since we are only treating the pro tate
gland with a mall but acceptable margin and avoid
exce ive irradiation to the urrounding normal tis ue,
we are able to grad u ally increa e the do e (d o e
e calation tudie ) and th e re ult of this exciting
re earch i awai ted.
u.

u1.

10

High Risk Localized Prostate Cancer
Standard therapy for the e patient yield poor re ults.
Re earch i under way to improve the re ul ts by
combining hormone therapy given before, during
and/ or after external beam radiotherapy. Multicentre
trials are underway to look at the efficacy a well a
the quality of life issue .
Metastatic Prostate Cancer
The conventional treatment for meta tatic pro tate
cancer i hormone therapy, i.e., ca tration, either by
urgical or medical mean . Although Andr ogen
ablation re ult in rapid and often dramatic
improvement in mo t patient , the duration of
re pon e i limited and ultimatel y mo t of them
develop hormone refractory di ea e. Almos t a ll of
the e patient with hormone refractory di ea e die of
their disea e within a year or two . Resear ch i
underwa y to tudy the mechanism of h ormone
refractionne and examine the role of drug re i tance
marker . U ltimately the goal of this re earch i to
develop treatment which will be effective for the e
patient , e.g., molecular directed therapy.
Q

Have you heard?
With HP Stethos, HP
has applied decades of
technology advances

to redefine a
fundamental tool of
medicine. HP Stethos greatly
expands acoustic thresholds,
amplifying sounds at the touch of a
button, filtering out unwanted
sounds, and eliminating sound loss.
The HP Stethos (M4504A) is a
product well worth hearing more
about! For information, or to place
an order, call l -800-291-6743,
option 1.

Informatio n about HP Medical Pr oducts
Group can be found o n the World Wide
Web a t h ttp://www.hp.com/go/me dical.

New product information:
Click on ffitrasound Imaging and learn more
about the ImagePoint Hx: HP's new
multispecialty ultrasound y tern with
Harmonic Imaging.

Fl,;'tl HEWLET T
~~PACKARD

- - - - - - - - - - - - - - - - - - - - - - - - U.W.O. Medica/Journal 69 (2) 1999

ETHICS
EDITOR: D AVID

J.

SATIN & NYAN NARINE

GUT REACTIONS: AN ETHICAL ANALYSIS OF
EMERGING BIOTECHNOLOGIES
By David J. Satin, MEDS 2001
or thi i ue' ethic editorial, I have cho en to
di cu
everal broad ethical con iderations
urrounding an article written b Glenna Cuccarolo
entitled, "AT RISK FOR BREAST CANCER? Tlze Ups and
Downs of Genetic Breast Can cer Tes ting. " 1 A it's title
ugge t , her article pre ent potentially positive and
negative a p ct of the biomedical application of per onal
genetic information; namel y elective creening for
mutations in brea t cancer u ceptibility gene (BRCAl
and 2) and the medica] manag ment thereof. I will employ
BRCA gene technology both a an e ample (albeit not an
e emplar) of a ver po itive development and a a foil for
potentially negative trend in the field of biotechnology.
I am a firm believer in the wi dom of the G.I. tract. It'
not that I di count more cerebral analy i , rather I
con ider vi cera! ensation
riou ly enough to merit
inve tigation. When we hear the term ' uclear' and the
name 'Ei n tein' in the same ntence we typically picture
an eccentric, kindly-looking old man, with white hair
flailing atop a head of geniu . - Thi i our gut reaction.
However, when we put the name ' Oppenheimer' together
with " uclear", few among u imagine the my terie of
the univer e unraveling in the ph ici t' cloud chamber.
Rather, mo t of u picture a very different cloud over
Hjro hjma or aga ab- Another gut reaction. I propo e
that these gut reactions repre nt a valuable di tinction we
can take to heart when con idering revolutionary
di coverie and new technologie . T day, our gut reaction
to the name 'Wat on and Crick' coupled with 'Genetic '
i mo t probably a pristine picture of the beautiful double
helix - A po itive gut reaction. I hope we feel the arne in
fifty yea r .
My gut reaction i rruxed. Ju t a nuclear power can be
a force of rna ive amount of energy a well a rna
de truction, genetic biotechnology hold the potential to
cure di ea e or devalue humanity. I do feel hopeful when
con idering our current capacit to empower orne
women with valuable knowledge of their own D A. I
marvel at the pro pect of curing genetic di ea e. But I feel
unea y when picturing the very rea] potentia] for trung to
go terribly awry. These are not apocalyptic scribble on
the picket ign of a street-corner fanatic. The e are the
view voiced by our cienti t , phy ician , ethici t ,
economi t , and politician . u~ M concern here, i no
more over the cientific di co ery of the gene than over
the di covery of the atom, for tho cat have long b en
out of the bag. Furthermore, I would hardly choo e to dedi cover uch phenomena, for I could never turn away
from their irnmen e po itive potential- but my family did

F

not live in ffiro hima, aga aki, Three Mile I land, or
Chernobyl. A emotionally laden a the term ' uclear' i
pre ently, I believe 'Genetic' may one day urpa it in
heer magnitude. Whether the direction of the e emotion
will be po itive or negative i the ubject at hand.
I believe we have a collective duty to actively promote
the positive technological developments and actively
denounce the negatives - or at very lea t contribute to
public debate. Di cerning the po itive from the negative
i an integral part of what I believe ought to be the moral
debate. The following i a fragment of the type of
rea oning I believe hould b involved in di criminating
among 'good' and 'bad' biotechnologie . I do not purport
to b providing a complete account of the i ue at hand.
Far from a doctrine, I offer food for the thought of
phy icians. I wiU employ the current practice of elective
BRCA (1 and 2) screening a repre entative of an overall
' good' technology. I will contra t the approach taken with
re pect to uch technology with the current approach of
the Human Genome Project.
Clas ically trained , I'm compelled to begin my
analy is by con idering how a given technology fare with
re pect to tandard etrucai theorie . The Utilitarian hold
tock in mo t biotechnologie for, like mo t technologie ,
they are de igned to improve outcome thereby incr a ing
the total happines of the u er. Selectively creening for
BRCA gene mutations may certainly achieve uch a goal
a early diagno is tend to improve overall outcome .1 The
Human Genome Project aim to con truct a complete
blueprint of the human genome. The Utilitarian ought to
approve of tru project under the condition that its re ult
ultimately increa e th total happine of the population.
Practically, thi means that if information derived from the
complete blueprint enabl phy ician to cure a given
di ea e uch a mu cular dy trophy, then the Utilitarian
would b wayed toward approval.
Thu far, both our candidate are doing well.
However, the moral tatu regarding the order (or lack
thereof) in which the Human Genome Project currently
uncover information ha recently been challenged.:uA The
project ha no mandate tating that we ought to fir t
uncover the natur of the genes responsible for
humanity's mo t prevalent di ea es, or tho e di ea e
a ociated with the highe t mortality or morbidity.
Without uch a mandate, the mo t ought after gene
patent effectively become tho e mo t economically
beneficial to the re archer.
ot only might we find fault in the project' lack of
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prioritie , but w e may question the w i darn of mapping
the entire human genome . For e x ample, there are
current) Biotech Corporations earching among the
Icelandic genome for the blond hair, blue eyed ca h-cow.2
The not- a-futuristic image of eugenics, o r the
bioengineering of ' perfect' people, ought to be di turbing.
But the Utilitarian may be les faint of heart, for it i a
continge nt matter whether a homogeneou 'master-race'
may indeed promote the greatest happine . This virtual
reduc tio-ad -absu rdum demon s trate wh y we cannot
entertain a unidimensional, or purely Utilitarian analy i our gut reactions ought to be negative.
Ju tice demand that no biotechnology marginalize a
group of people or create greater unfaimes . Selective
creening, uch a the aforementioned BRCA protocol,
ultimate ly bridges fairnes gaps by empowering and
indirectly promoting the phy ical health of tho e at high
ri k of disea e. There is alwa y a concern how ever,
regarding the question of who get creened and who
doe not. Currently, tho e who fulfill the creening criteria
(i.e. tho e at highe t ri k) are offered funded creen w hile
tho e who are at a les er ri k may purcha e the creen.
Thi rai e the specter of unequal health care, fo r the
w ealth woman can effectively purcha e empowerment in
the form of more informed deci ion with respect to a
wide variety of health care management trategie . While
thi i an important i ue to be worked out, it is n ot a
challenge particular to biotechnologie but rather to health
care in general.
The result of the Human Genome Project on the other
hand, will probabl y not only hares thi problem in
pade , but may allow parent of the future to purcha e
' p rfect' de igner children. The que t for ' perfection' i the
i ue here. The proce of attaining perfection force u to
identify, tigrnatize, and devalue ' imperfection'. Thi may
lead to the marginalization of tho e who fail to meet the
tandard ; a haunting theme often revisited in nov el
formerly known as fictional.
Finall y, Kantian (or more broadl y, Deontological)
ethic demand respect for human dignity. Selective
creening for oncogenic BRCA mutations promote
human dignity by giving women greater control over their
health, and enabling them to po sibly avoid a crippling
di ea e . Uncovering all human genetic information may
ultimately detract from the elf-re pect and dignity of the
' imperfect'. Se veral que tion ought to be con idered ,
"Can the earch for non-di ea e-cau ing genes be halted?
What count a a di ea e-cau ing gene? For example, i
Tourette' ufficiently di abling to merit re earch with the
goal of eradicating the di ea e from future generations? I
rneiopia? How about hart, or even average stature?" 3 We
ought not promote the reduction of human valu , or
dignity, to the urn of our attributes.
The allure of biotechnologie re ide in our
o v erw h e lming, pervasive, and mo t ea ily acce ible
Utilitarian leaning . 'Succe ' i ty pically judged by
practical outcomes, accurately mea ured and preci ely
calculated to the nth decimal place. Utility is conducive to
science. Justice and human dignity are not. They cannot
be quantified. Some therefore interpret them as b ein g
invaluab le, others see them as having no value at all. It
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thus s tand s to reason that w e must see beyond science if
w e a re to a pp r eciate w hat is at s ta k e in e v aluating
biotechnologies. We must embrace our roles as f hY icians
qua persons, and physician qua political entities, le t our
legacy be a gut feeling of the war t kind.
Ein tein wa once quoted in conversation with
colleague H .A. Lorentz aying, "One must divide one's
time between politic and equations. But our equations are
much more important to me." 6 Einstein often spoke in a
Kantian way by referring to duty . He recognized that
there can be no uch thing as a complete, exclu iv e,
scientist qua scientist; for all cienti t are persons, and all
per on are, by definition, moral beings. Due to the nature
of their w ork, phy ici t of that time ought to have openly
expre sed political commitments as well a scientific one .
Phy icians today are in a very similar position.
The purpo e of the opening to this editorial wa not to
demonize Oppenheimer, for I hold him in high regard .
Rather i t is to illustrate how exclus ive scientists qua
scientists, even great one , cannot fulfill their social
obligations. While Oppenheimer may have had the be t of
intention and the mo t noble of beliefs, he nevertheless
went unheard. Einstein on the other hand, i known for
his objection to the very project for which he constructed
the theoretical groundwork.
The type of warnings we currently hear regarding
biotechnologie re ernble tho e voiced by Einstein. His
insight and public a sertions helped separate his per ana
from Oppenheimer' s. Let u ensure that when we look
back upon Wat on and Crick, our gut reaction leave us
with a pleasant atiety rather than a bellyache and a
feeling of impending doom. Let u be more gourmet than
gourmand. I'm dedicated to the belief that the outcome of
medical biotechnology lie in the hand of the phy ician
that employ it. Some believe that since they did not make
the world the way it i , they cannot be held accountable
for upholding the tatu quo . In truth, I believe w e a ll
make the world the way it i .
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ONCOLOGY ON THE INTERNET
By Munsif Bhimani, MEDS 2002
ike any other medical field , oncology has an
appreciable repre entation on the Internet. This i
not surprising, a cancer is one of the leading cau e
of mortality in developed nation like Canada
(www. s tatcan.ca/Dail y/Engli sh /980416/d980416.htm).
Therefore it i important a medical practitioners, to rely
on ource of information that are reliable and evidenceba ed . A may be expected, a short article cannot do
ju tice to all the internet ite on oncology. However, the
beauty of the Internet lie in the pre ence of 'hyperlinks'
that connect ite to one another. Therefore, if one can
begin an adventure of web surfing by looking up a few
ite on a particular topic, then one i bound to be
infinitely linked to a plethora of additional site , each
containing va t amount of enlightening information.

L

A a medical student, perhap the mo t important
que tion in my mind i one of re ource allocation. The
word 'cutbacks' ha become an anthem to mo t Canadians
and e pecially to phy ician who bear the brunt of
government cutback in health-care. When dealing with
oncology, my first impul e would be to ask how acce sible
is specialized cancer treatment for people in rural area .
The internet hold the answer to thi dilemma by uniting
information from around the w orld at your fingertip .
Perhap the fir t web- ite to vi it for such
information is the Cancer Care Ontario (CCO) page
(www.cancercare.on.ca). ceo i an agency formed by the
government of Ontario to provide leader hip to variou
cancer-care ervices in Ontario. The web-page ha much
information regarding government initiatives in oncology
including uch recent news as the opening of new cancer
centre in 0 hawa, Mi i auga and Kitchener-Waterloo
a well a the long waiting li t for radiation therapy. It
a lso contain hyperlink to the eight regional cancer
centres in Ontario which are located in Hamilton, London,
Toronto, Wind or, Kingston, Thunder-Bay ( orth We tern Ontario) and Sudbury ( orth-Eastern Ontario).
Web- ite for each of the e regional cancer centre contain
a wealth of information on the service available at each of
the e localitie , the re earch being carried out there, and
various medically relevant material. All eight cancer
centres can be acces ed from the ceo web page and
w ould be an excellent tarting point to apprai e the
facilitie available in rural regional cancer centre . It
would al o be a good way of getting in touch with health
care profe ionals at different community based cancer
centres.
After thi , the next tep would be to find out more
about the therapeutic and re earch aspect of oncology.
Basically, surgical excisions of tumor , chemotherapeutic

intervention, radiation therap y or combinations are
currently used to treat most malignancie . Physician
pecializing in each of the e area (surgical oncologists,
medical oncologi t
and radiation oncologi t
re pectively) carry out the different therapeutic strategie .
The Oncolink web-site at the Univer ity of Penn ylvania
ha a detailed ection devoted to each of the therapeutic
mode (www.oncoli nk.upenn.edu/speciality) . The site
al o keep track of frontier therapeutic re earch such a
monoclonal tumor- pecific antibodie conjugated to toxins
or anti-tumour cytokine .
On the commercial side, Genentech, a biotechnology
company experimenting with everal anti-cancer
therapie , maintain a very informative oncology ite
(www .biooncology.com). One area they adverti e i a
novel therapeutic agent Herceptin®, a monoclonal
antibody u ed to treat breast cancer. This site al o include
information on upcoming meeting , an oncology glossary
and link to other equally informative ite . Entremed, the
company that hold patent for Angio tatin and
Endo tatin, ha a web ite (www.entremed.com) with
much information on new therapie including update on
when human clinical trial are expected to begin.
To enhance our knowledge of the ongoing advance in
the world of oncology even further, we can urf over to
the Oncology Therapeutic
etwork web site
(www.otnet.com) or vi it the immunotherapy and genetherapy weekly new relea e at www.newsfile.com . I
al o ugge t visiting the medicine-online web site at
www. meds.com where one can find an online cancer
library and a databa of chemotherapeutic agents. Thi
ite al o has an online calculator for calculating the
do age of variou chemotherapeutic drug .
Another idea for the net surfer would be to vi it the
web ite of variou cancer centre in the United State .
Some of them are definitely involved in novel therapie
that may be of intere t to u in Canada. All the American
cancer centres are li ted with the
IH at
www .nci.nih.gov/cancercenters/centersl.htm.
Keeping up with clinical research i highly
important for oncologists . The Oncolink ite has a
de v oted a ection to ongoing clinical trial
(ww w .oncolink. e du/ clinical_ trials) . One could even
ub cribe to an automated electronic mailing list giving
update on recent novel anti-tumour therapie . Another
li t of clinical trial in the United State can be accessed at
www. centerwatch .co m . Furthermore, the American
ational
Cancer
In titute
( CI)
ite
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(cancernet.nci.nih.gov/nci.htm) at IH ha inter ting
ections in various branche of oncology for both a ba iccience re earcher, and a clinician.
In keeping wi th the need for phy icians to b well
informed of their patient population, it is es entia! to be
aware of th tati tic a socia ted wi th cancer incidence
and mortality . Such ta ti tic ar readily obtain d by
doing a earch on the Stati ti c Canada web - ite
(www.statcan.ca) for cancer, oncology or indeed an other
health related item . After a few eco nd , the arch
re pond wi th numerou document , chart , and table
ummarizing a multitude of relevant Canadian tati tic .
However, if one want e en ea ier acce s to uch figure
pecilically for cancer, I ugge t con ulting the Statistic
ection of the ational Cancer In titute of Canada
(www.cancer.ca/stats) where updat d 1998 stati tic can
b obtained.

ite created by uppor t gro up compri ed of cancer
patient and their familie . A goo d e am ple of the e
upport group can b
en at www.w illow.org (mainly
for brea t cancer pati nt ) and at www.cancerkids.org (for
familie of children uffering from cancer) . The e
r ource would b u eful to cancer patient and thei r
familie in pro v iding informa tion, a d v ice and mu ch
n ded upport.
Q

The internet ites mentioned o far are only a few
e ample of what i available out there . For tho e
intere ted in vi iting a many web- ite a po ib le, I
ugge t consulting a ite maintain d by the Univer ity of
ewca ti e in England which ha a compilation of
cancer link
from a round the worl d
(http :// www .ncl.ac. u k / -nch ww w/ gui de s/
clinksl.htm). The have done an excellent job of
ca taloguing the ite into categorie ba ed on
region and type of cane r. In addition, the
have indicated the usefulne of the e ite for
patient , familie , phy ician and re earcher . If
For a challenging practice opportunity, consider the 28 Fir t
you are intere ted in cancer and enjoy urfing the
arion communities in the ioux Lookout Zone. Practice
Internet, a vi it to thi web page may begin a long
5 day /month in fly-in aboriginal communitie , 3 weeks/month
journey into the multi-dimen ional nature of
in the ioux Lookout Zone Ho pita!.
oncology.
salaried positions, from S150,000 - S185,000, no overhead

Family Physicians needed lor
Sioux Lookout Zone, NW Ontario

La tly, I would like to point out a few site
that are good reference for our patient . Mo t of
the reputable ite I have indicated o far contain
a pedal ction directed pecificall to patient
and their familie . The e include the Oncolink
ite at the Univer ity of Penn y lvania and the
American CI ite at the IH. Among Canadian
re ource , the eight regional cancer centre all
ha ve orne ort of information for patient .
However, I found that the London Regional
Cancer Centre (LRCC, www.lrcc.on.ca ) and the
Toronto-Sunnybrook Regional Cancer Centre
(TSRCC, www.tsrcc.on.ca ) are excellent in thi
regard, directing patient not on! to credible
information re ource but a! o to community
re ource that patients may want to acce . The
TSRCC ha a earchable 'community cancer
re ource guide' which cover uch i s ue a
prevention, home-care, caregiver re lief, and
women and cancer. A imilar cancer re ource
directory exists at the LRCC. In addition, the
Canadian Cancer Society (www.cancer.ca) and
the American Cancer Society (www.cancer.org)
ha e va t amount of general information on
cancer. Finally, clinical centre often have links to
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ALTERNATIVE CANCER THERAPIES
AND THE 714X STORY
By Mahmoud Shnraf, MEDS 2002
ancer morbidity and mortality is the major
problem facing orth American public health
today . 1 Chemotherapy and radiation therapie
have been successful in improving the quality of life for
many patients, but a definitive cure remains elusive.
Partly in search for a cure, and partly to improve the
quality of life for patients non-re ponsive to conventional
therapie , age and quack alike are touting alternative
therapie . Alternative therapies, including herbs,
nutrition, chemical and electromagnetic timulation, have
rapidly ari en over the past 25 year . 1 Only a few of the e
treatment have been rigorously te ted, and even fewer
have been validated .5 A a re ult, a great debate ha s
emerged between skeptics who await firm evidence before
using them and tho e who tre that there i no time to
wa te waiting for cientific authorities to come around
while cancer patients are uffering.
The u e of non-conventional therapie has al o
parked many legal battle again t the companies and
per on that upply them. The ca e of Charle Pixley and
the drug 714-X is a particularly alient example?
714-X is trimethyl bicyclo nitro-amine heptane-cl, a
nitrogenous camphor product developed by
biochemist I microbiologi t Gaston ae ens. He rea oned
that cancer cell u e " co-cancerogenic K factor" to
uppress the immune sy tern and harne the bod y's
nitrogen to replicate. By providing an exogenous source of
nitrogen, cancer cell could till replicate, but would not
release "co-cancerogenic K factor" becau e there would be
no need to capture endogenous nitrogen. This would keep
the immune sy tern strong and allow for immunity to
effectively out-compete low cancer growth and defeat the
cancer. 1
Ga ton ae ens received his microbiology training in
France. In the 1960' , he developed an ultraviolet and La er
light microscopic technique capable of viewing live blood
with high magnification and re olution. 6 Around 1962,
ae ens reported the discovery of a previously unknown
rnicroorgani m using hi micro cope. Thi he termed
" omatid". Hi de criptions of the findings correspond to
Mycoplasma, di covered by American researchers in the
arne yearl. Working out of Canada, aessens applied his
knowledge of the " omatidian" life cycle, gathered with
u e of his new micro cope, to cancer cells and patented
714-X a an anti-cancer agent in Canada in Augu t 19 0.7
He developed a protocol u ing homeopathic rea oning.
714-X is not intended to attack cancer cells specifically. It
provide nitrogenou compound to the cell and in so
doing, suppre ses production of what aes en termed
"co-cancerogenic K factor ", an anti-immune toxin. The
agent is made more dilute before admini tration ince
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homeopath rea on the dilution proce to potentiate the
medicine. 1
ae ens' protocol involves daily intralymphatic
injection (1 I day) for 21 days, followed by 2 days re t. This
is repeated on a cyclical ba is until adequate re ults are
achieved . Vitamins E and B 12 should not be taken
concurrently. 1 A tudy by Bigel on, MD ha shown that
714-X, in combination with other alternative therapie ,
results in 60-80% effectivenes at rever ing cancer. 1
In 1989, ae ens wa charged with 4 counts of illegal
practice of medicine and one count of contributing to the
death of a person (a patient taking 714-X). 7 He wa
acquitted on all charge . The arne year, his drug was
approved in the United State under the Emergenct; Drug
Relief Act for u e among de perate terminally ill patients.1
Since 1990, Charle Pixley's company Writers and
Research Inc. has marketed 714-X in the United State , with
pre criptions being filled by direct order from aessen '
private lab in Rock Fore t, Quebec. Advocate of 714-X
claimed 75% effectivene in treating cancers u ing the
ae ens protocol.
In 1992, the happy state of affairs wa brought to it
fir t cri i point. The Food and Drug Admini tration, in a
move contradicting it own per onal import policy on
non-conventional remedie , i ued an import alert on 714-X
even as 5000 orders were to be filled. 7 Pixley countered in
1993 by e tabli hing an In titutional Review Board, a
vehicle mandated by Congre s to make unapproved drug
available to the public in preliminary trials. Dietmar
Schildwaechter, MD, PhD was placed a chief medical
inve tigator. To satisfy the law on informed consent and to
ensure proper under tanding, the IRB put out a protocol
guide entitled Do o Hnrm. 7
The FDA wa not completely satisfied, however.
Pixley complied by deleting all mention of the IRB from
the protocol and eliminating the link with physicians
established under the Emergenct; Drug Relief Act by filling
order directly to individual customers from the lab in
Canada. 1
In 1994, Canada' s Health Protection Board concluded
that 714-X i unsafe and refused official drug status.
Under the terms of the Canadian In ves tigational an d
Emergency Drug List, the agent was nevertheles accorded
availability on compa sionate grounds in Canada. 6 This to
date has not been re cindedl. We note that in 1994, 714-X
wa available, albeit under limited term , in both Canada
and the United States.
The Institutional Review Board did not escape the eye
of the FDA for long. In 1996, charge were brought against
the IRB in circuit court for impeding an FDA investigation
into it operation and for illegal importation of a drug
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into the United State . Pixley and hi a odate were tried,
convicted and entenced and the IRB wa disbanded and
it publication suppressed . Mo t recently, Pixley is
actively fund-raising to mobilize an appeal before the
Second Circuit Court of Appeal to be headed up by the
famed lawyer Alan Dershowitz. 1
The ongoing saga of 714-X i only urprising in that
government action ha been relati ely wift and ded ive.
An immen e body of alternative and natural ag ents
geared toward cancer and many other illnes e exi t and
i being u ed by patients, in potentially unsafe way . The
claim of their producer vary from ba ele to fairly
rea onable, a in this ca e. Given the tremendou amount
of concern these ill patient expre , and their
vulnerability to opportuni tic manufacturers or wi hful
thinking, it i advisable that the onu for proving efficacy
be put on the advocate of al ternative treatment before
their product can b marketed as having any medicinal
value. Criminal penalty hould be the consequen e for
infringement.
The e recommendation will admitted! prejudice
mall- cale producer who cannot challenge th monopoly
held by the big pharmaceutical companie . However, it i
fea ible that mall- cale producer could cooperate with
academia to validate their product cientifically in
exchange for profit haring or government re arch
funding given on a merit ba i to group with alternative
therap propo al . It i crucial that ound cientific
evidence about medicinal treatment be ought in a timely
fa hion, and then tran lated into safe product with
therapeutic potential.
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THE CAUSE AND THE CURE:
ILLNESS AND HEALING IN
TRADITIONAL CULTURES
By Sherry Rohekar, MEDS 2001

n traditional culture , health and healing have been
unified with the concept of religion and morality.
Historically, healing practice have been ritualistic and
religiou . Similarly, ickne ha been linked to the
violation of e tablished moral norm . In many culture ,
phy ical illne s has been a ociated wi th a disharmony
between the individual and the univer e. The concepts of
bad karma in Hinduism and the connection in Christianity
of illne and in are example of how moral digre ion
can be considered to manife t in phy ical di ea e. Thu , in
traditional cultures, ickne s ha distinct cau ation .
Tradition culture al o often have pecific type of healer
that can cure illnes through rituali tic or religiou
method . Thi article i a brief review of di ea e causation
and disea e cure in traditional culture .

I

DISEASE CAUSATION
Theories of disea e cau ation in traditional culture
u ually involve personalized agents that afflict the
unluck y or morally tran gre sive individual. Many
traditional culture hare the view that all natural object ,
even tho e that are inanimate, po e a oul. The soul i
e pecially potent in living things, and even more o in
human being . This belief i termed anirni m (from anima,
oul). Tho e who believe in animism con ider the world to
be alive, and all objects in the world to have a will and
per onality. Bad thing , uch a ickne , occur becau e
they are willed by another, often for per onal rea ons. By
calling ickne the re ult of a di harmonious interaction
with another, it is framed in a moral context. The ill per on
ha in ulted or offended omeone, u ually a deity, an
ance tor, or another human being.
Deitie exi tin mo t traditional cultures. They are
re pon ible for the creation of both human life and the
rule that human life mu t abide. Violation of the e law
invite puni hment from the god or god , in the form of
mi fortune, ickne s and death. Both Judaic and I Iamie
tradition , for example, have very detailed and rigid code
of conduct that are maintained by a ystem of reward and
con equence. In orne culture , p cific di ea e are even
directly linked with a god. For e ample, offence of the
Hindu godde Shitala is thought to lead to mallpox.
Offen e can al o be given to the dead, who in many
traditional cultures are believed to have the ability to exi t
in a noncorporal form. In the e culture , the dead take
g reat intere t in the living, particularly in the activitie of
their de cendant . Tho e that die in an unhappy tate may
be tran formed into gho t or demon , who in their
fru trated tate, try to avenge them elves on the living.

The e traditional culture believe that illne s is caused by
not re pecting and revering deceased relatives, or through
the maleficence of angry and Listie s gho t .
Traditional culture al o often view sicknes and bad
luck a the con equence of more mundane interaction .
There often exists a belief that inconsiderate behaviour to
other can cau e illne . Thi is epitomized by the concept
of the mal ojo or evil eye. Sickne is directly correlated
with the hatred, jealou y, envy or wrath of an offended
human being. The offended party may cau e the
individual to become ick them elves or they may con ult
a rna ter of charms, uch a a witch or sorcerer.
Whether an illne i triggered b an angry human, an
offended pirit, or a cro ed deity, there are u ually
repeating theme in traditional culture of how thi energy
i pent to cau e actual di ea e. Soul loss, object intru ion,
pirit intrusion and di ea e orcery are the mo t common
theorie of how illne is immediately cau ed.
So ul los involve a relationship between the
weakening of the body and the weakening of the soul. If
the oul is in poor health, the body reflects thi and cannot
heal. Whereas common orth American belief place
greater importance in the exi tence of a body (no body, no
per on), traditional culture view the oul a the main
requirement for exi tence. Somewhat hypocritically,
though, mo t orth Americans will not find it unusual to
blame a per on' illne on a "lo t will to live".
Sickne s caused by object intrusion is due to a foreign
ub tance that has been introduced into the body. Many
traditional culture propo e that orne object ha been
injected into the afflicted; indeed, orcery is ba ed on the
ability to do so. If the obj ct i not removed, it make the
per on ill and then kill th m. Spirit intrusion i a similar
concept, involving the po e ion of the ill per on by a
pirit or ancestral gho t. It i often con idered the
mechanism of mental illnes . Even modern orth
American culture colloquially refer to the concept of
pirit intru ion: "He' not him elf today, something ha
gotten into him."
Di ease orcery i an e ample of a traditional belief in
which the immediate and ultimate cau e of illne ar the
arne. In this belief, a witch or sorcerer is able to channel
p ychic power or the energy of their will through charms
and ritual . Di ea e cau ation i viewed by traditional
culture as the re ult of personal interactions. The
conviction that all inhabitant of the earth po e a will
and soul allows tran gre ion against that culture'
ethical norm to be translated into disea e ju tification.
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DISEASE CURE
Diagno i and therapy of illne in traditional culture
relie heavily on the cau ative agent. The healer mu t b
able to connect religion, custom and interper onal kills to
determine the cau e of the sickne and thereby effectively
combat it. For example, if a per on ha developed an
illne due to soul Joss, the healer mu t be erudite in the
path that the Jo t soul ha taken. Alternativel y, if the
illne i largely piritual, the healer must be able to olve
the moral and religiou problem the tricken individual
ha . In traditional culture , there are everal ty pes of
medical peciali ts that appear repeatedly. The e are the
shaman, the pirit medium, the prie t, the holy per on and
the pre criptioni t.
The haman i con idered to be a rna ter of the oul.
He or he ha the ability to travel to the pirit realm where
the ouls of the ick have wandered. Through thi direct
connection with the spirit world, the shaman ha the
ability to ee the soul and a k the help of a pirit or
healing ally. In mo t traditional culture , the shaman i a
part of the divine as much a the world of healing.
The motif of a pirit medium u d to cure the ick i
al o one that commonly appears in traditional culture .
The pirit medium can summon spirit and allow them to
act through his or her body to affect the material world.
Unlike the haman, however, the medium is imply a
pa ive tool of the pirit, who in tigate the actual healing.
The theme of consulting pirituaJ power is repeated
in another type of traditional healer: the priest. If the
illne ha been triggered by offense or insult to a dei ty or
s pirit, the prie t can help appea e the offended party.
Only trained prie ts know the prayer and rituals that
upplicate angry deitie and pirit . Holy people derive
their healing power from a imilar bond with deitie ,
how ever, they ha ve an innate acredne s and hea ling
power due to their goodne sand piety. It may be believed
that a god i working through the holy per on.
A pre criptioni t, in traditional culture , pecializ in
preparing medicines. In addition to being learned in the
natural attribute of plant , they have a special connection
to the spirit of plant . The medicine i almo t al ays
compo ed with the practice of ritual , or the saying of
prayer . The ill per on may al o be given tringent rules
about taking the preparation, and prayer to recite.
Di ea e cure ha certain repeating theme in
traditional culture . The healer all pos ess pecial talent
that allo w them to be in intimate contact with the
piritual world. This allow the hea ler to u e hi or her
know ledge about the culture' belief and traditions in an
attempt to correct the di harmony that i cau ing ickne .
The concept of religion and moral con equence being
combined with sicknes and health i quite prevalent in
traditional cultures. To what extent tho e idea are
manife t in our orth American culture' s view of health
and healing i a topic that warrant further consideration.
Doe modem medicine al o imply a connection between
human behaviour, cau e and cure? An under tanding of
the cultural environment that urround medicine can
surely erve to improve medical practice.

18

REFERE CES
Kiu ley, D. Healtl!, Healing Aud Religiou: A Cross-Cultural Perspective.
ew jersey: Prentice Hall, 1996:5-11.
Q

PARKE D AVIS
STRrviNG To MAKE MIRACLES HAPPEN

A LrrrLE SooNER
Mirad es can happen.
But behind every mirad e is hard work and determination.
The determination to make our lives a little better,
the hard work necessary to g t d oser to a cur .
It d n't happen o ernight; it often takes ears of
dedica ted r arch. But when that research culminat in
a breakthrough or a n w pharmaceutical,
mirad become po sible.
Committed to Izard work, detem1ination and caring.
Tlze qualiti that can make miracles happen.

PAIIKE·IMVIS
rborough, Ontario M I L i\:3

- - - - - - - - - - - - - - - - - - - - - - - - U. W.O. Medical Journal 69 (2) 1999

PROMOTION AND PREVENTION
EDITOR:

DAN MENDO

<;:A & ERIC

Wo

G

THE TESTICULAR SELF-EXAM:
SHOULD A WIDESPREAD EDUCATION
PROGRAM BE IMPLEMENTED?
By Asif Doja, MEDS 2000

e pite the fact that te ticular tumours account for
approximately 1% of all neoplasms in men, they are
the mo t common form of cancer in men between
15-35 years old. As a result, in the la t 15 year , there ha
been an empha is by various groups to en ure that
phy icians are instructing young men on the testicular
elf-exam (TSE), and to en ure that men are in fact
performing this exam on themselves. It appear that many
groups see a parallel between brea t cancer in women and
te ticular cancer in men and thu , they also see a parallel
between the brea t self-exam (BSE) and the TSE. 1 The
question arises a to just how effective the BSE and TSE
are when compared to one another and if it is in fact costeffective to implement widespread TSE education to
young men and physicians.
Te ticular cancer, as mentioned above, is a mainly a
disease of tho e under 35, as 20% of cancer in thi age
group originate in the te tide. Thu the di ease tend to
affect individual in the prime productive years of their
life. The incidence of te ticular cancer in Caucasians has
doubled over the pa t 50 year and now is approximately
5.0/100,000 (in contra t, the incidence for breast cancer is
6 /100,00). The age adju ted mortality rate, however, has
been steadily declining, mo tly due to the development of
more effective treatment modalitie . The current 5-year
survival rate for most early stage testicular tumours is
about 95%, although morbidity from treatments tend to
be high.2
The mo t important risk factor for te ticular carcinoma
i cryptorchidism, or undescended te te . Other ri k
factor of le s importance include a family hi tory of
testicular cancer, high socioeconomic statu , Cauca ian
race, gonadal dysgenesis, a congenital inguinal hernia or
hydrocele and being the child of a mother who had
exposure to exogenous estrogen during pregnancy.
Testicular cancer can be grouped into 2 main major
pathological categories. Seminomas account for 40% of
te ticular tumours and tend to be radio ensitive. oneminomas (embryonal carcinoma, choriocarcinoma,
endodermal inu carcinoma and teratoma) make up 50%
of all testicular tumours and are generally les
radio en itive. 2 One al o often ee tumour of mixed
histology. Between 50-60% of eminomas and 30% of noneminomas pre ent at an early tage of di ea e. Despite
this, even patients with meta tatic di ea e have about a
90% cure rate.
Both types of te ticular tumour tend to pre ent with a
painle rna within the ub tance of the te tide and it is
with thi rea oning that the te ticular elf-exam wa
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developed. The exam hould be done while the scrotum i
warm, preferably after a bath or hower. Both hands are
u ed to roll each testicle between the thumb and finger .
The te tes, epididymis and spermatic cord hould all be
palpated and lump , irregularities and any dragging
sen ations should be noted. It is recommended that men
aged 15-40 years perform the exam monthly. 3
The American Cancer Society recommends that BSE
be performed by all women beginning at age 20 and thu
sho uld be taught to every teenager as a method of
preventative medicine. The ational Cancer Institute
recently found that 90% of women in the United State
were aware of the BSE, although only 24% actually
perform monthly elf-exams. 4 Thi can be contrasted with
a recent tudy in which a survey of male college student
indicated that over 41 % had been taught TSE, but only 8%
actually practiced TSE once a month. 5
It i thus argued that more of an emphasis needs to be
placed on teaching TSE to men in order to attempt to
detect te ticular cancer a early as possible, in an attempt
to achieve a near 100% cure rate . Should as much
emphasis be placed on the TSE a the BSE? Goldenring
and Purtell 1 ugge t that with the cure rate for cancer of
the teste being greater than that of brea t cancer, and with
the TSE being a much impler examination technique, our
current effort are nothing hort of inadequate. Their
sentiments are underscored ~ many in many other works
by public health advocate .u ·6
There ha al o been hown to be a documented delay
between the onset of y mptoms and the dia3nosis of
te ticular cancer - u ually in the order of around month .
Many point to this delay as support for more education
with regard to TSE. Unfortunately, thi delay appear to
have more to do with reluctance on the part of both the
physician and the patient. Patient tend to be reluctant
because the y fear the diagno i , believe the y are
respon ible (i.e . through masturbation or exce sive
phy ical activity), or fear that treatment will leave them
impotent or terile. Doctors have been shown in 1 I 3 of
ca e to be re pon ible for the delay, mostly due to the
a umption of the mas being a more benign condition
uch as a h ydrocele or epididymitis, or because they are
reluctant to diagno e a relatively rare cancer in a young
man .7 As are ult it doe not appear as if encouraging TSE
educa tion alone would be sufficient to prevent a delay, a
the actual finding of a rna does not appear to be the
primary problem.
Some argue against TSE by claiming that there would
be a great amount of anxiety caused by the number of
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false po itives generated as the re ult of yo ung men
mi takenl y assuming that benign condition w ere
cancerous. 6 Thi has been refuted by a tudy by Weist and
Finney w hich showed that training in the TSE among
college and high chool tudents was not a ociated wi th
elevated anxiety tates.
The bigge t evidence against putting more money into
the amount of TSE training comes by examining how co t
effective widespread education would be. A mentioned
before, there is an increa ing incidence in te ticular
carcinom a amongst yo ung men, but i an increa ing
incidence a good enough ju tification? The answer mu t
be no, since creening will only affect mortality and not
the actual incidence of the disease. Since mortali ty (a
hown above) is already o low, the scope for screening to
have an effect i very mall 9 . In other words, even if TSE
were to reduce mortality by half, 500,000 men aged 15-34
would have to perform monthly TSE' for one yea r in
order to prevent one death.7
The major problem with TSE is that no randomized
control studies have been performed to determine it
actual benefit. Moreover, it i unlikely that uch a trial will
ever be performed, due to the rarity of the di ease, the low
number of death from it, and the high co t of such a trial.
There have aJ o been no studies that show that men who
examine their te te are more likely to detect cancer earlier
or ha ve an improved outcome than men who do not.
Additionally, very few studies exist which show that
teaching TSE motivates men to perform it, yet alone to
perform it correctly.9
It eem clear that there is a need to educate young
men about the early pre entation of te ticular cancer in
order to reduce the delay in diagnosis, but there seems to
be little hard evidence supporting widespread education
regarding TSE. The que tion then ari e a to why there
eems to be o much support for TSE? Is it becau e of the
parallel being drawn with brea t cancer and BSE? If thi i
the ca e, it eem imperative to stre to all health care
advocate that a correlation cannot be drawn betwee n
the e two di ea e simply becau e they each affect only
one ex.
If wide pread TSE education is ineffective, then what
hould be done? It seems that if any education is to be
done, it hould be aimed at primary care physician . The
focus of thi education hould not be on the TSE, but
hould rather be to simply rai e awarene of te ticular
neoplasm in general. If family phy icain maintain a high
index of u picion for testicular carcinoma when dealing
with any crotal mass, we would mo t likely ee an earlier
diagno i of the e lesions. Additionall y, famil y doctor
hould be aware of the u e of other inve tigative tool ,
uch as scrotal ultrasound, when the clinical exam prove
to be equivocal.
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ANGLE TUMOR
By Allan Vescan, MEDS 2001

Y

ou are a econd year urgical re ident, rotating
through your two month ervice in otolaryngology
when presented with the following clinical scenario.

On Feb 15 an othenvise normal clinic has been booked for
the day. You are feeling particularly refreshed after a rare full
six hours of sleep the night before. The first patient you see that
day is a woman by the name of "Mrs. Smith." On history, Mrs.
Smith reveals that she was referred to the local E.N. T. specialist
for her recent difficulties with hearing in her right ear.

Upon further discussion, Mrs. Smith describes that her
hearing lo s has been getting progressively worse in the right
ear for the past 3 years . She also mentions that it is 110w so
evere, he is unable to use that ear when speaking on the phone.
2. Di cuss other points you would want to explore
during the hi tory that would be pertinent with re pect to
hearing loss.

Mr . Smith reveals that she has also been experiencing a
"hum" in her right ear that has been pre ent for approximately
the same length of time as the hearing loss. She also recalls
feeling unsteady at times, but denies any vertiginous epi odes.
The re t of the history reveals 110 other significant details. On
examination, a Weber test lateralized to the left and a Rinne test
was positive in both ears. Romberg's sign was positive with the
patient falling to the right. Further physical exam reveals no
other abnormalities. The audiogram below was performed today
prior to clime.
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4. Your clinical experience to date leads you to u pect
a cerebellopontine angle tumor, indicate the "gold
tandard" imaging modality in thi cenario and li t the
common tumor of the cerebellopontine angle.

You have now completed your history and physical exam of
Mrs. Smith and proceed to present the case to the consultant at
clinic.

and li t a few of

1. Identify two cia e of hearing lo
the common etiologies of each.

0

3. Discu the above finding with relevance to the
ca e at hand, including analysis of the audiogram.

---

Figure 1. Audiogram of Mr . Smith at time of presentation.

5. You are asked by the con ultant to give the mo t
common pre enting ymptom of an acoustic neuroma
and their relative frequencie .

The con ultant and yourself have viewed the MR1 images
and discussed the findings with radiology; you feel rather
confident that the problem at hand is an acoustic neuroma
affecting cranial nerve VIII. You discuss with Mrs. Smith your
suspected diagnoses and proceed to inform her that you feel
surgical removal of the tumor is the recommended treatment
modality.
6. Di cu the different surgical options available and
common complication a ociated with each.
ANSWERS
1. The two cla e of hearing lo s de cribed in the
literature are conductive and en orineural hearing lo .
Conductive hearing loss re ults primarily from lesions
involving the external and middle ear, including the
tympanic membrane. It can be further cia ified a either
congenital or acquired . Some example of congenital
malformations of the ear include atresia of the external ear
and ossicular abnormalitie . Acquired malformation
include most commonly, cerumen impaction of the
external canal, otiti media either uppurative or erou ,
chronic otiti media (cholesteatoma and ero ion of the
o icular chain), oto clerosi and traumatic perforation of
the drum with o sicular disruption.
Sen orineural hearing lo i the result of a lesion to
the cochlea or auditory divi ion of the VIII cranial nerve,
or both . It can al o be divided into congenital and
acquired, with genetic inheritance and maternal rubella
being two example of congenital hearing loss. Some
example of acquired hearing lo include, pre byacu i ,
noi e induced hearing lo , ototoxicity due to
arninoglycoside or cytotoxic , inflammatory condition
uch as meningiti , mea les, mump , syphili and chronic
otitis.
eoplasm
uch a acoustic neuroma and
idiopathic etiologie uch as Meniere's disea e have al o
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been implicated.1
2. Other features that would be important to elicit on
hi tory include: a ociated otalgia or otorrhea, tinnitu ,
imbalance or en ation of vertigo, exce sive n o i e
expo ure, pertinent drug hi tory (ototoxic agent ) and
family hi tory of hearing lo .2
3 . The result of the Weber and Rinne te t are
indicative of a ensorineural hearing lo in the right ear.
The po itive Romberg' ign can be due to a right- ided
ve tibular di order. The combination of a progre ive
a ymmetric hearing lo , tinnitu and ve tibular related
dy function i highly ugge tive of an acou tic neuroma
of the the right VIllth cranial nerve.3 Audiogram analy i
further validates our uspicion of a evere right ided
hearing lo .
4. The gold standard for the diagno e of an acou tic
neuroma i gadolinium-enhanced magnetic re onance
imaging. The ensitivity of high re olution cr to pick up ·
acou tic neuroma of le than lSmm ha been hown to
be only 4 %.~ It ha b en ugge ted that the increa e in
u e of MRI ha enabled the mean tumor ize at the time of
detection to decrease from 27.9mm in 1975 to
16.5mm in 19 9. 5
The common tumor of the cerebellopontine
angle include 78% acoustic neuromas, 6.3%
meningioma , 6.3% cholesteatoma , 5.9% gliomas
and remaining 3.5% ab ce e and mi cellaneous
tumour .6
5. The mo t commonly encountered
pre enting ymptom in patients with acoustic
neuroma were hown by Gillman and Parnes. 7
Thi wa done with a retro pective tudy of 83
patient , w ith 84 acou tic neuroma , over a 6 year
period. Hearing lo wa the mo t common
pre enting ym ptom at 91 %, tinnitu s 51 %,
imbalance 49%, headache 15%, trigeminal nerve
dy function 13%, facial nerve dy function 7% and
other 1%.

Some of the more common po t-operati ve
complications include CSF leak at 11.2%, evere headache
at 11.2%, wound 6%, cranial nerve injury (except VII and
VITI) at 4.2% and meningiti at 2.8%. 7
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ca r e solutions enabling peop le to live
lo nge r. healthier and more active lives

6. There are e entially three urgical options
available when con idering removal of an
acou tic n uroma. They are the translabyrinthine
approach (TL), middle fo a approach (MF) and
uboccipital approach. Each procedure ha its
own advantage and di advantage . The goal of
acou tic tumor removal i pre ervation of facial
nerve integrity, total removal of tumor to prevent
recurrence and mortality and, when po sible,
pre ervation of hearing. Preservation of hearing i
only po ible with MF and SO approache a the
TL approach must sacrifice hearing in the affected
ear. The other two objectives can be achieved by
all three of the surgical option . Other
management options in certain situations include
tereotactic radio urgery and observation 3
Further analy i of the urgical approache will
not be done in this case report.
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T

here i an adage that "a mediocre teacher teache , a
good teacher explains, and a great teacher inspire ."
Apparently, orne lecturer believe that a mediocre
teacher preache , a good teacher bore , and a great teacher
edate . It i rather amu ing to think of all the a orted
cenarios that can and have played out in the classroom.
Take for in tance the lecturer, who when que tioned,
w ill reply with "someone el e in this course will be
teaching you thi ." While thi certainly may be the ca e,
often it i not. This leave me wondering whether th
lecturer ju t doe n' t know the an wer, or whether it might
omehow go against the alignmen t of the co mic
con tellation to enlighten u with the answer. I didn' t
realize that a lecturer could plead the fifth .
It i al o rather comical to have a lecturer who ha
gotten stuck with teaching a particular clas . Thi i
unfortunate for both lecturer and cla alike. In orne case ,
the lecturer i unaware of what information to emphasize,
nor are they always as capable and knowledgeable on the
given topic. A the lecturer drone on, the ubconsciou ly
flog them elve with a Singaporean cane for agreeing to
cover their colleague' norkeling emergency. The cia

PHYSICIA NS NEEDED
Leamington Di trict Memorial Ho pi tal. ituated on the beautiful bore of Lake
Erie, a hon drive from Windsor and Detroit needs physicians in:
G. P. Anae the ia
Emergency Medicine

The Hospital provides a full range of services for a catchment area of 4- ,000
population. including 24 hour Emergency ervice. General urgery and
OB G
urgery. The Hospital ervice Re tructuring Commi ion has
mandated that the Hospital continue its· present range of services.
A well. the area has been de ignated underserviced and there i a need for
additional:
Family Pby ician
The Town of Leamington. located in the uthemmo t pan of mainland Canada,
enjoys numerous recreational facilities including excellent marinas and golfing.
as well a progre sive schools and churche of all denominations. Point Pelee
ational Park and Pelee Island are also local attraction .

ob erve thi unfortunate acrificial lamb with contempt a
they enjoy their third hand of poker.
Then there i the lecturer who engros es the cla into
a edated tupor remini cent of a good benzodiazepine.
The e lecturer are famou for inspiring impromptu
" nack-time " or regre ion to naptime of a childhood
pa t.
One of the greater challenge in li tening to lecture i
tran lating and decoding the rhetoric. "Don't bother
writing thi down" has come to mean "You better know
thi s word-for-word," and "Yo u are the doctor of
tomorrow" i now under tood to mean "God help us all."
Then there is the ea ily tran lated "Today, we have a
very pedal gue t for you" which ha come to mean "thi
wa the only per on we could find" and "thi material i
not te table" ea ily tran lates into "you have my
permi ion to go home and frolic among t your elve ."
While my argument may eem critical of lecturer , I
do hold them in high regard. In fact, if I could, I would
ing their prai e right her , for page and page on end .
But adly, I am no Pavarotti and thu will re trict my
inging to the tormenting of my brother.
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QrrerllllrQ-Iernt data frlJn ch:al tnals 00 i1Cl nicate .., adw!rse elfea ci 00 lhe IUnallens
~~~~~~~

Si!JWi3t decreases II c:mAaln,j ~ levels II pa
treated
aiDrVasla ;nl IIIler SlatllS haYe been
o!lser¥ec1. Til! ch:al sq1IICn:e ci a ~ m;rtoon statrl-llCl£8j de!i:tlny ci ~ has ra been
estaltislted l 'las been repm~ that a decrease 11 i11jOC<Wtial ~levels axil lead Ill~ t3liac
fln:oon II patentS
borOeoi1e ronges1M! tm1 faln (see SEl£CTID BIUlGfW'IM
Ellect on~ (al
h some pabenls, lhe beneficial elfea ci klwered mta1 ~ <n1 Ul.-C levels may be I81IY bU1Ied by a
an:omitr1t irmase II 4>(a) lew!ls.lhli fLrther e>periera is obtained, l is suggested, where · that measLiel1leflts ci sel\.ll1 Lp(a) be folowed ~ II patients plaa!d 00 aDvaslalrl thenl!lY (see SElECTID BIBUlGIW'HY).
"" ~ l1jJmensi:M!y syrOome has been repml
IIIler tt.1G-OlA recLaase rtixars wto:l1 has rcUted
1 cr nue ci lhe fcbw'g featiJes iWlallh)'laxiS. a1gOldema. ~ erylhematous-l<e syrOoine po!ymyaiQia
i11eu1W:a. va!Wibs. pt1Jll13.ltrnrnliocyl>pe ~ tem1ytx; anemoa. posiliYe NV<. ESR raease.
eosrqtolia,
• malgla. tlliC<m. aslhenia pl1ollserisitr;. !eYer. c:i*. lkJslwY,j. malaise. d!s!Jtea,I>XX:
ep<lermall1ilCIIItjsis, erylhema l1lililorme. rcldng Stelens-#nsoo syrOome. Alltr:l.9t ., date l1jJmensi:M!y
syr0-ome has ra been desatied as such. l.JliTOO strud be ci9:lnrued t ltjpersensltMty os suspectEd

Use jn f'IJcNncy
UPITOR Is contraiudicated dLring pregnancy (see CONT!IAINDICATIONSI.
Altterll!l:lera os a ctrtrw; IJili'!SS <n1 cls:xllCruaoon ci lipd-bterrJ ciugS clmg ~ strud haYe
rrca:t oo lhe u:ome ci llrQ-toon t!1eripy ci 1J111a1Y hypodde!>1eotti•oa. O'oeslilrol <nlllller IJll(tl:ls ci
ctOeslerol bllsyrltlOSIS a'e OSSillllal aJn1)CriefiiS ,... felal deYeq)mert (R:Uirl;j synlhesiS ci Sli!llXds <nl eel
mentJranes) Sn:e tt.1G-OlA rBiiJ::lse rtixars decrease ctOeslerol ~ <nl ~ lhe ~ ci IIIler
bUJgicaly aaM! Slbstltces derMld frlJn ctOeslerol, lhey may caJSe la-m llllhe fei!JS v.tat 3li1nSia8d ll Jleo-

.-.nworren.
Tlue a-ero IDta oo lhe use ci l..I'ITOO clmg ~ l.JliTOO strud be 3li1nSia8d to wanen ci ~
age my wl1en such pale1S a'e hi!tiY td<ely llllii!CeM! <nl haYe been l'1lonned ci lhe pocentJal hallrds • lhe
pa

becomes prBIJ1<It feWs.

IJ(m1!lal r9t ll

takllg l..I'ITOR. lhe B'ug -

be <isann.ed <nllhe patet iiR)I1Sed ci lhe

h latS, mil< cxn:enuanons ci allrv.!Stllrl a'e srnilar ll t11Jse II plasma. liS i1Cl wllelher 1tJs ci'ug IS excte!lld
11 IUna1 m1t BecaJse ci lhe pocentJal n adw!rse ieaciO\S it iUSI1Q 11farls. wanen takllg l..I'ITOO strud ra
t:reast-feed (see (X)NTRANJ(;A.Tn.!Sj.
Ti1!11liT'St~llapeOatnc~IS

lll<bsescil..I'ITOO~to!Kl~b'1year 11 8pallei1IS

l1omozygw; famllal hypoddtseittiloa. No clncalcr ba:l1emcal alramalilleS 'Mlll! reponed 11 these
palleniS.

~

Treatment ~ II aliAs 70 years lr older =2211W1lh <bses ci l..I'ITOO ~ ll!Kl mg/day has denmslla!Ed
that lhe safely m effeciNeness ci at~nas~alrl 11 1t11s ~ was Sillllla' to that ci pa!BltS <70 years ci age
~ evaklatrlll ci aDv.1S1a 11 Sliljecls rNI!flhe age ci 65 years i:tclcates a1 n:reased ALC N. a
~ measue. lhe lllwesl dose strud be aOrnstered il1illally (see PHARMAC(X_OGY ftmrt
~ SElECTID 88..KlGW'HY)
Plasma IXllnll1lllltl: m lll.-e o..emg e!li:acy ci l..I'ITOO was shown ., be srra 11 palJei1IS 'Mlh moderate
nrtalllSUtfictercy ~
pa
ncrrre1 nrta1 ftn:llon. ~. sn::e several cases ci ihabcbtty<tjsiS
haYe been repm!11 palJei1IS Wi1ll a hisl>ry ci nrtalllSUtfictercy ci lrl<i1lwn sewnty, as a ~ measue
<nl perxiJ;j fLrther ~ 11 nrtal disease. !he lllwesl dose (10 mglda)l ci l..I'ITOO strud be used II these
patats. Srnla- ~ apply 11 patJeniS Wilh severe llniiiiSUffoency (creatme c1eararce <:11 iTUmll
(<0.5 ntlsecl): lhe lllwesl cbsage strud be used <n1 fl1)lemented C3IOlUSti (see Wl>m~. ~Effects
~. Drug l1eraaxr$l
Refer alsO to DOSAGE IW ADMINSTRAllON.

Endocrine flllction
tt.1G-OlA nlllCiase rtixars mrfBe
c:hllestilrO syrftSIS <n1 as such mo;tt html:aly lUI aD'enal inW
gorslal saod fJO(Laot Ch:al Slides
<n!Oite' tt.1G-OlA ilW:Iase rli*rs haYe Sl.ll}.leSted that
these agons 00 i1Cl ill1l:e plasma IXJ1iSo! oornrvaiOllr ll1lilf aD'enalleseM! <nl 00 i1Cl ill1l:e tasal plasma
tesllSleRJle an:erca:ot tbnever. lhe effeas ci tt.1G-OlA lec1case
00 male rerti!y haYe i1Cl been su.ded
11 adecJ,iate ll.ll'bin o! patJei1!S. Til! effects. f Blfl, oo lhe pottJtry~ axos 11 ~ wanen n l.l1roN:t
Panems treatEd
atlnaslalrl who deYelop ch:al ewlence ci enOOc:rre dysf\n:OOn strud be evakla!Ed
3fliY!V'Itett camn strud be exerased .., tt.1G-OlA recLclase mbliX' cr 1111er agent used m kMer ct0es1ero1
levels IS aOrnstereO to palJei1IS I1!CI!I\onJ IIIler MJgs (e g keloan!l!ile. ~ lr cmetxilel tal may

rra:rs

decrease lhe levels ci erdlgerws Slerol! to1lo'es.
O!ua lntel'actions
Coocomitartt Therapy willt Other Lipid Metabolism Regulators: CaOOned B'ug t!1eripy strud be 3lliJOl!Ched
W1lh caJ!01 as rtfomta:m frlJn conllOied Slides IS imlted.

Bile Acid Sequestranls:
P;u:nts W'lt!
p modera!e tMlerd!lles!emlem!a l.Dl-c reci.CIIll'l was !11l<lter ..nen L.FITffi 1omg aro ~
20 g ~ um•• -ed (-45%) 11m..nen e1111er aug was aOOns:ered able (-35'1o lor L.FITffi aro -22'1. lor

"*'
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f';Q:nls Wi1h SlM!!l! twg:ui'W>1e!t*ma. l.Dl-c re<lam was srra (-53'1o)..tlen Lffiffi 40 mg aro cDe5qD 20 g
~ IXlilOmiSiered ..nen ttrl'!Bed " Ita WiilllJ'ITffi Ill mg able Plasma llli1B1IlilD1 ci amasw1 was (awoumtely 26%j..tlen lJ'ITffi 40 mg ~ cDesqD 20 g ~ IXlilOmiSiered ttrl'!Bed Wilh lJ'ITffi 40 mg
able
· lhe c:orrbraiXln aug ltoerill\' was less ettecwe 11 ~ lhe il1gl',a!rlles ~:mL.FITffi ~ 11
txxh types of ~ pa1JeniS (see f'HARMAC()_OGY Ch:al SIOOiesl
wten lJ'ITffi IS used cxrrurerlly Willi ~ a '&"If Olller resrl. <r1 rurval ci at least 2 hem shWd be
rrootalled lhe I'M) <iugs. sn::e lhe aboorplicn ci L.FITffi ill!)' be mpared l7f lhe resrl
Fib<ic Acid Derivatives (-~ Fenofibrate, Bezafibrate) and Niacin (Nicotinic Acid): Alltr:liJg1 there IS
ill expenerce
lhe use ci L.FITffi gr;en cxn:mentt,o Wi1h fin: aad denva!M!S aro roaan. lhe benefiiS aro nsks
of Sl.dl oorrbrled ltoerill\' shWd be careflly CXlOSidered The nsk ci ll1)'0ila!hy <i.mg treatmenl Wi1h- <iugS 11
thiS class IS roeaseo
canmnt aannsuatm (see w~ Muscle Effecls).
Coumarin Anticoagulants: L.FITffi hOO ill th:aly sqlifiC:ar'l effea on IJ(iltfllmlillllne ..nen aonnstered ill
patJefitS receYI1!l d'l1r«: wMlm ltoerill\' (see SEl£CliD Bll.XlGIW'HY).
Digoxin: Coaannsuaoon ci ~ <Dses ci L.FITffi aro 11gaxr1 roeaseo steady-Slate plasma 11gaxr1
an:eooaoons tJv awoxrnately 20%. Pate1IS 1a1<11g 11gaxr1 shWd be ITOlllllled cae~y aro awqJnately
0ra1 Con1rac:eptives CoaOrnsu1W1 ci L.FITffi iOih .., aa1 ~. !XJ1ar1r"g 1mg rae11w10tre aro 35iJ!l
ll!hr¥ esuadol. measro plasma~ (PI..C leYe!sl ci rae11w10tre aro ll!hr¥ esuadoltJv ~
:m~o aro 20%. respecwe~y Ttese rcreases shWd be CXlOSidered ..nen seloc:!n;l .., aa1 ~
Antlcids: Mnnsuatm ci
aro rna<;Jli!SU11 based . . - , Sl.dl as Maab<" TC Suspension. L.FITffi
decreased plasma c:oncen!ra1D'IS ci L.FITffi l7f awoxrnate~y 35% l.Dl-c reci.CIIll'l was Jill altered tu lhe
trlQI'IceRle-~ effea ci L.FITffi ill!)' be affecled
Cinetidine: Mnnsuatm ci cmetDre
L.FITffi lid Jill alter plasma an:eooaoons a l.Dl-c ~ etfi:acy
ci L.FITffi. howeo.e'. lhe ~-~effect ci L.FITffi was reOJ:ed from 34%10 26%.
Cytochrome P-450-mediated ln1l!ractions: AnvaSialrliS ll'li!tltdled bV lhe cyiXtrome P-450 ISOIW)me. CYP
3A4 Etyttrorn)on. a CYP 3A4 mini', meased aDVaSialrl plasma leooels bV 40%. Calinr&slralm ci CYP 3A4
riUas. Sl.dl as ~ ~ IT<Il't*le ardm:s ll'cldr!l er)1trarr,u1 aro clan1trtlrTr,CI. llllfTU'OSlWI!S
~). 32!lle ~ agem J e ilaarez!lle. ke10cona2!lle). a lhe ~ refa2!xb'e l1liY haYe lhe
potefllai " raease plasma ilJIB1IIa1mS ci tM:l-cM recU:tase rllliiDs. tiCI.drl;l Lffiffi (see SB.£CTHl
l3ll.()GW'HY) CaDln shWd lll.IS be l!lleiCISed iOih aroJl'litl'l use ci these agentS (see WNHK3S.
Plmracd<nell: n.mms. Musde Etl!as; l'lffillJ1X)!S. Aera mJ1i:IErY;y aro ErO:x:rre Ftrctm; £XJS.~« f!W

aunn.m

A!M'.ISTRATnl; SB.£CTHl131l.()GW'HY)
~ sn.dy Wi1h l'ealtt1y SliJ!ec!s. <nOrn;natm ci

a

maxm.m <ilses ci txxh alllMSialll (8) mg) aro Tafenach
( 20 mg). a CYP 3A4 9bilrale. was sllaMlill pnxix:e a rrodest raease 111Bferai'e AI£. The Ole l'1teMI
remaned li'Cimged. sn::e .., rtera:~D~ belv.een these 1>10 <iugS cam be ellixled 11 pa:B1lS Wilh
Jlll(isposr1g tacm lor <11t1y1tma. (e.g preexJSIIlg IJ1)01ged OT flti!MI. seYere cao:ay arterY llsease
h)!D<alemoaj. taWX1 shWd be l!lleiCISed when these agentS in ruDnnstered (see WNNN3S. l'lamacXlkret.c

ruraams. £XJS.~« f!W AOMNSTRATml

Antipyrine: ~ was used as a rm-speafic model for <iugS IT>!IaiJoized tJv lhe iliDOSOI11al hepatJ: enzyme
system (CytDclircrre P-450 system). L.FITffi 1100 ill ettea on lhe ~ ci ~. lll.IS rneracoons Wi1h
Olller <iugS IT>!IaiJoized Yla lhe same cyiiXtrome ISOZyiTleS in Jill e>peeted.

&yttvomyan: ~ heallhy · plasma an:et1l'a1DIS ci meased awoxrnately 40'Io W!j!J
umrn 511i!OOII ci L.FITffi aro eryhum)m. a 1mwn rl1bllr ci CYP 3A4 (see WAfN.lGS. Musde EtfaasJ
Other Concomitant Therapy: ~ dirw:al 51\Jies, L.FITffi was used CXJ1COOll1<r1ll Willi arltr,lJerter&o agentS aro
es1r0ge11 replacement ltoeriiJI' WiltoJt eYidence " date ci th:aly sognfi3lt a<tooem! rneracoons k1lerlicOOn 51\Jies
W'1h speafic agen1S haYe Jill been cord.cted
Patienls with Severe l!ypeu:ho!esle!o!emia: Hi!jler aug 005ages (8) mg/da)i ~ fa sane pateliS Wi1h
seYere hyperdOesleroie {il::IJdng familal hypeichoiesteoolei I i.a) in assroated
meased plasma i!M!Is fi
ai!JVaSiall1. caution should be exercised in such patien1s who are also severely renally impaired, eldet1y,
or are concomi!antfy being adninistered digoxin or CYP 3A4 Inhibitors (see WARNINGS, Pllannaalkineti
Interactions, Muscle Effects; PRECAU110HS, Drug lnteraclions; DOSAGE AND ADMINISTRATION).
Drug/l.aboratory Test lntmctions
L.FITffi l1liY eiMI1e sen.m tr.I1SafTW'BSe aro aea1n1e ~ ~eooe~s (from- rruscle). ~me <itferenllal
diag'a;IS ci chesl par1 11 a pa1et on ltoeriiJI'
L.FITCR catiac aro roncatiac tractms ci these i!OZj!Tli!S shWd
be delennni!d
ADVERSE REACTIONS
L.FITffi IS generaav wei-IOielated. ~ reaams haYe USlJaly been
aro llllllSii!ft. ~ aJillliJied dirw:al 51\Jies
~ aro ~ ~oYe Slides iOih Olller i!Jd-UoYemg agentS) rNOiw1g 2502 patets
<2% ci patJefltS ~ discontnJed rue 10 act.oerse expenerces anrtutallle 10 L.FITCR Of these 2502 patets,
1721 ~ trealed fa a least 6 IT'O'IItiS are 12531or 1 YfR1 a mae
~ expenerces llCCIIT'tg at .., llCiderce <!1"' 11 pateliS fB!iCpatrlg 11 placello<onlrol ch:al Slides ci
L.FITffi aro '"IXJITed 10 be posstlly, ~ a defntely aug reta ed in sl1aMl 11 Table below
TABLE 1. Associated Advelse Events Reported in <!1% of Palierrts in Placebo Conlrolled Clinical Trials
Placebo % !n 270!
UPITOR % !n 1122 1
GASTROitmSTlHAl
Constipation
Diart1ea
Dyspepsia
AatUence
Nausea
NERVOUS SYSTEM
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MISCWAHEOUS
Pain
Myalgia
Asthenia

<1

<1

1

The folowrg --.at a<tooem! everts ~ '"IXJ(1ed 11 dirw:allnals. Jill al eYentS isted below haYe been assroated
Wi1h a causal retato1Ship ill L.FITffi therapy: Muscle trarT'!JS, IT1)'0SIIIS, lll)q)allly, pareslhesia, pef1i1eral neuopallly,
p;rcrea
hepa • ciOestatx: jlllllOOl, - . 'oU!lllllg. ~ flM!US. rash . ~. hypelgt,ocemoa. arC

['rmry tt.g:u;tdes!ero arcj CarOOed !Mpcedl tt.g:rtilQma. kQ.<h mia! CarOOed tM!!!!1iJoderT!
The rearnmended 005e ci L.FITffi IS 1omg once a day The rnap11y ci pa
~ aro ITii!il1lan Wget
cl'oles1arol leooels
L.FITffi 10 mglday A5q'llfi3l ifleralaJbc response IS E!'o'OeR
2· llld lhe
maxm.m response IS USlJaly acheYed Wi1hl1 2-4 weelcs. The response IS mal1lalled <i.mg d'l1r«: ltoerill\'
Doses C3l be gr.oen at '&"If 11ne ci lhe day
a Wll!nl food. aro shWd ~ be gr.oen 111he IM!IWYJ Doses
shWd be niYOJai2ed acco:OOg 1D ba5eft LDl.C aro'a TG leooels, lhe desred LDl.C aro'a TGlirge! (see lhe
De!eclm aro Maragemert ci HyJ:ed"*">1att:~•oa. l'b1<r1!J ~on~ aro Olller Dyslpdemlas
(Canada) aro'a me 1.5 Nai01al 01>1es1era EdJ:alm Progam [lnl'l). lhe !J)al ci ltoerill\' aro lhe paoort's response
~ ci cb;age. if roecess..y, shWd be 111a<2 at l1leMils ci
a mae. The rearnmended 005e ooge lor
rrost patJefitS IS 10 " 40 mgA:Iay The mamun 005e IS Ill mgA:Iay, whch l1liY be ~ 11 a nwoty ci patJefitS
(See

4-

seam belolrol

Upid le¥els should be monilored periodically and, if nocessaty, the close of UPITOR adjusted based on
target lipid le¥els recommeoMied by guidelines.
The 1o1owrg reru:oons 11 uatcl'oleslarol aro l.Dl-c ~eooe~s haYe been OOseMd 11 2 OOse-response sruies, aro
l1liY 5el'le as a~" treatment ci pateliS Wi1h
10 moderaie hypeid-oleiioa.
TABLE 2.1lose-Response in Patien1s Wi111 Mild to Moderate l!)llen:holesletoleniia
•
Percenl O!a!lje from
l.IPITOR Dose (mg/day)
40
Ill
10
20
(!i=?O)
~21 )
~22)
IN=23l
Totai-C: 7.1 ITllld/l'
-37
-45
-33
-29
(273mW<lJ'
LDl-t: 4.9 mmoiA.'
-39
-50
-43
(1 90mW<lJ'
'ResU1s are pooled from 2 OOse-response siJJdies.
'Mean baseline vaus.
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Seym Dyslioidemias;
~ patJeriS

aro heletozygous f3nial hypelcholesteoolei•e aro
(T)!le 1), t'qler 005ages ~ 1D Ill mg/da)i may be~ (see WNN~ . l'lamacXlkret.c

seYere ~. n:ldr'g horrozygoJs

~

ruraams.Muscle Effecls; PI£CAlJTl:N). D'ug nteraclionsl
Concomitant Therapy
See PR£CAIIT10NS, Drug Interactions.
Dosage in Patien1s Wi111 Renal Insufficiency

See PR£CAIIT1QNS.
PHARMACEIJTICAL INFORIMJION
P!l!!! SUbstance
Pqler N<rne· Al;t'I3Sia!r1 C<icun
Olernl:aiN<m! (R-f!"R1J-2-(4- ~. ~- 5-(1 - ~3-phenjl-4-(~ 1tlil\'mlfe-' .J'ietlGnlC aad. C<icun sail (2.1) Ui1)<iale
Err4W'cal FanUa (CJ!;.FN,O,),Ca• JH,O
lot8:IAar Welijt. 1209 42
SlnalaiRirnlAa.

r

C<icun IS a
ID cif-wtl!e aySialile powder illat IS IJactl:aly I'ISOUlfe 11 a<JJeCl.iS
4aro below AllrvaSia e<icun IS oe:v 'fiiP.If SllUlle 11 wat!>", ~ 1 4Jta;itlare buffer aro
sigl1ly SllUlle 11 e~~mo~. aro fre8y SllUlle 11 rnelta'd

~: Allrvastatll

solJIIn; ci ~
ace~~JrWE

Tablet Composj!ion:
Each Iailie! anar&S eslher 10 mg, 20 mg a 40 mg alOIVaSiatrl as lhe aciM! rvedieft. Each ialllel also contar1S lhe
lobwY;j ron-rnedl:nll ~ C<icun cartmale. i31lella wax. aoscamelose scOOn, ~ atilse.
taaose rnorn'iy<tate rna<;Jli!SUOsteaate m01lCiySialine atilse. ~ ~. polyelhylene
rJyr:JJ.. tat:. utnun cbxle. pdysabate 111 aro Sll1'lellw:ale errUsion.
S!abi!ity and S1or)ae Recommendations
S10re at anroled roan lerr!leran.re 15 ill 25~
AVAILABIUTY OF DOSAGE FORMS
L.FITffi (ataVastalll cai::uri IS available ., 005age stl'l!r¢15 ci 1o mg, 20 mg aro 40 mg ar:rvas~a111 per Iailie!.
10 mg: wtore, elliptx:al, ttn-coated Iailie!. coded "10" on one Side aro "PO 155" on ill! <m!r. AvMie 11 bollles ci 90
ialllels
20 mg: \'hie elliptx:al, lim-coated Iailie!. coded "20" on one Side aro "PO 156" on lhe <m!r
11 bollles ci 90
ialllels
40 mg: \'hie. elliptx:al. lim-coated Iailie!. coded "40" on one Side aro "PO 1'57" on lhe Olller. AvMle 11 bollles ci 90
ialllels.
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Referentt!S
1. LI PITOR (atorvastatin calcium) Product M~raph, Parl<e-Davis Div., Warner-lambert canada
Inc , Oec.1998. 2. Dan A. Jerums G. eta/. A multicenter, double-blind, one-year study comparing
safely and efficacy of alorvastatin versus smmstatin in patients wi1h hypercllolesterolemia
Am J Gatr1io/1997;80:39-44. 3. Bertolim S, B•tlolo Bon G. eta/. EffiCaCy and safely of atorvastatin
compared to pravastatin in patients Wilh hypercholesterolemia. Alhetosderosis 1997;130:191 -7.
4 DaVIdson M, McKenney J, Stein E, et a1: Comparison of one-year efficacy and safely of
a1orvastat10 versus lovastatin in pnmary hypercholesterolemia. Am J Carr1io/1997;79'14 75-81 .
5. Hemonen TM, et al. Alorvastatin, a new HMG-CoA reductase inhiMor as monolherapy and
combmed with colestipol. J can1iovasc Phannacli ~ 1996;1(2). 117-22.

For a copy of the Product Monograph or full Prescribing lnformatJon. please contact

~

Co-promoted With

!'!!s!-ma1<etm !!l!!!ef!!!!lCe' Very rae repa1S ci seYere lll)q)ailly iOih a WI1IW rllabcilrn)Oysi haYe been '"IXJ(1ed

aro

cases

(see w~ . Musde Elfeas; I'!E'IJOOt,S, Rernl nsutDercy
[)ug nteractms). lsolaled
ci
~
allergic
(i1iOO,l lllitala. <W1QD'IIllJitt edema
~ ~~a l1liY haYe ill

aro

reaams

causal~~~-

aro

haYe also been '"IXJ(1ed

~ 005erVa1o1s- see PI£CAlJTl:N)
L.alloralory TesiS n:reases 11 sen.m tr.rlSallW1aSe ~eooe~s haYe been Jllled 11 dirw:allnals (see WAIHf:iSl.

SYMPTOMS AND TREATMENT OF OVERDOSAGE
Tlee IS ill specifi: treatmerllor atrvaSialll <M!I'OOsage Sfn*l<Wl o.oertbse OCill', ill! pa!iert shWd be trealed
~ aro &watM! mea5IJ1!S rmuted as reqnd. DJe "e<III1SM! aug ~ 1> plasma IJOflliiS,
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THE MUTAGENICITY OF SURGICAL
SMOKE IN ELECTROSURGICAL
PROCEDURES
By Sandy W idder, MEDS 2001
ecently, the safety of urgical smoke generated by
electrosurgery devices has become a topic of much
concern. Electrocautery is u ed to dissect ti sue or
cauterize blood vessels with a high radio frequenc y
electrical current. During the cauterizing proces , copiou
amounts of visible smoke are produced. The smoke is
malodorous and tends to irritate operating room
personnel by producing burning, watery eyes, respiratory
problems and nausea . Many animal studies have
demonstrated the ill effects of electrocautery smoke
plume, though its specific effects have yet to be
determined in humans.

R

SURGICAL SMOKE STUD IES
The combu tion of animal tissues lead to the
formation of carcinogenic amines. 2 Heterocyclic amines
have also been identified from environmental components
like airborne particles and cooking fumes. 3• 4• 5• 6 Animal
studie have shown that the mutagenic agents in smoke
from cooking fish and meat cause tumor formation in
rodent organs such as liver, lung, large intestine, and
mammary gland?
In recent years, electrocautery smoke has be en
demon trated to possess mutagenic properties. Analysis
of electrocautery smoke determined that its chemical
compo ition consisted of significant levels of benzene,
ethyl benzene, styrene, carbon disulfide and toluene.
Individually, these chemicals have all demonstrated
carcinogenic effects in both animal and human studies.
Styrene exposure in humans causes irritation of the eye
and respiratory tracts; some studies have even indicated
increa e in the frequency of lung and other cancers wi th
tyrene expo ure, though the studies are considered
inadequate by some.9 Carbon disulfide has been hown to
cause mutagenesis of human 9erm cells and to induce
embryonic growth retardation. 0• 11 Toluene exposure in
humans has led to increased risks of various
gastrointe tinal cancer a well as lung cancer. 9 Benzene
expo ure is trongly as ociated with an increased ri k of
leukemia. 12 As well, a large Chinese cohort study linked
benzene exposure to a greater ri k of lung a nd
nasopharyngeal cancer. 13
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Gatti et al. tested airborne smoke particles for
mutagenic potential in two strains of Salmo nell a
typhimu riwn (TA 98 ands TA 100) and found that smoke
induced by an electrocautery knife was mutagenic to the
T A 98 strain. 14 The aforementioned study supports an
older, similar experiment by Tomita et a1., which concluded
that the mutagenicity of electrocautery smoke condensates
was comparable to that of cigarette smoke. 15
SMOKE SAFETY MEASURES
Currentl y emplo y ed surgical masks filter
5 micrometer size particles.16 However, more than 77% of
the particulate matter contained in surgical smoke is less
than 1.1 micrometers in size. 16 As a result, other methods
are nece ary in order to diminish exposure to
electrocautery smoke.
The ational Institute for Occupational Safety and
Health in the United States has demonstrated several
methods whereby airborne contaminants generated by
electrocautery can be controlled. It is recommended that a
combination of general room and local exhaust ventilation
be u ed. Smoke evacuation methods may consist of the
simple attachment of a suction apparatus to the cautery
hand piece or having an assistant with a high flow suction
tip. 17 Additional means include commercial smoke
removal systems and high filtration surgical masks I
respirator worn by members of the surgical team.18
Unfortunately, though several studies have proven
the deleterious effects of surgical smoke plume, many
members of the perioperative team are indifferent or
negatively inclined towards the u e of protectiv e
ventilatory devices (general or local). 16 The most likely
reasons for the aforementioned attitudes are as follows 19:
• Some individual believe that smoke plume i not a
hazard to one's health.
• There is a perception by many surgical personnel
that surgical masks provide adequate ventilation.
• It is also thought by orne that evacuating
equipment may interfere with surgical procedures
or the surgeon's dexterity.
• Lack of re ources available to purchase a smoke
evacuator.
• Lack of the availability of personnel needed to hold
an evacuator wand.
CO NCLUSIO N:
Surgical smoke plume contains known carcinogens
and irritants, which can produce watery, burning eyes,
dermatitis, central nervous system effects, hepatic and
renal to xicity, and bronchitis or emphysema-like
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conditions. · 16 Though there have been no formal studies
determining the exact effect of inhaling mutagenic
s urgical smoke in humans, it has been proven that
e lectrocautery moke condens ates collected during
urgery ha ve geneticall y altere d strain of Salmo nella
bacterin. 14•15 Further studies ought to therefore concentrate
on the specific hazard s of s urgical smoke plume by
determining the level of exposure by the surgeon and
urgical taff; longitudinal studie w ouJd also be valuable
in assessing any detrimental effects which might be
suffered a a con equence of electrocau tery moke contact.
Until such addition al studies a re inve tigated, simple
te chniques such as high filtrat ion mask and local
electrocautery moke uction ought to be employed in
order to minimize electrocau tery smoke exposure in the
operating room etting.
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ANGIOGENIC INHIBITORS:
NEW POSSIBILITIES FOR CANCER
THERAPY
By Tisha Joy, MEDS 2001

BACKGROUND
he formation of new blood vessels, known as
angiogenesis, is a critical component of tumour
biology, in both local tumour growth as well as
distant metastatic spread. Without neovascularization,
tumours have been found to be unable to grow beyond a
size of 2 to 3 mm3 due to an equilibrium present between
the cellular proliferative rate and the apoptotic ra te. 1•2
Thus, the e tumours may persist for months, or even
years, in a "dormant" state until a particular subs t of
malignant cells converts to an angiogenic phenotype. The
exact mechanism involved in this conver ion is still not
completely understood . Yet, it involves some form of
va riation in the local balance between positive and
negative regulators of angiogenesis. 3
Shedding of tumour cells to distant sites has been
demonstrated to begin only after a tumour has become
vascularized. 4 In fact, it has been shown that the greater
the vascular density of a tumour, the greater the chance
for malignant cells to enter the circulation. 5 Interestingly,
proliferating capillaries of the tumour neovascula ture
have been found to consist of fragmented ba ement
membranes, resulting in these capillaries being more I aky
than mature vessels and thus, more conducive to entry of
malignant cells into circulation? This correlation between
vascular density and metastasis, relapse, or mortality has
been hown in several neoplasms, such as breast cancer
and colorectal cancer, and has been a key factor in the
recent intere t in angiogenic inhibitors as a form of cancer
therapy.6•7
Angiogenic inhibitors or antiangiogenic agents were
first proposed as a form of antitumour therapy in 1971. 1
Since the primary target of antiangiogenic agents is the
proliferating endothelium, there are many advantage to
the u e of these agents, as summarized in Table 1. One
important advantage is that the e agents are less likely to
result in resistance because endothelial cells are iliploid
cells po essing a stable genome. Thus, the potential for
angiogenic inhibitors as an effective cancer therapy is
enormous . This article will focu on two classe of
angiogenic inhibitors, namely tumour-derived inhibitor
and matrix metalloproteinase inhibitors.
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TUMOUR-DERIVED INHIBITORS
Angiostatin and endostatin are two angiogenic
inhibitors that have received a lot of media attention
recently. Angio tatin is a 38 kD fragment of the precursor,
plasminogen. 3 Although plasminogen itself i not
antiangiogenic, angio tatin is indeed a potent inhibitor of
endothelial cell proliferation and migration as well as a
circulating angiogenesis inhibitor. 9 Angiostatin is actually
a tumour-derived inhibitor since it only appears in the
serum in the presence of the primary tumour, and upon
removal of the primary tumour, angiostatin disappears
from circulation, resulting in growth of metastases. 10
However, even though angio tatin is tumour-derived, it is
not thought to be produced by the tumour cells per se, but
instead to be the result of cleavage of plasminogen by
protea e produced or activated by certain tumours, such
a pro tate cancer. 9• 11
Treatment of certain cancers with angiostatin has
shown promising results. In mice xenotransplanted with
three human cancers (breast, colon, or prostate), ystemic
treatment with angio tatin inhibited the growth of breast
cancer by 95%, colon cancer by 97%, and prostate cancer
by 100%. The mechanism of growth inhibition in these
tumour involved a marked increase in apoptotic rate in
the treated mice, while the proliferative rates in both the
untreated and treated mice were the same. Interestingly,
no toxic ide effects were ob erved. However, cessation of
angiostatin therapy resulted in relapse of the dormant
tumours.12
Endostatin, a fragment of the non-antiangiogenic
precursor collagen XVIII, is another potent tumourderived inhibitor of endothelial cell proliferation and of
angiogenesis. Systemic treatment with endostatin ha been
shown to cause significant regre ion of primary tumour
size as well a inhibition of metastatic growth, without
development of toxicity or of drug resistance . Like
angio tatin, the mechanism of action is via an increased
tumour cell apoptotic rate. Discontinuation of endostatin,
however, was shown to result in relapse. 13 lntere tingly,
combination therapy involving both endostatin and
angio tatin eems to cause complete tumour regression,
even after therapy is discontinued. 9
Recent studies have investigated viral-vector
mediated angiostatin therapy (via adenovirus or
retrovirus) to deliver high local concentrations of
angio tatin . 14• 15 This ha been termed "targeted
antiangiogenesis" and ha been found to cause a
ignificant arre t of tumour growth in v ivo via an
increased tumour apoptotic rate. This will have important
applications for the therapy of tumours that are locally
invasive but not necessarily metastatic, such as gliomas. It
is important to note, however, that this targeted
angiostatin therapy did not cure the mice tested, but
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Characteristic

Therapeutic advantages of angioinhibitory therapy

• Are quiescent in normal ti ues of the adult whilst
they are activated, proliferating and migrating within
the stroma of invasive tumours

• Little toxicity on normal vasculature

• Are genetically stable, normal diploid cells that are
required for tumour growth

• Their genomic and phenotypic characteristics are
stable in time

• Have similar characteristic in different solid tumors

• Repre ent a uniform target

• Are easily targeted by sys temic administration of
antiangiogenic agents

•

• Proliferate under the stimulus of partially known
endothelial growth factor

• Pharmacological neutralization of the angiogenic
peptides i a po sible therapeutic trategy

• Proliferation and migration can be inhibited by
endogenous angiogenesis inhibitors

• Therapy with endogenou antiangiogenic peptide is
fea ible and well tolerated

o difficultie related to the amount of drug that can
reach the cellular target

Table 1
Favourable characteristics of endothelial cells as a target for anticancer therapy

merel y prolonged their survival. 15 Improvement in
vectoriza tion efficiency will be required for eventual
attainment of maximal clinical benefits and hopefully, the
ynergistic effect of angiostatin combined with endo tatin
for complete tumour regression may al o one day be
achieved with vector therapy.
MATRIX METALLOPROTEINASE INHIBITORS
eovascularization is dependent on not only the
proliferation of endothelial cell but al o the migration of
the endothelial cells through the urrounding extracellular
matrix. Thi require degradation of the component of
the tissue matrix via the enzyme , matri x
metalloproteinases (MMPs) . These enzyme are
upregulated in proliferating endothelial cells and thus,
as i t in the neovascularization and ultimate growth of a
tumour.3
TIMPs (tis ue inhibitors of metalloproteinases) are
naturally occurring MMP inhibitor and are all inhibitors
of angiogenesis. 9 TIMPs inhibit both tumour growth as
we ll as metastasis, mo t likely due to their ability to
suppre s matrix degradation.16-18 TIMP have al o been
shown to directly block the proliferation of tumour and
endothelial cells in vitro. 9 Thu , this dual mechanism of
action makes them very potent antitumour agents. In fact,
one study found that retroviral-mediated transfer of TIMP
into a limited population (only 13%) of tumour cells in
mice was still sufficient to inhibit tumour growth and limit
local tumour invasion. 16 These findings how the great
potential for the e agent in cancer therapy.
Synthetic MMP inhibitors al o exist. Batimastat and
marimastat are two such compounds, and they act by
binding reversibly to the zinc in the active site of MMPs.
In the mouse model, batimastat was shown to increa e the
survival of mice xenotransplanted with human ovarian
cancer by 5- to 6-fold. 19 These results were supported the
following year by an experiment demonstrating that
treatment with batimastat cau es reduction in primary

tumour size, local I regional inva ion, as well as metastase
in mice xenotransplanted with human colon cancer. 20
Importantly, no significant side effects with batimastat
therapy were found . Ba ed on these finding , batimastat
wa one of the first MMP inhibtors to be te ted in cancer
patients, primaril y tho e with malignant effusions.
Unfortunately, batimastat was found to have poor oral
bioavailability and thus, could only be given to the cancer
patients via intraperitoneal or intrapleural suspensions.21
Marimastat, a compound similar to batimastat, is an
orally active drug that i able to inhibit cell inva ion,
meta ta i , and angiogene is. This drug is currently in the
process of clinical trials, which have shown that the mo t
significant side effects are musculoskeletal complaint .
Despite thi , marimastat eems to have potent biological
activi ty in patients with advanced ovarian, prostatic,
pancreatic, or colorectal cancer, and thereby, demonstrates
subs tantial promi e for acceptance as a novel form of
anticancer therapy in the near future.22
CONCLUSION
MMP inhibitors (TIMP , batima tat, marimastat) and
tumour-derived angiogenic inhibitors (angiostatin,
endostatin) are ju t two classe of antiangiogenic agent
that have shown significant findings for future cancer
therapy. In fact, it is interesting to note that several
antica ncer agents already in clinical use (such as
tamoxifen) have been found to have antiangiogenic
activity.23 Even certain non-cancer pharmacologic agents
uch as thalidomide also have demonstrated
antia ngiogenic activity and are currently being
inve tigated as a form of cancer therapy. 9•24 Although it
eems that treatment with angiogenic inhibitors will not
necessarily cause complete regression of tumours,
combination therap y of antiangiogenic agents with
conventional chemotherapy has been found to reduce
tumour metastases to a greater degree than when either
therapy i used alone.25 Thus, angiogenic inhibitors seem
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to be quite prorni ing for cancer therapy, and it is po ible
that we may soon see the incorporation of angiogenic
inhibitor into the standard treatment protocol of various
cancer .
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SENTINEL NODE LYMPH 0 SCINTIGRAPHY:
THE ROLE OF NUCLEAR MEDICINE IN
THE INVESTIGATION AND TREATMENT
OF MELANOMA AND BREAST CANCER
ByKent Dunn, MEDS 2001
BACKGROUND
rea t cancer and melanoma occur at high frequency
in Canada. In fact, brea t cancer is the leading cancer
diagno ed in Canadian women, accounting for about
30% of all new cases.1 There has been a dramatic increa e
in the incidence of cutaneous melanoma a ociated with
damaging sun exposure during childhood. The incidence
rate for melanoma has tripled ince the late 1960s, from 3.2
per 100,000 population in 1969 to an e timated rate of 10.5
per 100,000 in 1998.2 Fortunately, early diagnosi ha
reduced the death rate from almost 90% earlier thi
century tole than 20% today.2
For mo t patient with olid tumour , the most
powerful and predictive progno tic factor of one's
urvival i the sta tus of one's regional lymph node .3
Patients with malignant melanoma with no lymph node
meta ta e have a 10 year urvival rate of 70-80%, while
tho e with nodal involvement have a 10 year 20-30%
urvival rate. 4 In brea t cancer, regional nodal meta ta e
decrea e the 5 year urvival by 2 -40%. 4 Hence, it remains
important to identify th o e patients with nodal
involvement in order to differentiate tho e patients that
will clearly benefit from y temic treatment from those
who will not.
The management and staging of breast cancer u ually
include an axillary lymph node di ection. Likewi e,
melanoma patients with palpable regional lymph node
meta ta es undergo a ther apeutic nodal di ection .
However, the approach to melanoma patients who may
have ly mph node micrometa tases ha been quite
controver ial- ranging from complete node dis ection to
imply "watch and wait". 4

B

THE SE TINEL NODE CO CEPT
The entinel node i that ly mph node in a given
lymphatic ba in that fir t receive lymphatic flow from a
primary tumour. 5 As a result, the hi tology of the entinel
node u ually reflect the hi tology of the basin. If the
entinel node i cancer free, there i greater than 98%
likelihood that the remaining node in the basin are
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negative, but if there i cancer in the sentinel node there
may _be metastatic di ea e in other nodes. 4 A urning the
entmel node can be reliably identified and
hi topathologic exam reveal no cancer cell , the
remaining nodes in the basin should be clear a skip
meta ta e are rare.6 Thus a total re ection of the lymph
node basin with its as ociated surgical morbidity ( uch a
para thesia, wound infection, eroma, drain di comfort,
acute and chronic lymphoedema, as well a potential
7
delay~ in adjuvant therapy) can be avoided. Particularly,
chrome lymphoedema can po e a significant morbidity.
Sentinel node lymphoscintigraphy (S L) has been
developed for thi purpose. It involves injecting
radiopharmaceutical ( pecifically radiolabeled colloid of
uitable ize and propertie ) ju t out ide the periphery of
the primary tumour site where they are transported by
lymphatics and localize in drainage lymph node . Thi
allows one to trace the path of lymphatic from a
cutaneous melanoma or breast le ion to the regional node
basin. Using the nuclear images as a road map, gamma
probe guided surgery (wi th a hand-held, wand-like
in t_rumen~ that detect gamma rays emitted b y the
radiocolloid) successfully locate the sentinel node,
a~lowi~g a directed di ection and minimizing tissue
d1 ruption. When a pathologi t i given a sentinel node
in tead of many node to examine, a thorough
examination with more sectioning or with the use of
specific staining method or PCR-based assays is afforded,
which contributes to more accurate di ea e staging. 6
Furthermore, lymphatic mapping and entinel node
biopsies direct di ection to all lymph node beds that
potentially receive or have received tumour cells. ot
infrequently, a sentinel node that shows micrometasta e
i in a lymph node bed that would not have been
pr dieted to receive lymphatic drainage from the primary
tumour based on conventional estimates. In fact, the
cla ic concept of a lymphatic watershed de cribed by
S~pp~y's lines (anatomic coordinates governing the
direction of lymphatic flow from any point on the trunk)
has been shown by lympho cintigraphy to be inaccurate
in many patients.

The Ideal Radiocolloid
Debate exist regarding the most appropriate
radiocolloid for u e in SNL. The rate of colloid transport
and movement through lymphatic pathway i mo t
s trongly related to the ize and surface charge of the
colloid. Tho e larger than 0.004,um to O.OOS,um are
preferred, a mailer particle have been reported to
penetrate the capillary membranes and are therefore

U. W.O. Medical Journal 69 (2) 1999 - - - - - - - - - - - - - - - - - - - - - - - -

31

Fea t ure

Art i cles

unavailable to migrate through the lymphatic channels
resulting in ob cured images. Particles smaller than 0.1,um
show the most rapid disappearance from the interstitial
s pace into the lymphatic vessels and have significant
retention in the ly mph node . Large colloid particles
(-O.S,um) show a much slower rate of clearance from the
interstitial space with significantly less accumulation in
the lymph nodes.6
Three important questions mu s t ultimatel y be
answered in the assessment of a colloid's suitability for
SNL. Firstly, is a stable, safe and efficacious product made
during the radiolabelling process? ext, how w ill the
body deal with a charged particulate, taking into account
its many other ph ysical properties? Las tly, will this
particulate be biochemically altered, metabolized and
excreted? Research is currently taking place at London
Health Sciences Centre9 in the development of suitable
radiolabeled colloids and assessing them in ca n cer
patients after appropriate animal biodistribution studies.
SENTINE L N OD E LYM PH OSCI NTI GR A PHY IN
MALIGNANT MELANOMA
In patients with malignant melanoma, the sentinel
node(s ) is (are) resected and biopsied and, if fre e of
metastases, radical nodal dissection is not required, thus
avoiding potential morbidity which could result from
radical nodal dissection. If the sentinel node is involved
with malignancy, radical nodal dissection of the affected
basin is then performed. Such an approach is currently an
accepted practice.
The use of a v ariety of radiotracer agents for
ly mphoscintigraphy and intraoperative gamma probe
localization of sentinel nodes in patients with stage 1/ II
melanoma (ie. no evidence of tumour spread) is firml(o
documented in the literature. For example Berman et al 0
reported on 135 patients with malignant melanoma of the
head, neck, shoulder and trunk. A discordancy rate of 41%
was found between drainage that would have been
predicted by the surgeon based on location of the primary
skin lesion and what was found on imaging. Surgical
management wa s changed in 33 % because of the
lymphatic drainage revealed on lymphoscintigraphy.
Uren et al 11 reported 209 patients with high r isk
melanoma of the trunk . The y found that
ly mpho s cintigraphy was 94% sensitive in detecting
sentinel nodes that contained metastases. Similarly, Krag
et al 12 reported on 121 patients with invasive malignant
melanoma and clinically negative lymph nodes. Before
s urgical lymph node resection, the se patients h ad
intradermal administration of 99mTc sulfur colloid around
the primary melanoma. A gamma probe was used in the
operating room to identify radiolabeled nodes which were
then electively removed. Patients with identified
metastatic lesions then underwent regional
lymphadenectomy. Radiolabeled sentinel lymph nodes
were successfully resected in 98% of cases. Fifteen patients
had pathologically positive sentinel lymph nodes and in
10 of those, the sentinel node was the only node w ith
metastases.
Glass et al13 reported on 132 patients with intermediate
thickness malignant melanoma . Sentinel nodes were
exci ed and examined for metastases by light microscopy
32

with conventional stains and immunohistochemis try.
Only patient with micrometastases received comple te
lymph node dissection. Sentinel nodes were identified in
all patients while micrometastases was found in 23%. Of
those with metastases the sentinel node w as the only node
with tumour in 83% based on subsequent complete nodal
dissection.
O'Brien et al14 studied 97 patients with cutaneous head
and
n e ck
melanom a
u sing
preoperati ve
lymphoscintigraphy to identify sentinel nodes. Sentinel
node s w ere identified in 95 of 97 s cintigram s.
Lympho s cintigraph y wa s discordant with clinical
prediction in 34% of cases.
The sentinel ly mph node biopsy is a particularly
appealing surgical management strategy for patients with
stage I/ II melanoma because of the controversy about the
alternative surgical intervention - namely elective lymph
node dissection (EL D). Approximately 80% of patients
with s ta g e 1/ II disease do not have nodal tumour
involvement demonstrated by EL D. Thus the expense
and morbidity of the dissection would be unnecessary in
that group.6
S EN TI NEL N OD E LYM PHO S CINTI GR A PHY IN
BREAST CANCER
In the case of breast cancer, surgical management,
over the years, has evolved from radical and mutilatory
surgery to the less extens iv e s imple mastectom y or
lumpectomy with radical nodal dissection still being
performed on a significant number of patients. The
sentinel node localization and biopsy should eventually,
after val idation b y large clinical trials, lead to the
elimination of unnecessary radical nodal resection,
another step towards optimizing the surgical management
of this disease.
Uren et al15 reported on 34 patients with breast cancer
who were studied with lymphoscintigraphy. Unexpected
drainage across the centre of the breas t to axilla ry or
internal mammary nodes was reported in 32% of patients
with inner-or outer- quadrant lesions; drainage to supra
clavicula r or infra clavicular nodes in 20% of upper
quadrant lesions; drainage to ipsilateral axilla in 85% of
cases where a single sentinel node was seen. Furthermore,
Solin 16 has shown that the frequency of internal mammary
node metastases in breast cancer parallels metastases to
axillary nodes and correlates with the size of the tumour.
The implications of drainage to unpredicted lymph node
for patient surgical management are profound. In a large
number of centres, current management of breast cancer
does not include ly mpho s cintigraph y to identify
lymphatic drainage from the breast cancer site. However,
it does include ipsilateral axillary node dissection for
staging invasive breast cancers regardless of location. The
therapeutic impact of sentinel node localization, excision
and biops y directed b y ly mphoscintigraphy in all
potential nodal beds invol ved with tumour is being
evaluated . If the frequenc y of metastases to axillary,
internal mammar y, and other nodal groups is
proportional to the frequency of lymph drainage to those
node groups, then surgical management should probably
be modified to include internal mammary and other nodal
bed dissections.6
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CONCLUSION
Like all currently practiced radionuclide procedure ,
interstitial lymphoscintigraphy is easily performed, w ell
tolerated by patients, and is free from either local or
systemic toxicity. Patient di comfort or inconvenience
with the procedure as well as allocated resources are small
considerations relative to the potential benefits. Greater
familiarity with the technique will enhance its role in the
investigation and treatment of patients with melanoma
and breast cancer.
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HEALTH AND HARMONY:
LIVE MUSIC AT THE LONDON
REGIONAL CANCER CENTRE
By Jennifer Wong, MEDS 2000 and Michael Sanatani, MEDS 2000
magine y ou have just taken your seat on the th ird
balcony, front row centre. From far below, a colourful
hum of notes rises towards you as a string quar tet
begins to play. You are impressed by the clarity of the
ound as it fills the four-storey-high atrium. The hall with
such remarkable acoustics is, in fact, the London Regional
Cancer Centre (LRCC). And the musicians are participants
in the LRCC Live Music Program.
Music has been a part of medicine for many centuries,
and the establishment of the LRCC Live Music Program
shows an increasing awareness of this relationship today.
It is the goal of this article to review the role of music in
medicine, and to describe the LRCC program based on our
experiences at the Cancer Centre as a piano-cello duo.
Medicine, religion and the arts were closely connected
in many ancient cultures. The use of music and other
healing modalities reflected a culture's view of illness. For
example, chants and magic songs were used by various
ative American tribes who viewed disease as being due
to the intervention of spiritual forces . 1 Ancient Gr ek
mythology and historical literature contain many
references to the use of music in healing, for instance, in
the works of Homer and Plutarch . 2 During the
Renaissance period, many philosophers tried to develop a
scientific approach to the relationship between music and
the human being. For example, the four musical voices
(bass, tenor, alto, soprano) were related to the four
temperaments (melancholic, phlegmatic, sanguine,
choleric), and the four humours of the body (black bile,
phlegm, blood, yellow bile).3
The first English book on the use of music in medicine
was Robert Browne's Medicina Mu sica: A Mechanical Essay
on the Effects of Singing, Musick, and Dancing on Hu man
Bodies (1729). 4 Of significance, Browne put forth several
postulates that still serve as a basis for music therapy
today. He proposed that music can change and evoke
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moods, influence physiological processes, does not require
the attainment of a certain level of proficiency when used
therapeutically, and could be useful in preventive health
care.
Music therapy is the modem term for the use of music
in medicine . Music therapy can be defined as the
"controlled use of music, its elements and their influences
on the human being to aid in the physiologic, psychologic,
and emotional integration of the individual during the
treatment of an illness or disability." 5 It involves listening,
singing, playing instruments, improvising, and
composing.6
Most people have an intuitive awareness of the
relaxing and calming effect of music.
Background music is commonly used in hospital
waiting areas, delivery suites, orerating rooms, and in
occupational and physiotherapy. In the medical setting,
attentive listening can distract from the "here and now" of
an illness . Specifically, music can divert a person' s
attention away from the pain, stress, anxiety, and isolation
of his or her illness and hospitalization.
Furthermore, it is important to recognize that illness is
an experience that goes beyond reason and word s.
Finding a way to express this experience may prove
crucial to the patient's sense of well-being : "For the
patient, expression of unspeakable concerns not
infrequently provides renewed creative energy that is
usually lost in the process of an illness. This not only
enriches the quality of life at such a time but may provide
the impetus to live." 8 As such, improvising, singing,
composing, and playing an instrument can provide an
avenue for expression and creativity.
At this time, it is important to point out that the term
music "therapy" suggests a procedure that has an effect on
the disease process itself. Is this justifiable? Physiological
processes, to some extent, can reflect our emotions. We
hold our breath when we are anxious and exhale when the
moment of tension passes. We blush when we are
embarrassed. Yet can the experience of music directly
influence physiology and possibly disease as well? Some
basic evidence-based research in this area has begun. 9 For
instance, in Munro and Mount's study of chronic pain,
they found that music could decrease the intensity of the
pain experience. Music has also been shown to decrease
heart rate, systolic and diastolic blood pressure. 10•11 Of
interest, music played at the tempo approximating that of
the heart rate is thought to promote relaxation?
In this century, music therapy was initially used in the
mental health services. Norma Sharpe, who worked at St.
Thomas Psychiatric Hospital in Ontario, was one of the
pioneers of music therapy in Canada.6 In fact, some of the
inaugural conferences of the Canadian Association for
Music Therapy took place in St. Thomas (1974) and
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London, Ontario (1976). 6 However, mo t of the current
literature about the use of mu ic in medicine involves the
field of palliative care and oncology.
Regarding the u e of music in cancer care, it i felt that
"the diver ity of its potential i particularly suited to the
diver ity of the challenges - phy ical, psycho ocial and
spiritual - that these [cancer] patients pre ent." 5 The way
in which mu ic can help cancer patients at various tage
of the disea e de erve an entire discu ion of it own.
However, in general, mu ic help tho e afflicted with
cancer in the proce of coping and acceptance through
relaxation, di traction, and expre sion of feeling .
One of the most e tabli hed music therapy programs
in Canada i the 20-year-old program of Montreal's Royal
Victoria Ho pita! palliative care ervice. Music u ed in thi
etting has been shown to help patients with advanced
malignant di ea e. In particular, case report from this
service document the importance of the power of
as ociation that music can invoke.5
Specifically, "mu ic can reduce feelings of loneline s
by producing familiar, comforting stimulation reminiscent
of family, homeland, or pa t experience ." 5 Mu ic may
al o be beneficial as an adjunct to antiemetic agents used
to treat chemotherapy-induced nau ea and vomiting. 12
Mu ic not only helps to decrea e the anxiety that may
precipitate the nau ea and vomiting, but also the degree
and length of this unpleasant side effect. 13
While mo t of the literature deals with adult oncology,
the u e of mu ic in pediatric oncolo~, particulary in yhe
United State i well documented. 4 The u e of mu ic
therapeutically hare a imilar concept to that of art and
play therapy - to provide a diver ion and help to enhance
elf-expre ion of the child. The latter i particularly
important for children who, a a group, are less capable of
expres ing their feeling in concrete terms. Of interest, there
has also been me documentation of potential phy iological
therapeutic effects of music used in pediatric setting . These
include decrea ed crying, decreased re piratory rate, and
even increased oxygen saturation.14 onethele , a mu ic
therapy is lowly but urely being di covered by other
medical specialties, it is becoming apparent how music can
benefit patients in almo tall illness ituations.
It is intere ting to note that mo t of the literature
written about mu ic in oncology and medicine revolve
around its u e a tap d background music. There is little
written about the u e of live mu ic. Yet, a live
performance ha much to offer patients. In contra t to
taped background mu ic, live music provides the human
pre ence that can enhance the mu ical experience of the
audience. A live performer is able to pre ent the music to
the li tener in a per onal way which can be very
meaningful to the patient. 15 Moreover, an advantage of a
live performance i that the mu ician is continuously
aware of the audience' respon e and can spontaneously
tailor the choice of mu ic, and to orne extent the tyle of
the performance, to the li tener.
These benefits were recognized by Jan Searle, a flauti t
and cancer urvivor from Stratford, Ontario, and Shelley
Markland and Dr. Le lie Levin of the LRCC. 16 In 1997,
they organized trial performance with the flute and harg
in an attempt to make the LRCC "a after, gentler place." 7
These performances met with an overwhelmingly po itive
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re pon e. Although orne taff member initially found it
more difficult to get the patients' attention when it wa
time to ee the doctor, mo t were supportive of the live
mu ic. The unique program developed quickly, aided, for
instance, by the donation of a piano . The program
currently involve mu ic tudents, community mu icians,
and mo t recently, patient themselve , who play for one
to two hours during clinics.
When we fir t heard about the program, it
immediately appealed to u but we did not quite know
what to expect. At our fir t performance at the Cancer
Centre a year ago, we were initially intimidated by the
hu hed, impersonal ilence that pervade the LRCC.
Would we dare to - or even want to - introduce orne
ound here? Everything eemed so subdued and quietly
functioning. However, a we gingerly began to play and
the LRCC revealed it true acou tical qualitie , our doubt
were dispelled . The atmo phere became lively a the
patients, previously following variou train of thought,
turned their attention to the new pre ence.
Importantly, we were well aware of the fact that many
patient were in an emotionally demanding situation and
therefore, we would have to choo e our music carefully.
What type of mu ic would be mo t appropriate for the
LRCC? We played a wide a pectrum of mu ic a we
could to cater to the different mu ical ta tes of the
patients. A chronological progre ion eemed to work
well, from Bach and Vivaldi, to Brahms, Schubert and
Chopin, to the "hits" of the 1950's and 1960' and orne
oft contemporary mu ic.
In addition to choosing the music carefully, we
learned that we had to pay pecial attention to the
interval between piece . Intere tingly, we found that it
wa e pecially important to be aware of the moments
immediately after the end of a piece. The patients at the
LRCC tended not to applaud by clapping. Instead, a
remarkable, attentive ilence u ually followed the Ia t
note. It was a if the mu ic continued to linger on in the
mind of the patients. In particular, Brahm ' Waltz in A
Major and Chopin' Claire de Lune were usually followed
by uch a "li tening" ilence, completely different from the
"frozen" ilence that preceeded the performance .
Remarkably, it often took everal minutes before the u ual
background noi e and movement re umed.
Perhap one of the mo t rewarding a pects of playing
at the cancer centre wa experiencing the patient '
gratitude. They appreciated not only the mu ic itself, but
al o the fact that we were taking the time to play for them.
We felt that the supportive miles and appreciative
comments the patient gave us benefited them as much a
it did us. Many patient were e pecially appreciative of
the fact that we volunteered our time. Thi tell u what an
important part of the live performance the musicians'
per onal dedication is to thi audience.
However, in our opinion, one of the greate t
achievements of the Live Music Program i the
involvement of the patients in the performance . As
mentioned earlier, orne cancer patients are now
them elves performing at the LRCC. Experiencing the
progre ive illne , and perhap many rather imper onal,
standardized procedure uch as MRI, Cf, chemotherapy,
and radiation protocol , can easily give a patient a feeling
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of po w erless ne s s . Becoming acti v e and creativ is
empowering and can serve as a strong support during
such an uprooting life experience.
Although most p atients do not perform themsel es,
th ey ofte n ex press a n a cti ve interes t in the live
performance. How often ha ve w e been told about th e
patients' own musical backgrounds, or about a relative's
accomplishments! It was as if the performance offered a
much-needed opportunity for personal communication
and conversation.
Our e xperience at the LRCC ha s gi v en u s a n
a ppreciation of the tremendou s potential of musi c in
cancer care. As w e di scove red, music h as the uni q ue
a bility to fulfill a need that ari ses during an illness
ex perience . Thus, we would e ncourage e v ery one to
contribute their talent whenever there i an opportunity,
to help secure and expand the role of music in medicin
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FUNCTIONAL BRAIN MAPPING AND
THE REMOVAL OF BRAIN TUMOURS
By Peter Howard, MEDS 2000

hether malignant or benign, tumour that lie
within the brain po e a treatment dilemma.
Surgical removal of the tumour may jeopardize
urrounding brain ti ue, thu causing a profound
neurological deficit. In order to minimize the neurological
deficit that will re ult from a tumour's re ection, th e
function of the brain tissue urrounding the tumour must
be identified. We shall start by briefly ketching the typical
organization of brain functions within the human cerebral
cortex, which provide an approxi mate guide to the
functions that may be threatened by a tumour. Definitive
identification of the functions threatened by a particular
tumour is made po ible by the techniques of functional
mapping. We hall briefly d.i cu the tandard technique
for functional brain mapping, which involve applying an
electric current directly to the brain' urface to stimulate
the cortex. We shall then focu on an experimental method
of functional brain mapping with magnetic re onance
imaging. Finally, we shall pre ent a ingle ca e in which
both technique of mapping were u ed prior to th e
re ection of a cavernous hemangioma.
The brain is the mo t complex organ in the human
body, both in terms of structure and function . One of the
ongoing challenge of neuro science is to relate the
anatomical tructure of the brain to the cognitive proce e
that occur within it. Hi torically, there have been two rival
theories of the relation hip between the tructure of the
human cerebral cortex and it functionl. At one extreme i
the view that the cerebral cortex i homogeneous, with all
regions capable of contributing to all mental ta k 1. At the
other extreme i the view that each mental proce i
"localized " to a di crete anatomical area pecialized for
the ta k. 1 The model supported b y today' evidence
combine element of the e two view . The primary
ensory and motor function s of the brain are certainly
localized to characteri tic area in the normal human. For
instance, the vi ual area i in the po terior occipital lobe,
the primary auditory area i in the uperior temporal
gyrus, and the ensorimotor area lie on the banks of the
central sulcu . 1 Even the more abstract function of
language ha a ded.icated area urrounding the left ylvian
fi ure in mo t individual .1 It i worth noting, however,
that thi characteri tic arrangement of functional area in
the brain can be dramatically reconfigured in re ponse to
injuries, particular! tho e that occur during development
of the nervou y tem.1 Thi indicate that there is a fair
amount of homogeneity between area of the cerebral
cortex at lea t in their potential to perform variou
cognitive ta k .
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The area of the brain that are pecialized to proce
motor output and linguistic activity are of particular
concern when the urgical re ection of a tumour i
planned, since the urgeon wants at all co t to avoid
leaving the patient hemiplegic or aphasic. Becau e each
brain may how ignificant idio yncrasie in the location
of functional area , vital functions can be pared only if
they are mapped prior to urgery. Between the 1930's and
1950's, Dr. Wilder Penfield of the Montreal eurological
Institute pioneered functional mapping of the brain a a
guide to neuro urgery. 1 Hi technique involved
performing brain urgery under a combination of local
and neuroleptic anae thesia, o that the patient remained
con cious and re ponsive during the operation. The
urface of the cortex was timulated with a mall electric
current. Motor area were identified by ob erving the
contraction of mu de in re ponse to the current. Sensory
area were identified by asking the patient to verbally
de cribe any en ation that the electrical timulation
evoked. Finally, peech areas were identified when
timulation of the area cau ed a temporary arre t in the
flow of a patient' peech. Once the e critical areas were
labeled (see figure 1 upper left), urgery could proceed
giving them a wide a berth a po ible.
The recent development of functional magnetic
re onance imaging (fMRI) provide another method of
crea ting functional brain map . FMRI exploits the
deoxygenated hemoglobin normally found in the blood a
a "contrast agent" ind.icating brain activity.2.3.4 In magnetic
re onance imaging, the signal emanating from each mall
block of ti ue i produced by the prece ion of protons
within the ti ue. The rate of each proton's prece sion i
proportional to the trength of the magnetic field acting on
the proton. Since d oxyhemoglobin contains iron with free
va lence electron , each molecule of deoxyhemoglobin
create it own magnetic field. 2•3 High numbers of
deoxyhemoglobin molecule in a mall block of ti sue
therefore create many small d.i tortions in the magnetic
field within the ti ue block. In the pre ence of uch
di tortions, the protons in the ti ue prece at different
rate , thereby lo ing phase with one another. The resulting
MR ignal i d.imini hed by the lo of pha e in the same
way that two water waves of different pha e will partially
cancel one another. The key result i that high
deoxyhemoglobin concentration within a ti ue cau e a
darkenin§ of that ti ue on appropriately acquired MR
image .2. 3• When an area of brain i activated, it extract
more oxygen from it blood upply, thu creating
deo yhemoglobin. However, an increa e in blood upply
to the active area more than compensate for the increa ed
oxygen extraction,
o the concentration of
deoxyhemoglobin within the venous microva culature of
the active brain area drops.4 The net effect on MR images
i that active cerebral cortex i approximately four percent
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brighter than the arne cortex at re t. If a serie of image
are taken while a ubject alternate between re t and task
performance, the brain areas responsible for the task can
be identified by their significantly increased brightness
during ta k performance. FMRI ha been used to map
primary sen orimotor and visual activity, higher order
motor and vi ual proce ing, and even comrlex cognitive
functions uch as learning and language u e. 13
The following case illustra tes the use of fMRI in
conjunction with electrical cortical stimulation for the
purpo e of brain mapping. A 52 year-old lady pre ented
with a history of headaches and with simple partial
eizures involving the left thumb. Clinical MR images
suggested that the le ion was a cavernous hemangioma in
the middle portion of the cen tral ulcu of the ri g ht
hemisphere, located in the depths of the sulcus. The
urgeon's preoperative asse sment was that removal of
the le ion might cause a deficit in hand and arm
movement. FMRI was u sed to map the brain regions
re ponsible for left finger to thumb apposition, olo left
thumb movement, left wri t flexion and extension, and left
to right tongue movements. Extensive cortical stimulation
mapping was performed at the time of surgery, locating a
range of sensory and motor activitie in the upper limb,
head, and neck.
The volume rendered fMRI data was oriented to
re emble the view of the brain obtained at surgery. The
fMRI rendering i uificiently detailed to identify all of the
gyral contours visible in the operative photograph.
Comparisons of the fMRI maps to the operative data are
made in figure 1. From figure 1, it is evident that finger to
thumb oppo ition cau ed fMRI brain activity within 3 mm

of operative label A, where electrical stimulation caused
the patient to clench her left hand. Furthermore, finger to
thumb opposition caused activation in the po tcentral
gyru in the area identified with finger and thumb
ensation during surgery. The ta k of finger to thumb
oppo ition would be expected to activate both en ory
and motor components of the primary ensorimotor cortex
respon ible for the fingers and thumb. We thu conclude
that the fMRI and cortical stimulation map agree on the
location of the hand ensorimotor cortex. Wrist movement
caused fMRI activation at label C, which marked forearm
pronation and hand movement during surgery. The e are
clo ely related movements that also involve the wri t joint.
Tongue en ation could only be elicited during urgery by
probing beyond the edge of the craniotomy at U. Thi
region is within 3 mm of the activation shown by fMRI
during tongue movement, a ta k that will also elicit
tongue sensation. In this patient, then, fMRI and cortical
timulation create comparable maps of the functional
areas found along the banks of the central sulcu .
The ability to identify the function performed by an
area of brain tis ue is of obviou benefit to a surgeon
considering the resection of that ti sue to facilitate the
removal of a tumour. Cortical stimulation mapping has
long been u ed uccessfully in this capacity . Early
experimental results such a the case study described
sugge t that fMRI may play a role in thi type of brain
mapping in the future. FMRI has several feature that
make it an attractive method of brain mapping. Fir t, since
it i non-invasive, fMRI can be performed on patients both
before and after neurosurgery . This gives fMRI the
potential to how the plasticity of brain function in

Figure 1. In the upper left is the view of
the patient' s brain through a craniotomy, with
labels on the surface indicating the results of
cortical stimulation mapping. The prominent
ve el running between the labeled gyri marks
the central ulcu . Left of page is anterior, and
bottom of page is uperior. Stimulation at the
foUowing letters eHcited the following relevant
re ponses: A - making grip; B - ensation in
hand, shivering of hand, arm, and shoulder;
C - pronation of forearm and hand ;
G- wri t sensation; H, J, K, L, M- sensation in
fingers or thumb; U - sensation on left side of
tongue . The upper right shows the fMRI
activation during left to right movement of the
tongue. The lower left shows fMRI activation
during finger to thumb oppo ition. The lower
right show s fMRI activation during wrist
flexion and extension.

Figure 1.
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THE ROLE OF PROSTATE-SPECIFIC
ANTIGEN FOR SCREENING IN THE
FAMILY PHYSICIAN'S OFFICE
By Raj Waghmnre, MEDS 2000 and Mark Evans, MEDS 2000

ro tate cancer i ranked among the mo t common
cau e of cancer-related death in men. In 1997, it
urpas ed lung cancer as the most frequently
diagnosed cancer in Canadian men and its estimated
incidence per year has exceeded that of breast cancer in
Canadian women. 1 Prostate Specific-antigen (PSA) has
been available as a screening test in Canada ince 19 6,
although its u e did not become widespread until the
early 1990's. Screening guideline for prostate cancer in
the Uni ted State include PSA testing, however no such
guidelines have been establi hed in Canada. Why have
creening programs for pro tate cancer, like tho e of
breast cancer, not been implemented in Canada? There are
no clear cut answers, however, an understanding of PSA
as a creening tool will help physicians determine how to
be t apply this tool in the management of their patient .

P

Prostate Specific Antigen; Historical Aspects
The earch for a pro tatic tumor marker more pecific
and ensitive than prostatic phosphatase began in the 1960's.
By the 1970's several groups of researchers had discovered
antigen pecific to the prostate. Work on the e antigen
continued in hopes of developing forensic identifiers in
rape ca e (never very effective) as well a tumor marker
for pro tate cancer. In 1971, Hara et al, isolated PSA from
eminal plasma and named it y-seminoprotein. Soon
afterwards, Li and Beling characterized El, an antigen from
eminal plasma using a serie of protein chromatographic
technique . In 1978, Sensabaugh identified PSA in human
emen and called it p30. When it was discovered that
anti era to the partially purified antigens did not react with
extract from tissue other than the prostate, the term
pro tate-specific antigen or PSA was coined?
In 1981, Wang et al, reported isolates of pro tatic
antige n from seminal plasma and prostatic antigen
purified from prostatic ti ue were identical. 3 Alma t a
quarter of a century after the three separate antigen were
initially di covered, inve ligation revealed that the three
an tigens where in reality a single pecific antigen pro tate- pecific antigen. PSA i an organ-specific erine
protea e, produced by pro tatic epithelial cell lining the
acini and duct of the prostate gland. Functionally, this
protease i known to cau e liquefaction of the seminal
coagulum.4
Current Screening Techniques for Prostate Cancer
There are several criteria a clinical test should meet
before being considered a a di ease screening te t: (1) the
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disea e must be an important health problem; (2) the
di ea emu t have a recognizable early stage; (3) treatment
at an early stage should be more beneficial than treatment
at a later tage; (4) the test must be convenient and
tolerable for the patient; (5) necessary facilities must exist
for diagno i and treatment; (6) the cost of creening must
be acceptable to society. 5
Currently there are four potential screening te ts used
for pro tate cancer. The e include the digital rectal exam
(ORE ), pro tatic pho phatase (PAP), trans-rectal
ultra ound (TRUS); as well as, the seromarker prostatepecific antigen (PSA) approved in 1986 by the Food and
Drug Admini tration for the u e as an aid in the prognosis
and management of patient with pro tate cancer. 6
Although PAP is also a seromarker for prostate
cancer, unlike PSA, PAP level do not become elevated
until the disease ha reached an advanced tage. This
gives PAP no advantage over a ORE screening exam.
Thus, PAP is not u ed for creening but for taging the
disea e only after it i diagno ed? Performing a TRUS of
the pro tate as a creening te tis not an effective creening
test because a TRUS can not differentiate many small
cancer from urrounding benign prostatic ti ue. TRUS'
mo t appropriate use is in directing biop ie in men who
have abnormal findings on ORE and/ or PSA testing.7
Although inexpensive and time tested, DRE-ba ed trials in
pre-PSA eras showed that only 33% of ORE-detected
pro tate cancers had pathologically organ-confined
di ease. Thus, 67% of men were diagnosed at a stage of
prostate cancer associated with a very poor 10-year
progno i . If men with organ-confined prostate cancer
undergo radical prostatectomy, they are essentially cured
of the disea e and have a urvival rate equivalent to that
of age-matched men without the disea e. 9 In contrast,
pro tate cancer that i not organ confined is incurable.
PSA creen.ing ha shown it elf to be a very effective tool
in finding organ confined and thus curable prostate
cancer. PSA testing is convenient, tolerable and
inexpensive. Serum PSA te ting meets most established
criteria' for a clinical te t be con idered a a creening
tool.
Physiologic Reasons for PSA Elevation.
The physiology by which elevated levels of PSA enter
the blood stream has lead to some inaccurate assumptions
regarding the specificity of elevated serum PSA levels.
Serum PSA levels deviate from reference value for two
basic rea ons: (1) an increase in PSA production, such as in
the ca e of benign prostatic hyperplasia, which creates a
shift in the diffusion gradient; (2) a change in the
membrane permeability or normal physiological barriers,
for example prostate cancer and pro tatitis.
Early re earch indicated the potential for false-po itive
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re pon e to change during urgery. Secondly, many
comple cognitive ta k that cannot be inve tigated u ing
cortical timulation can be inve tigated with fMRI. Finally,
whil cortical timulation give acce only to the brain'
urface, fMRl can show functional areas deep within the
brain. Thus, there is rea on to be optimi tic th a t the
difficult urgery currently performed to remove cerebral
tumour will in the future benefit from advance in
functional mapping technique
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elevations in serum P A level

after pro tatic

manipulation and/ or ejaculation. However, Chybowski et
al 10, via a prospective randomized controlled trial, howed
that the median erum PSA elevation caused by ORE
repre ented a clinically in ignificant increa e in the erum
PSA level. Thu the author concluded that the erum PSA
concentration in the immediate post-ORE period i
accurate and would not com~romi e clinical value of the
marker. Similarly, Yuan et al 1, found that ORE, pro tatic
rna sage, and TRUS, produced orne elevations in erum
PSA levels; however, th e author concluded that the
elevations were not tati tically ignificant and that the e
e am had minimal effect on erum PSA level in mo t
patient .
PSA level may become elevated by age (therefore,
age pecific range of value are employed), acute urinary
reten tion and urethral catheteriza tion. The use of
Fina teride can lower PSA level by approximately 50%. 11
Sensitivity and Specificity of PSA
The fact that pro tate cancer ha recently become one
of the most prevalent cancer in our society is primarily
due to increa ed diagno i a a direct re ult of the u e of
PSA a a creening tool. Of the cancer now detected, 95%
that are detected are clinically localized. While ensitivity
i relatively high at 92%, pecifidty is lower becau e of the
other way in w hi ch PSA can be rai ed . W h en other
condition or rea ons for the eleva tion of PSA are
u pected, th e finding of a low percentage of free,
unbound PSA increa e the pecifidty. Al o, PSA velocity
can be followed . While it i increa ed by factors such a
age, it hould not increa e by more than 0.75 ng / rnl per
year. PSA density (ng/ ml / ml) can also be followed for
creeningY Regardles of it limitation , erum PSA i
currently the best creening tool available for pro tate
cancer. If there is suffi cient u pidon of prostate cancer
ba ed on PSA level , then TRUS guided biop y of the
pro tate can be performed for a d finitive diagno i .
Management of Prostate Cancer
There i currently orne controver y urrounding the
wi de pread u se of erum PSA levels as a screen for
pro tate cancer. A noted previou ly, PSA i currently the
be t method for detecting pro tate cancer. It i highly
en itive, and ince PSA te ting began, there h as been a
lower incidence of meta tatic disease at th e time of
diagno i .15 This is important, a there i a reali tic chance
for cure of prostate cancer only if it i detected and treated
early in it cour e. Argument against the wide pread use
of PSA for prostate cancer creening are not ba ed on

Table 1 Age-specific reference ranges for serum prostate-specific
antigen.14
Age
(years)
40-49
50-59
60-69
70-79

Serum PSA
(n g/ml)
0.0-2.5
0.0-3.5
0.0-4.5
0.0-6.5

PSA density
(ng/ml/ml)
0.0-0.0
0.0-0.10
0.0-0.11
0.0-0.13
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whether or not PSA i a reliable tool for the detection of
cancer. Thi ha already been proven and accepted. What
tho e oppo ed to PSA creening question, is whether or
not there are effective treatment available to patient
which will increa e their quantity and / or quality of life
once the cancer has been diagno ed.
There are currently four approache to the
management of pro tate cancer. The first and imple t
app roach i watchful waiting. Thi may be the mo t
appropriate management for pro tate cancer diagno d in
men 75 or older, a 4% of the e patient will urvive 10
year without treatment and it a odated ri k . Another
option for older patient i hormonal therapy uch a a
luteinizing hormone-relea ing hormone agoni t or an
antiandrogen. This i an acceptable option to many older
patient who will not accept watchful waiting. While it
may not affect their life expectancy, many patient fe 1
that watchful waiting i an un a tisfactory treatment
cour e for cancer. The gold tandard treatment for
pro tate cancer i urgery. A radical pro tatectom y i
a ociated with a 10-year urvival rate of up to 94%.
However, this i only an option if the tumor is confined
within the pro tatic cap ule. Finally, radiation therapy i
an option. It i as ociated with a lower 10-year urvival
rate than a radical pro tatectomy (74%), but thi i largely
due to the fact that radiation therapy is re erved for
patient with larger tumor and higher PSA levels.16
Widespread Use of PSA as a Screening Tool
There are everal argument that fuel the controver y
of PSA creening. An important question that mu t be
addre ed before creening for pro tate cancer i , "What
grade or stage of pro tate cancer i worth treating in order
to improve quality of life?" At 55 yea r of age, a man
wi thout pro tate cancer ha a life e pectancy of 21.4 year .
If the arne man ha a well-differentiated, micro copic
cancer and doe not undergo treatment, hi life expectancy
wil l till be 21.4 y ear . However, a moderatel y
differentiated cancer will cut life expectancy by four year .
A wide pread ere ning will identify case in which
treatment will benefit the patient a well a ca e in which
treatment will have no benefit, the willingne of patient
to leave a cancer untreat d, no matter what the tudie
indicate, mu t al o be que tioned.
It i likely that a large number of patients, even when
coun eled that treatment will have no effect on life
expectancy will go forward with management to remove
the cancer from their bodie . Thi de ire to treat pro tate
cancer regardle of the fact that it may not alter life
expectancy i a prim ary argument again t wide pread
creening. Treatment may not only be of little benefit, it i
as odated with several ide effect which can diminution
a patient's quality of life. Radical pro tatectomy i
a odated with a 30% ri k of incontinence and impotence
a lingering patient problem . Radiation therapy i
a ociated with tre s incontinence in 50% of patient ,
exual dysfunction in 30% and chronic proctiti in 10%.
Hormonal therap y i a ociated with hot fla he ,
decrea ed libido, and brea t tenderne although the e
effect are u ually hort-lived.17 Only watchful waiting i
without treatment-induced ide effects.
A second important argument again t PSA creening

U. W.O. Medical Journal 69 (2) 1999 - - - - - - - - - - - - - - - - - - - - - - - - -

41

Feat ur e

A r t i c l es

i co t-effecti vene . As with all a p ct of health care in
toda y' ociety, co t-effecti vene i a great cone rn.
Analy e b Krahn et al 1 and Fleming 19 found that there
wa littl or no clinical benefit deriv d from treating
clinically localized pro tate cancer. While the e tudie
received a good deal of attention from the media and
were well-cited in medical literature, their election of
patient ha b en questioned . In their tudie , the average
age of the men tudied wa 72 y ear , whereas t he
recommended age for creening i 50-70 years. A I o,
34.2% of the men with cancer in the tudy had moderately
or poor! differentiated di e a e, w herea in the .S.,
creening trial have shown that o ver 77.6% of men
diagno d with cancer had the arne lev I of di ea e.20 A
well, everal tudie ha ve hown that men treated by
radical pro tatectomy have the arne life expectanc as
age-match d m n without pro tate cancer, whereas there
i no available data demon trating the number of year
lo t if the e arne men were not treat d for their cane r.21
There ar
tudie s both for and a gainst the co teffectivene of PSA creening; how v r, conclu ive d ata
from long-term randomized clinica l trial will not be
available for another ten year .22
Conclusions
Wide pread creening for pro tat cancer by PSA ha
not yet been accepted in Ontario, evidenced by our lack of
Canadian guideline for creening, a well a the fact that
PSA te ting i not covered by OHIP. The American Cancer
Society, th American Urological A ociation and the
College of Radiology (U.S.) currentl y recommend that
men o er the age of 50 year hould undergo an annual
DRE and erum PSA for the purpo e of detecting early
pro tate cancer. Annual creening hould begin at the age
of 40 year in African-American men or patient with a
known famil hi tory of pro tate cancer.23
Curr ntly in Ontario, laboratory te ting i covered by
both public and private ector . Pri va te laboratorie
reco ver th ir co t by billing OHIP fo r in ured te t
covered by the provincial plan. Public lab ratories operate
mainly within hospitals and te ting co t are recovered
from ho pita! budget .24 Therefore, pati nt must pay for
the PSA creen if it is reque te d out ide of a hospi tal
etting (i .. in a famil y phy ician' office). The fact that
PSA creening i not yet cover d by OHIP hould not be
rea on to w ithhold it from patient in the identified ri k
group . The controver y of PSA creening come at a time
when co t control i a dominant cone m to the health care
y tern . In reality, cerv ical and brea t cancer creening
program were implemented at tim during which the
effect of th e creening program on mortality wa not
known.25 The fact that the burden of co t for this te t
currently lie with the patient, coupl d with the fact that
Canadian guideline do not currentl y upport the
wide pread u e of te ting, leave the family physician in a
tate of uncertainty a to whether or not to use PSA a a
creening tool in their practice.
One ce rtainty remain , pro tate cancer i a highly
prevalent problem in our odety. While the controver y
o er creening and treatment continu , all patient must
be educated on the ignificance of po itive test re ult ,
different mod of treatment (including watchful waiting)

and potential benefit and ide effect of the e treatment .
Thi edu ca tion mu t be fa irly comprehensive and take
place before the option of PSA te ting is given to th e
patient. While the jury i till out regarding both creening
and ub equent treatment, the magnitude of the problem
i uch that inaction cannot be tolerated. PSA screening
mu t be offered to informed patients 50-70 years of age
and tho e with risk factor 40-70 year old.
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o n y meta ta e a re a hall m ark of o m inou ,
d i eminated di ea e. They are more common than
primary bone tumour . In fact 70% of all
malignancie in bone are meta ta e from another primary
ource. 1·2.3 Skeletal meta ta e are pre ent in up to 85% of
all people with terminal carcinoma.1 The e metasta es are
frequently the pre enting complaint from which the
disease i di covered.
Alma t all malignant neopla m have been de cribed
to meta ta ize to bone at orne point. 3 However,
carcinoma of the brea t, pro tate, lung, kidney and
thyroid comprise 90% of bon y meta tases . u 3 . Le
common primary tumour include carcinoma of the kin,
e ophagu , oral cavity, tomach, cervix and colon. Only
23% of terminal colon cancer ca e how bony meta ta es
on autop y? In men, pro tate cancer i re ponsible for 60%
of bony meta ta e and bronchogenic carcinoma i
re pan ible for 25%. 2 In women, brea t cancer produce
70% of bony meta ta es with kidney, thyroid and uteru
causing nearly 30%. In children under five year old,
neurobla toma is th e mo t common primary neoplasm
meta ta izing to bone.
The mo t common ite for bony meta ta e i the
thoracic spine. Thi i followed by the lumbar spine,
pelvis, femur, rib, sternum, proximal h umeru and skull. 1•5
It i rare to ee bony me ta ta e di tal to the elbow or
knees. When the e o called acral metasta es are pre ent,
lung i the mo t common primary.1
Tumou r arrive at bone u ually via hematogenou
pread, although local inva ion i po ible. The pine in
particular i u rrounded by an ana ta mo ing va cular
network known as Bat on' Plexu _I.:z.s Thi rich plexu of
veins ha no valve .3 Thi fact allow for retrograde flow
of blood that bypa e the caval y tern and facilitate the
eeding of tumour cell in the pine. The hematopoietic
marrow of the axia l keleton i a l o upplied by rich
in u aid . Th e e may al o play a role in meta ta es
formation.
In the early tage , bony metasta e are u ually
a ymptomatic. 5 They often progre to pain, tenderne
and welling, increa ing in idiou ly for week or month _3
Thi pain i u ually war e at night. In the much rarer ca e
of sudden onset of pain, a pathological fracture i u ually
re ponsible. Other po ible presenting complaint may be
related to nerve root or pinal cord compromi e. p to
10% of patients with bony meta ta e will develop a
clinical picture imi lar to hyperparathyroidi m, due to the
productio n of rara thyroid hormone-like 0 teoclastactivating factor.
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Bony meta ta e can be either o teobla tic, o teolytic
or both.' 0 teobla tic le ion con titute 15% of all bony
meta ta e . They carry a better progno i than o teolytic
tumour . 1 They are frequently painle and have a lower
chance of pathological fracture . In men, pro tate and
te ticular seminoma are mo t often the primary tumour .2
In women, brea t, ovary and uteru are u u ally
re ponsible for bla tic metasta e .
0 teoblastic tumour produce cytokine that activate
o teoblast Y There i al o an a ociation with increa ed
alkaline pho phata e level and cau ing h pocalcemia. A
plain film of an o teobla tic le ion may how increa ed
bone den ity or clero i . However, a bone can i u uall
u ed to detect the e le ions.
Seventy-five per cent of bony meta ta e ar
o teolytic. Common primarie of lytic le ion include
kidney, brea t, lun g, ga trointe tina) and thyroid
tumour .3 The e le ion are more often a ociated with
h ypercalcemia. 0 teol y tic le ion re ult when tumour
produce sub tance that cau e bone re orption uch a
pro taglandins or vitamin D-like teroid . The tumour
may al o produce cytokine that induce o teocla t activity.
(eg. interleuken 1 and tumour necro i factor) .
Most tumour ma y produce both ly tic and bla tic
meta tases. Ten per cent of all le ion are ac tually a
mixt u re of both bla tic and ly tic component .2 Some
carcinomas, uch a hypernephroma, multiple myeloma
and thyroid carcinoma, can induce va cu larity at a
meta tatic ite producing an a neury mal le ion. 1 It i
important to note the e a they may need to b embolized
prior to urgery.
APPROACH
It i not unheard of for a cancer to pre ent a a focu of
bony metasta e . In the e ca e , the pre nting complaint
is u ually that of progre sive pine pain that may or may
not progre to include neurological ymptoms. Le s
often, the pre enting problem may be that of a
pathological fracture. In either ca e, a full work-up to
diagno e the primary le ion i indicated.
The recommended inve tigation into bony meta tase
of unknown origin begin with a detailed hi tory and
phy ical exam.1.6 In the female, concentration hould be on
the breast exam and Papanicolou mear. In the male, a
pro tate exam and Pro tate Sp cific Antigen are of pecial
intere t. Brea t and pro tate hould be the fir t thought in
a diagno tic inve tigation. The thyroid gland hould al o
be palpated thoroughly and an I-131 i otope tudy of the
thyroid i often indicated . A complete blood count,
electrolyte , urinaly i and alkaline pho phata e level are
the initial laboratory inve tigations of choice. 6 Pathology
examination of a biop y of th meta ta i may provide a
diagno is if the above inve tigation fail to yield the
n eded information.
Imaging i more helpful in finding the primary Je ion
than it i at det cting bony meta ta e . A che t x-ray,
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Prescri bing Information
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AREOlA*

(pamllronate disodium for onjecbon)
30
90
For I.V. infusion only

mo. so mo. mo

THERAPEUTIC CLASSIFICATION
Bone Metabolism Regulator
INDICATIONS AND CLINICAL USE
Tumor- Induced hypercalcemia follow ing adequate saline
rehydration.
Prior to treatment with AREOlA. renal excretion of excess calcium
should be promoted by restoring and mamtaming adequate fluid
balance and unne output
- Conditions associated with Increased osteoclast activity:
predominantly lytle bone metastases and multiple myeloma.
- Symptomatic Paget's disease of bone .
CONTRAINDICATIDNS
Known or suspected hypersensitivity to AREOlA. to any of its
components (see COMPOSmON in PIIARMACEUTICALINFORMATION
section), or to other bisphosphonates.
WARNINGS
AREOlA MUST NEVER BE GIVEN AS A BOLUS INJECTION SINCE
SEVERE LOCAL REACTIONS AND THROMBOPHLEBITIS MAY
RESULT FROM HIGH LOCAL CONCENTRATIONS.
AREOlA SHOULD ALWAYS BE DILUTED AND ADMINISTERED
AS A SLOW INTRAVENOUS INFUSION (see DOSAGE AND
ADMINISTRATION). REGARDLESS OF THE VOLUME OF SOLUTION
IN WHICH AREOlA IS DILUTED , SLOW INTRAVENOUS INFUSION
IS ABSOLUffiY NECESSARY FOR SAFETY.
AREOlA should not be giVen together with other bisphosphonates to
treat hypercalcemia since the combined effects of Utese agents are
unknown.
AREOlA should not be mtxed wtth calc10m-contammg mtravenous
inluSIOnS.
PRECAUTIONS
It is essenbal in the mitial treatment of tumour-indured hypercalcemia
that intravenous rehydration be instituted to restore urine outpul
Patients should be hydrated adequately throughout treatment but
overhydral!on must be avoided.
In pa ents with cardiac disease, especially in the elderly, additional
saline ovelload may precipitate card~ac fatlure (lett ventricular
failure or congestive heart failure). Fever (influenza-like symptoms)
may also contribute to this deterioration.
Although AREOlA IS excreted unchanged by the kidney, the drug has
been used without apparent mcrease in adverse effects in patients
with Significantly elevated plasma creatinine levels (includtng
patients undergoing renal replacement therapy with both
hemodialysis and peritoneal dialysis). However. experience w~h
AREOlA in patients with severe renal impairment (serum creatinine
>440 ~mol/l, or 5 mg/dl in TIH patients; <180 ~mol/l , or
2 mg/dl in muniple myeloma patients) is limited. If clinical
judgment determines that the potential benefits outweigh the risk in
such cases. AREOlA should be used cautiously and renal funcbon
carefully mon~ored .
Patients with Paget's disease of the bone, who are at risk of calcium
or vitamin 0 deficiency, should be given oral calcium supplements
and vitamin 0 to minimize the risk of hypocalcemia.
Patient Monitoring:
Patients should have standard labOratory (serum creatintne and
BUN) and clinical renal function parameters periodically evaluated,
especially those receiving frequent AREOlA infusions over a
prolonged penod of time, and those with pre-existing renal disease
or a predisposition to renal impairment (e.g., patients with multiple
myeloma and/or tumour-induced hypercalcemia). Auid balance
(unne output, dally wetghts) should also be followed carefully. If
there IS deterioration of renal function during AREOlA therapy, the
infusion must be stopped.
Serum electrolytes, calcium and phosphate should be monitored
followmg initiation of therapy with AREOlA. Patients with anemta,
leukopenia or thrombocytopenia should have regular hematology
assessments. Occasional cases of mild, transient hypocalcemia,
usually asymptomatic, have been reported. Symptomatic
hypocalcemia occurs rarely and can be reversed with calcium
gluconate. Patients who have undergone thyroid surgery may be
particularly susceptible to develop hypocalcemia due to relative
hypoparathyroidism.
In tumour-tnduced hypercalcemia, either ionized calcium or total
serum calcium corrected (ad1usted) for albumm should be
mon~ored during treatment with AREOlA. Serum calcium levels In
patients who have hypercalcemia ol malignancy may not reflect the
seventy of hypercalcemia, since hypoalbuminemia is commonly
presenl Corrected serum calcium values should be calculated using
established algorithms, such as:
I eta =tea + (0.02 x 140 - ALB)) I
where:
cCa =adjusted calcium concentration (mmol/l)
tCa = measured total calcium concentration (mmol/l)
A!.B = measured albumin concentration (gil)
Drug Interactions: AREOlA has been used concomitantly with the
follOWing medtcations without evidence of signtficant adverse
interactions: aminoglutethimide, cisplatin, corticosteroids.
cyclophosphamide, cytarabine, doxorubicin, etoposide, fluouracil ,
loop dturetics, megestrol, melphalan, methotrexate, mitoxantrone,
paclitaxel, tamoxifen. vinblastine, vincristine, and. in patients with
severe hypercalcemia. calCitonin or mithramycin.
Use in Pregnancy: There is no clinical evidence to support the use
of AREOlA in pregnant women. Therefore, AREOlA should not
be administered during pregnancy except for life-threatening
hypercalcemia.
In animal experiments, pamtdronate was not teratogenic and did not
affect general reproductive performance or fertility. In rats,
prolonged parturition and reduced pup survival were probably
caused by a decrease in maternal serum calcium levels. The tertii~
of the pups was also reduced. Pamidronate crosses the placental
barrier and accumulates in fetal bone.

lactation: There is no clinical experience with AREOlA in lactating
women and ~ is not known whether AREOlA passes into breast
millt A study in lactating rats has shown that pamidronate passes
into the mil Mothers treated with AREOlA should therefore not
breastfeed their intants
Pediatric Use: The safety and efficacy of AREOlA in children have
not been established. Until further experience is gained, AREOlA is
only recommended for use in adun patients.
EHects on Ability to Drive or Use Machines: In rare cases,
somnolence and/or diZZiness may occur, in which case the patient
should not drive, operate potentially dangerous machinery or
engage in other activities that may be hazardous.
ADVERSE REACTIONS
Adverse reactions with AREOlA are usually mild and transienl The
most common adverse reactions are influenza-like symptoms and
mild fever (an increase '" body temperature of> 1"C, which may last
up to 48 hours). Fever usually resolves spontaneously and does not
require treatment. Acute "influenza-like" reactions usually occur
only with the first AREOlA infusion. The table below shows the
inctdence of the more commonly observed adverse effects overall
and by indication.
Adveru experiences by body system: Frequency estimate: frequent
>10%, OCtaSIOnai >1-10"4, rare >0.001-1 '/o, isolated cases <0.001 '/o.
Body as a whole: Frequent fever and influenza-like symptoms
somebmes accompanied by malaise, rigor, fatigue. and flushes.
Isolated cases: allerg~ reaction (swollen and ~thy eyes, runny nose
and scratchy throat).
local reactions: Occastonal: reactions at the infusion site: pain,
redness, swelling, induration, phlebitis, thrombOphlebitis.
Musculoslleletal system: Occasional: transient bOne pain, arthralgia,
myalgia, generalized pain, skeletal pain. Rare: muscle cramps.
Gastrointestinal tract: Occasional: nausea, vomiting. Rare:
anorexia, abdominal pain, diarrhea, constipation, dyspepsia.
Isolated cases: gastritis
Central nervous system: Occasional: headache. Rare: symptomatic
hypocalcemia (paresthesia, tetany), agitation, confusion, dizziness,
insomnia, somnolence, lethargy. Isolated cases: seizures, visual
hallucinations in one case
Blood: Occasional: lymphocytopenia. Rare: anemia, leukopenia
Isolated cases: thrombocytopenia. One case of acute lymphoblastic
leukemia has been reported in a patient with Pagefs disease. The causal
relationship to the treatment or the underlying disease is unknown.
Cardiovascular system: Rare: hypotension, hypertension. Isolated
cases: left ventricular failure (dyspnea, pulmonary edema),
congestive heart failure (edema) due to fluid overload
Respiratory system: Isolated cases: adult respiratory distress
syndrome, interstitial pneumonitis.
Renal system: Isolated cases: hematuria, acute renal failure ,
deterioration of pre-existing renal disease.
Skin: Rare: rash, prur~us .
Special senses: Isolated cases: conjunctivitis, uveitis (iritis,
iridocyclitis). scleritis, episcler~is, xanthopsia.
0\he!$: Isolated cases: reactivation of herpes simplex and herpes zoster.
Biochemical changes: Frequent hypocalcemia, hypophosphataseia
Occasional: hypomagnesemia. Rare: hyperkalemia, hypokalemia,
hypematremia, symptomatic hypocalcemia
Isolated cases: abnormal liver function tests. increase in serum
creatinine and urea
Many of these adver58 events may have been related to the

underlying dise<lse.
Tumour-Induced Hypercalcemia and Paget's Disease: Adverse
experiences considered to be related to AREOlA occurring in :!.1 '/o
of patients in the specified indication·
Adveru
Experiences
No. of patients
Fever
Headache
Hypocalcemia
lnfluenza-li e
symptoms
Infusion site reaction

Malaise
Myalgia
Nausea
Pain (bOne)
Pain (unspecified)
Rtgors

Tumour-Induced
Hypercalcemia

Paget's Disease

n=910

n=395

('lo)
6.9
0.0
3.2

('lo)
B.9
4.8
0.8

0.0
1.7
0.0
0.0
0.9
0.0
0.0
0.0

11.9
1.8
5.8
2.0
2.0
8.9
7.9
2.8

Oetenoration of renal function has been noted 1n patients treated
with bisphosphonates. Since many patients with tumour~nduced
hypercalcemia have compromised renal function prior to receiving
antihypercalcemia therapy (see PRECAUTIONS), ~ is difficun to
estimate the role of tndividual bisphosphonates in subsequent
changes in renal function . Oeteriora ·on of renal function (elevation
of serum creatinine of >20'1o above baseline) which could not be
readily explained in tenms of pre-existing renal disease, prior
nephrotoxic chemotheraptes or compromised intravascular volume
status has been noted tn 7 cases of 404 patients treated with
AREOlA where these data have been reported. The role of
pamidronate disodium in these changes in renal function is unclear,
but merits cautious observation.
Bone Metastases and Multiple Myeloma:
The most commonly reported adverse experiences regardless of
relationship to therapy have been shown.
Deterioration of renal function (including renal failure) has been
reported following long-tenm treatment with AREOlA in patients
with multiple myeloma. However, underlying disease progression
and/or concomitant complications were also present and therefore
a causal relationship with ARE OlA is unproven.
DOSAGE AND ADMINISTRATION

Dosing recommend3tJOns differ for tumour-induced hypercalcemia,
lytic bone metastases and multiple myeloma, and Paget's disease.

For p;~ffents suffering from TIH and muffiple myeloma, see the TIH
dosage guidelines.

AREOlA must never be given as a bolus Injection (see WARNINGS).

AREOlA should be administered tn a compatible calcium-free
intravenous solution (e.g., sterile normal saline or dextrose 5'/o 1n
water). AREOlA should be infused slowly.
To minimize local reactions the cannula should be carefully inserted
in a relatively lauge vein.
The infusion rate should never exceed 60 mg/h (1 mg/min), and the
concentration of AREOlA in the infusion solution should not exceed
90 mg/250 mL A dose of 90 mg should normally be administered as
a 2-hour infusion in 250 ml infusion solution. However, In pallents
w~ multiple myeloma and in patients with tumour-Induced
hypercalcemia it Is recommended not to exceed !10 mg In 500 ml
over 4 hours (i.e., an infusion rate of 22 5 mg/11)
Renal Impairment: Pharmacokinetit studies indicate that no dose
adjustment is necessary in patients with any degree of renal
impairment when AREOlA is administered as recommended. However,
until further experience is gained, a maxtmum infusion rate of
22.5 mg/h is recommended in renally impaired patients.
Dosing Guidelines for Tumour-Induced Hypercalcemia:
The recommended total dose of AREOlA for a treatment course depends
upon initial plasma calcium levels. Doses should be adapted to the
degree of severity of hypercalcemia to ensure normalilalion of plasma
calcium and to optimize the duration of response_ Rehydration with
normal saline before treatment is recommended (see PRECAUTIONS).
A dose of !10 mg shcMIId be administered In 500 ml of Infusion
solutioo. The infusloo rate shcMIId nolexceed 22.5 rng/llollr.
The total dose for a treatment course may be given as a single
infusion, or in multiple infusions spread over 2-4 consecutive days.
The maximum dose of AREOlA per treatment course is 90 mg
whether for in~ or repeat treatment courses. Higher doses have
not been associated with increased clinical effect.
Decreases in serum calcium levels are generally observed within
24-48 hours after drug administration, with maximum lowering
occurring by 3-7 days. If hypercalcemia recurs, or Hplasma calcium
does not decrease within 2 days, repeat infusions of AREOlA may
be given, according to the dosing guidelines. The lim~ed clinical
experience available to date has suggested the possibility that
AREOlA may produce a weaker therapeutic response with repeat
treatment in patients with advanced cancer.
Dosing Guidelines For Bone Metastases And Multiple Myeloma:
The recommended dose of ARE OlA for the treatment of
predominantly lytic bOne metastases and multiple myeloma is 90 mg
administered as a single infusion every 4 weeks. In patients with
bOne metastases who receive chemotherapy at 3-weekly intervals,
AREOlA 90 mg may also be given every 3 weeks. A dose of 90 mg
should normally be administered as a 2-hour infusion in 250 ml of
infusion solution. However, in patients with multiple myeloma it is
recommended not to exceed 90 mg in 500 ml over 4 hours.
Radiotherapy is the treatment of choice for patients with solitary
lesions in weight bearing bOnes.
Dosing Guidelines For Paget's Disease Of Bone:
The recommended total dose of AREOlA for a treatment course is
180-210 mg. This may be administered either as 6 doses of 30 mg
once a week (total dose 180 mg). AAematively, 3 doses of 60 mg
may be administered every second week, but treatment should be
initiated with a 30 mg dose (total dose 210 mg) as influenza-like
reactions are rornmon only with the first infusion. Each dose of
30 mg or 60 mg should be diluted in at least 250 ml or 500 ml,
respectively, of normal saline or OSW. An infusion rate of 15 mg per
hour is recommended. This regimen, omitting the initial dose, can
be repeated after 6 months until remission of disease is achieved,
and when relapse occurs.
Stability And Storage Recommendations:
Protect vials from heat (i.e., store below 30" C).
Reconstitution Of lyophilized Vials:
Each vial of sterile lyophilized powder should be reconstituted with
Sterile Water for Injection prior to dilution as given in the following table:

~----------~~R~e~co~n~st~it=uti~
P o~
n ~Ta~b~le~--~~~~--~
Y1al stze

30 mg/10 ml vial

AlltJroximate

Volume of
diluent to
be added
to the vial

available
volume

10 ml

10 ml

Nominal
concentration

3 mgtml

60 mg/10 ml vial 10 ml
10 ml
6 mgtml
L90
~mg/1
~0~m
~l~vial
~·~~1~
0~
m~
l --~1~
0~
m~
l ~~~
9~
mg/m
~L~~
Dilution Of Reconstituted Solution For I.V. Infusion:
Reconstituted solutions that have been prepared with Sterile Water
for Injection should be further diluted with e~r 0.9% sodium
chloride or 5'/o dextrose prior to intravenous infusion administration.
O~uted solutions prepared in this manner should be used within
24 hours from initial entry (reconstitution) when stored at room
temperature (t 5-30"C) due to the possibility of microbial
contamination during preparation. Discard the unused portion.
All parenteral products should be visually inspected for particulate
matter and discoloration prior to admtnistration. Any solution found
to have particulate matter or discoloration should be discarded.
Incompatibilities: AREOlA must not be mixed with calciumcontaining infusion solutions, such as Ringer's solution.
AVAILABILITY OF DOSAGE FORMS
AREOlA 30 mg vials for injection:
Each vial of white to practically white lyophilisate contains
pamidronate disodium (30 mg). Available in cartons of 2 vials.
AREOlA 60 mg vials for injection:
Each vial of white to practically white lyophilisate contains
pamidronate disodium (60 mg). Available in cartons of 1 vial.
AREOlA 90 mg vials for Injection:
Each vial of white to practically white lyophilisate contains
pamidronate disodium (90 mg). Available in cartons of 1 vial.
Product Monograph available upon request.
References: t . Hortobagyi GN, et al. Jof Ciin One 1998; 16(6): 1-B.
2. Berenson JR, et al. NfngiJMer1 1996; 334: 488-493.
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abdominal CT and pelvic CT are usually indicated in
dis eminated neoplastic disea e. 6 Plain films of the bone
where metastases are su pected are often of little value.
0 teolytic le ions tend to show up on plain films only
after the cortex has become involved. 7 Usually, tumours
embolize to marrow fir t and only invade the cortex after
orne growth (usually at least 1 em diameter) has
occurred. This invasion of th e cortex produces the
o-called "cookie-cutter" le ion on a plain radiograph.2
Typically, 30% to 50% of cortical bone mineral must be lost
before the lesion how up on x-ray. Therefore, bone scans
often how po itive meta tase up to four months before
plain film _3
In 3% to 4% of case of isolated bony metasta e , a
primary is not found. 6 Although most bony meta ta es are
from pro tate or breast, tho e that remain unknown are
not likely to be from either of the e two common cancers.
The e are both ea ily examined and local symptoms are
usually pre ent. Undiagno ed primaries are more likel to
be from deeper visceral organs such a kidney or lung. If
the aforementioned inve tigations do not yield a
diagno is, further investigation is likely not indicated. The
disease is severe and the progno is is already known to be
poor. It should seriou ly be considered to treat this patient
palliatively and pare them the di comfort of further
aggre ive te ts.
MANAGEMENT
The pain cau ed by bony meta ta e hould not be
undere timated . Palliative pain management is often
neces ary to reduce the morbidity of the di ea e .
Hormonal regulation plays a role in controlling the
ymptom of bony meta ta e ! AI o effective for the e
common tumour is local radiation therapy consisting of
3000 cGy for ten day . More radiore istant tumour , uch
a renal cancer or melanoma, may re pond favourably to
4000 cGy to 5000 cGy for ten days. This ha been hown to
ignificantly reduce pain one month po t-treatment in 0%
of ca e ! Thi i al o a ociated with a change from an
o teolytic picture to an osteoblastic one.
Pathological fracture of a bone due to metas tatic
di ea e i mo t often an indication for urgical treatm nt.
Twenty y ear ago, the mean urvival followin g a
pathological fracture was 7.8 month ... Due to the
development of better surgical technique and
radiotherapy, the current mean urvival following all
pathologic fracture i 1 .8 month . Specifically, the m an
urvival following fracture due to pro tate cancer i 30
month , breast cancer i 22.6 months, kidney cancer is 11.8
month . The wor t progno is follow pathologic fracture
due to lung cancer with a mean urvival of 3.6 months.
75% of all pathological fracture urg ry i performed
on the hip. The most common site for fracture is
intertrochanteric followed by the femoral neck. Often a
meta ta i to the femur i identified befor fracture occurs.
In this ca e it is the responsibility of the Orthopaedic
Surgeon to decide whether prophylactic internal fixation
i nece ary prior to local radiation. The current criteria for
prophylactic tabilization con ist of one of: 50% cortical
lysi ; 2.5 em diameter femoral le ion; avul ion fracture of
the les er trochanter and f>ersi tent pain four w ek after
local radiation therapy . Other site of pathologi cal
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fracture that commonly require surgical stabilization
include the hafts of the femur and humeru and the
acetabular area.
Metastases to the spine produce further issues in
management. The presenting complaint of pinal
metasta e is that of progre ive pain persisting for weeks
to month . Mo t pinal metasta e can be adequately
managed with local radiation therapy and medication.
However, in the event of neurological symptoms such as
motor or ensory changes, radicular pain or alterations in
bowel and bladder function, more aggressive treatment
needs to be instituted. The mid-thoracic pine is the mo t
common ite for pinal meta ta es. 1•9 The narrow vertebral
canal in this area also make it more prone to spinal cord
compression. This is followed by the thoracolumbar area.
The cervical pine i more rarely affected partially due to
the wide vertebral canal at thi level. Prostate and breast
cancer u ually appear at multiple ite along the pine
wherea lung cancers often metastasize to one focal
point.s,9
Spinal cord compre sion occurs in 5% to 10% of all
cancer patient .5•6•1° Cord injury occurs when meta ta es
from the vertebral body or pedicle encroach upon the
pinal canal and compress the dura. Alternatively, it is
pos ible for a tumour from the paravertebral area to
invade into the pinal canal through the intervertebral
foramina.
If neurological symptoms pre ent with back pain, an
emergency work-up for cord compre ion i indicated.
Upper motor neuron finding (ie, upgoing toes, spa ticity
and hyper-reflexia), en ory lo s and lo of autonomic
sphincter control may all be present. MRI is the
investigation of choice to diagno e cord compre ion. If
cord compre ion is u pected on history and physical
exam, dexamethasone can be given immediately (do e 6
mg po q6h, can be doubled if nece ary). 5 The goals of
therapy are to reduce pain and to pre erve neurological
function. This i u ually accomplished with radiation
therapy and glucocorticoid . With thi protocol, 75% of
tho e patient who are ambulating on pre entation will
remain ambulatory . However, only 10% of those who
have lo t their ability to walk will regain it.
Surgical decompre ion and tabilization is required
in orne ca e of vertebral collapse and cord compromi e.1
The current indications for surgery are: a radiore i tant
tumour; local radiation failure; pathological fracture; and
rapidly developing neurological symptoms. 5• 11 •12 Formerly,
a laminectomy alone wa the procedure of choice;
however this led to a destabilized pine, kyphosi and
further cord damage. 12 ow, an anterior decompre ion
with pins and bone cement or a femoral allograft is used if
this aggre ive anterior thoracotomy can be tolerated. Thi
i a particularly effective procedure as most le ions are
actually anterior to the cord it elf. In the lumbar area, due
to the large amount of force that the spine mu t bear,
posterior tabilization is al o nece sary. Bone grafting is
contraindicated as local radiation therapy follows
surgery. 11
Cancer is a disease that no physician can avoid
dealing with . A large component of cancer treatment
consi t of treating the complications of the di ea e. In the
case of bony meta ta e , correct identification, approach
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and mortality from the primary di ease.
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OVERVIEW OF THE PALLIATIVE
ROLE OF RADIOTHERAPY
By Eric Wong, MEDS 2002

I TRODUCfiON
adi~th_erapy

play major roles in both radical and
palliative cancer treatment . Radical radiotherapy i
more aggre ive form of management that target
cancer patient who have limited tumour and a
reasonable chance of cure. Meanwhile, palliati ve
radiotherap manage incurable patient , with the goal of
alleviating their cancer-associated
ymptom .
Radiotherapy i further categorized by technique of
delivery into two Proup : external beam therapy and
internal therapy . Modern external beam therap y
primarily utilize megavoltage teletherapy, which
include linear accelerator that produce proton and highenergy electron beam , and cobalt-60 units that emit
gamma ray . 1• 2 It is uitable for many uperficial and
deep- eated malignancie . Internal therapy is divided into
brachytherapy and y temic therapy. Brachytherapy refer
to the direct implantation of ealed radioactive ource or
intracavitary ource placement, 1• 3 and is mainly u d for
urface treatment, tumor in the intracavitary pace
(cervix, uterus), and inter titial implant within ti ue
(brea t and tongue) . 1 Sy temic therapy u e un ealed
radioi ope . It major applications include th yroid
carcinoma and hyperthyroidism, polycythaemia vera, and
cancers of the peritoneal cavity.1
BASIC PRINCIPLES
Radiotherapy i an important palliative tool becau e
of its ability to remarkably relieve certain ymptom of
advanced- tage cancer . It i often pre cribed to effectively
manage pain from bone metastases and ulceration,
vi cera! ob truction, bleeding, neurological deficit ,
pathological fracture , and other systemic symptom . 1• 4
However, ince radiotherapy i not the only modality that
can alleviate ymptom a ociated wi th advanced- tage
tumour , indication and contraindication ha ve been
outlined to guide its u age ( ee Table 1).
Be ide directing the appropriate u age of palliative
radiotherapy, the indication and contraindication in
Table 1 also emphasize the goal of palliati ve
radiotherapy. The e include achievement of rea onable
ymp tom relief with horter duration of therapy than
radical radio therapy, complete and durable palliation,
minimization of patient inconvenience and di comfort,
and minimization of toxic effects and hospital tay. 4• 6
Other palliative modalities,
uch as
urgery,
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chemotherapy, and analge ics, may contribute to
ymptom management a adjuvant palliation.
COMMO USAGES
There are pecific clinical manife tation for which
palliative radiotherapy ha proven to be effective. The
mor dominant one include keletal or bone meta ta e ,
pinal cord compre sion, brain meta ta e , and
media tina1 meta ta e .
Skeletal Metastases
Meta ta e found in the bone are mo tly multiple, and
originate primarily from tumor of the brea t, prostate and
lung . 4 • 5 The main role radiotherapy play in the e
ituations i the relief of pain. Radiotherapy i u ed only
when the patient i ymptomatic, and thi occur in threefourth of patient with keletal meta ta e .2. 5 Pain is th
re ult of two proce e triggered by the tumour cell :
o teoly i and o teo clero i .5• 6 There are two main
mechani m of o teoly is. In the direct method, tumor
cell either re orb bone them elve , or activate o teoda t
through th relea e of chemical uch a growth factor ,
pro taglandin , and cy tokine . On the other hand, the
indirect mechani m involve timulation of immune cell
by the tumour cell to produce the arne chemical that
induce o teocla tic activity .2 • 6 Pain produced b
o teo clero i rarely occur , and i usually limited to
meta ta e from pro tate cancer, and in about 10% of
brea t cancer. 5
Once the bone pain ha been confirmed to be the
re ult of bone cancer, a therapeutic deci ion i often mad
between urgery and external beam therapy.2 Surgery i
required if bone ha already be n fractured, or if there i
an impending fracture in the affected long bon . In ca
where urgery i not required, local ionizing radiation
alone ha proven to be very effective in managing keletal
ymptom . Moller' 5 meta-analy i of 19 retro pective
tudie observed that 40% to 50% of patient reported
com plete pain relief in re pon e to localized irradiation,
while an additional 30% reported partial pain relief. The e
re ult agree with tho e of a randomized trial conducted
by the Radiation Therapy Oncology Group (RTOG )
between 1974 and 19 0. The RTOG trial found that 90% of
all patient treated wi th local external beam therap
received partial pain relief while 64% received complete
pain relief.
Although the ucce of local e ternal beam therapy in
alie iating keletal ymptom i unque tionable, there i
controver y over which type of treatment module i mo t
effec tive and efficient.H Main variation in treatment
plan include do age of radiation and fractionation
chedule . Moller5 analyzed ix pro pective randomized
tudie and concluded that there wa no con ensu on the
optimal type of treatment delivery module ba d on the e
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vanahons.
In the pre ence of multiple bone le ions, local external
beam therap become le applicable, and i u ually
replaced b hemi-body irradiation. The upper body and
lower bod are u ually treated quentially, with a 2 to 4
week interval to allow for the recovery of bone marrow.
Although hown in everal tudie to provide faster pain
relief, thi method of delivery re ult in more prominent
toxic effect than conventional, local irradiation. 5• 6 The
ide effect u uall involve the lung , ga trointe tinal
tract, and mucou membrane .5 Erne i i the mo t
common one, which affect up to 0% of patient w ho
receive a ingle high do e of radiation to either half of
their bodie .6 Pneumoniti i a po ible side effect, but can
be avoided by u ing lower do age to the upper body. 4
Pretreatment ho pitalization with dru ~ prophylaxi i also
u ed to minimize patient di comforts.
When bone meta ta e are too numerou , or when
they are unre pon ive to ext rnal beam therapy, the
patient can be managed with y temic therapy, a le
widely u ed treatments. 6 Meta ta e from the pro tate
and brea t re pond mo t avidl y to thi form of
radiotherapy. Pre ently, two main type of radionuclei are
u ed for the alleviation of y mptom a ociated with
keletal meta ta e : pho phoru 32 and trontium 9.2.-1-6
They are both introduced into the body intravenou ly, and
are absorbed more efficiently by tumour and bone ti ue
than normal ti ue .5• 6 Re ult from randomized studie
on mptom alleviation have b en encouraging for both
radionuclei. Approximately 70% of patients trea ted with
pho phoru 32 report orne degree of pain relief, although
myelo uppre ion wa a major ide effect. Strontium 9
ha al o been a ociated with ignificantly greater pain
relief than placebo, but with le
eve re
myelo uppre ion. 2• 5• 6 One etback for trontium 89 i it
long half-life, which re ult in a longer latency period than
pho phoru 32 b fore pain relief b gins. 5
Spinal Cord Compression
Meta ta e to the vertebral column that result in
pinal cord compre ion occur in 5-10 % of cancer
patient .4-6 Like meta ta e to other part of the keleton,
brea t, pro tate, and lung cancer are u ually the common
primary tumour in the e ca e .5 The thoracic vertebrae i
the mo t common ite of meta ta i , accounting for 70% of

all vertebral meta ta e . Becau e vertebral bod y
involvement i frequent, mo t compre ions a ociate with
the anterior a pect of the pinal cord. Con equentl y,
compromised motor functions repre ent dominant, early
ymptom .5• 6 Other cia ical ymptoms of pinal cord
compr
ion include back pain, bladder and bowel
dy function, and numbne .4
Spinal cord compre sion require
prompt
management becau e a patient' s neurological function i
at take. Radiotherapy i highly indicated a treatment
unle
the patient expre e vertebral in tabilit y,
compre ion due to bony deformity, high cervical cord
compre ion that jeopardize re piratory function, or
unre pon ivene s to radiotherapy. In the pre ence of the
cenario , urgery i the alternate treatment. 6 Prior to local
external beam irradiation, patient are usually prescribed
cortico teroid
(e .g. de amethasone) to reduce
neurological ymptom due to va ogenic edema .2• 4• 6
Localized external beam therapy that include 1 or 2
vertebrae above and below the cord block to be treated i
extremely effective in relieving pain. From an analy i of
everal tudie , Molle reported a 50% to 95% pain relief
for patient treated with external beam therapy alone.
Meanwhile, rever al of neurological deficit depend
largely on pretreatment neurological tatus.5· 6 If a patient
could ambulate independently at the tart of treatment,
there i a 70 % to 90% chance that mobility can be
maintained. This contra t with a 10% to 30% chance of
regaining ambulatory ability after irradiation for patient
who were paretic prior to treatment. 5
Brain Metastases
Patient with brain meta ta e have extremely poor
progno i . Untreated, their median urvival time range
from 1 to 2 month .4• 6• 7 The mo t common ource of brain
meta ta e i lung cancer. 4• 6 Prevalent symptom include
headach , focal weakne , behavioural change, eizures,
ataxia, and apha ia. 4 At time , more eriou condition
uch a hydrocephalu , herniation of cranial content , and
va ogenic edema often complicate treatment. 2 Like
treatment of pinal cord compre ion, initial therapy
include cortico teroid , which i effective in extending
urvival to about 2 to 3 month if pre cribed alone. And
complications, uch a ei zure and hydrocephalu , mu t
be tabiliz d before radiotherapy can be initiated.

Table 1. In dications and Contraindications fo r Usage of Palliative Radiot!Jerapi· 4
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Indications

Contraindications

relief of pain
relief of neurological deficit
re toration / pre ervation of
function I co mesi
relief of ob truction
control of bleeding
re traint of tumor growth
maintenance of keletal integrity
prevention of fi tula
relief of
temic symptom
Promotion of healing

availability of more effective therapy
availability of more ea ily admini tered therapy
unrea onable ri k of quelae
low probability of ucce
pregnancy
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External beam therapy for the whole brain i an
effective method in relieving symptom and increasing
urvival time for bo th solitary and multiple cerebral
meta ta e . Surgery i usually indicated prior to radiation
treatment in the pre ence of olitary meta ta e . Together
with the admini tration of cortico teriod , whole brain
irradiation typical yield urvival time between 3 to 5
month .~. 6• 7 Collectively, tudie have shown that external
beam therap y a a primar y treatment of cerebral
metastases relieves symptom and improve neurological
tatu in 50 % to 90% of patient .2• ~. 6• 7 There i al o
indication that po toperative whole brain irradiation i
able to increa e durability of palliation from urgery and
median urvival time, and decrea e recurrence rate .4• 6• 7
However, thi only applie for patient who have one or
few brain meta ta e that are acce ible by urgery, and
who are generall y in good condition .7 One major
imperfection in whole brain irradiation i the high
recurrence rate , which often require patient to be reirradiated. Even though re-irradiation from everal tudie
point to a 69% to 79% impro vement in all patient
treated, the concern for acute and ubacute equelae
ari e .7
Patient generally tolerate toxic effect of whole brain
irradiation quite well. 6 Acute adver e effect from whole
brain irradiation include fatigue, epilation, and kin
erythema. 6• 7 Subacute toxicity u ually ari e within 3 to 10
w eek after radiation treatment, and may con ist of the
omnolence yndrome, or tran ient neurological
deterioration that u ually re olve in an additional 6
w eek .7 Late equelae are le common becau e of the
limited life e pectancy of the patient , but dizzine ,
headache, hort-term memory lo , and severe dementia
have been noted. Moreover, cortical atrophy, ventricular
dilatation, and hypoden e white matter have al o been
ob erved.6• 7
A more aggre ive form of treatment, like tereotatic
radio urgery, may al o be of value for patient with
olitary or few cerebral meta ta e . It involves the delivery
of high do e of radiation to limited volume of ti ue
u ing a cobalt-60 gamma knife. Although further studie
are required to tudy it b nefit and setback , tereotactic
radio urgery ha been a ociated with high local tumour
control, 64% to 99% in evera1 inve tigation , and with few
morbidity.H 6 Brain toxicity becom a concern only when
there are more than a few meta ta e to be treated.~

A rti c l e s

u ually the fir t and main treatment for relief of the e
ymptom . It i extremely effective, having re pon e rate
from 70% to 0% that can begin ubjectively a arly a 3
to 4 days, and obj ctively b tween 1 to 3 week .~. 6 Toxic
effect are generally mild and tolerable, with dysphagia
being the more prevalent one? The external beam therap
involved begin with higher do e of radiation in order to
illicit greater r ponse, and then turn to lower dose and
more fractionated chedule . 2 • ~ At time , relief of
ymptoms do not correlate with an increa e in venou
drainage through the uperior vena cava. Thi i
indicative of ob tructive thrombo i , which can b readil
re olved if thrombolytic therapy wa prescribed
promptly .~ In the event of recurrence or unre pon ivene
after radiotherapy to tolerance do es, patient may be
eligible for an intra venou in ertion of expandable
pro the i into the uperior vena cava that ha been
a ociated with high ucce in relie ing ymptom .6
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Mediastinal Metastases
Meta ta i to the media tinum is a common
complication of advanced lung cancer. Common
media tina! meta ta es include ob truction of the
e ophageal, bronchi, and uperior ena cava. Ob truction
of the uperior vena cava i the mo t freq uently een type
of complication, and account for 75% of all thoracic
meta ta e . The progno is of the e patient i poor, with a
median survival time of only 3 months. 6 Being regarded a
a medical emergency, uperior vena cava obstruction
receive prompt interventions.
The ymptom of superior vena cava yndrome
include dilatation of veins, edema in the che t, neck and
upper extremities, cough, orthopnea, headache,
d y phagia, dizzine s, and che t pain.:z. · 6 Radiotherapy i
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PALLIATION OF INOPERABLE
CANCER OF THE ESOPHAGUS WITH
STENTS: A SYSTEMATIC REVIEW
By Gabriel Chan, MEDS 2000
he diagno i of esophageal cancer carries a v ry
grave progno i . In Ontario, the median survival i
le than a year and the 5-year relative urvival rate
i 12% for male a nd 15% for female . 1 The onset is
in idiou and the majority of patient pre ent at an
advanced stage with pain, evere dy phagia and weight
lo . Cure i only po ible by urgical re ection, if the
cancer i detected at an early tage. When the tumor i
unre ectable, then th e main objecti ve of therap i
palliation.
At pre ent, there is no definitive palliative treatment
for inopera ble e ophageal cancer. Conventio na l
intervention include e ternal radiation therapy a nd
chemotherapy. Different centre worldwide apply variou
other therapie , including imple dila ti on, endoluminal
la er therapy, brachytherapy, electrocoagulation, alcohol
injection clerotherapy, photodynamic therapy and tent
placement. However, mo t of the palliative therapie are
a ociated w ith a ignificant morbidity and mortali ty.
E ophageal s tent are u ed primarily to tre at
malignant d y phagia and re ultant cachexia. They do not
directly tern the growth of th cancer. Initial endoluminal
tent were rigid pla tic tube and had to b introd uced by
laparotom involving a high mortality rate. 2•3 The
development of lapro copic technique allowed for a le
traumatic placement, but the delivery y tern wa till
cu mber orne and res u lted in many proced ure-rela ted
complication .-1-6 Pia tic tent have the ad antage f a
one-time treatment and the additional ability to eal off
fi tula with a modified cuff. Recently, expandable m tal
tent ha ve been de igned for an ea ier delivery, fewer
complication and les ened chance of migra tion. The
deployment i guided by Barium w allow, fl uoro copy
and po ibly endo copy. Some of the current model in
u e include the Wall tent endopro the i (Schneider AG,
Zurich, Sw itzerl a nd) 15, the Ultrafle device (Bo ton
Scientific Corporation, Watertown, MA, USA) [16] and the
Gianturco tent (William-Cook Europe, Bjaever kov,
Denmark). 17
Thi article review the literature for ra ndomi zed
controlled trial comparing the effectivene of vari u
tent to other pallia tive therapie for patient w ith
inoperable e ophagea1 cancer. The primary focu i on the
improvement of the pa tient ' q uality-of-life, especia lly
w ith regard to the d ysphagia, a significant ourc of
morbidity and mortality. The econdary focu is on the
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improvement of urvival.

METHODS
The MED LINE, EMBASE and CANCERLIT databa es
were earched for randomized controlled trials tudying
the treatment of inoperable e oph ageal ca n cer. The
MEDLI E da taba e was searched w ith the OVID
program, through the year January 1, 1966 to September
11, 1997. The earch parameter included the MeSH
su bject term, "esophageal neopla m " the publica tions
term , " clinical trial, pha e III" and " random ize d
controlled trial " and the text words, " u nre ectable",
"advanced" and "inoperable" . The EMBASE da taba e and
CA CERLIT databa e were earched for article from
1980 to 1997 using the MeSH term "esophagus cancer"
a n d the publication terms " experimen tal con trolled
t u dy ", "double blind procedure" and "single blind
procedure" . The reference li t of trial and review articles
were al o re v iewed, a w ere textbooks related to
e ophageal oncology.
Articles were included in thi review if they were
randomized controlled trial comparing the u of tents
for inoperable e ophageal cancer. Article were excluded
if they w e re not limited to patient with e op h ageal
can cer, we re not focu ed on palliation or treatment, or
included urgery a part of the treatment.
Data concerning the patient population, interventions
and the end-point of median urvival, quality-of-life and
the rate of complication were extracted . Quality-of-life
data cone rning the improvement of wallowing function
or reli f of d y phagia were u ed to gauge the effectivene
of the therapies.
RESULTS
The initial method intended wa a meta-analy is of
the publi hed trial to reach an Ev idenced-Sa ed
Recomm e n dation for the treatment of inoperable
e ophageal cancer according to the protocol set out by the
Cancer Care Ontario. At pre ent, thi i not fea ible with
the numb r of publi hed trials and their heterogeneity. A
y tematic review of the e trial w as done and pre ented
in Table 1.
DISCUSSION
Two publi hed randomized trials compare the efficacy
of plastic tents and e pan ile metal t nt in the palliation
of malignant d y phagia are reviewed. Kny rim et al'
compared the Wil on-Cook pla tic stent to the Wall tent
expan ile metal stent and found no significant difference
in urviv al, nor in the impro ve ment of d y phagia or
Karno£ ky core . Both the pla tic and metal type of tent
improved dy phagia cores significantly. The advantage
of expan ile metal stents was that complications uch as
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TABLE 1. Randomized Controlled Trials with Oesoehageal Stents in the Palliation
of Malignant D ysphagia
Investif(ator
Knyrim 1993 7
DePalma 1996 8
Adam 1997 ' 0

Alderson 1990 9
Reed 1991 u

I Nicolaou 1982 11
Alberts 1992 13
Schmid 1993

14

I 11 terven tion ( # )
WiJ on-Cook (21)
Wallstent (21)
Wilson-Cook (20)
Ultraflew (19)
Nd :YAG Laser (18)
Uncovered Strecker (19)
Wallstent or Gianturco (23)
Nd :YAG Laser (20)
Celestin or Atkinson (20)
Atkin on (10)
Atkinson + RT ( )
Nd:YAG Laser+ RT (9)
Cele tin + CT' (12)
Celestin (12)
Cele tin or PL + IT + RT (10)
Celestin or PL (10)
Cele tin or PL + RT (41)
Cele tin or PL + cr<l (40)
Cele tin or PL (46) 9 w k.

Median Survival
146 ± 29 d .
167 ± 28 d.·
6.2mo.
6.6mo.
56 d .
60 d.
48d.
12 wk.
16 w k.
119 ± 82 d.
72 ± 62 d .
169 ± 92 d ..
i82 d .
117 d .
11 wk.
19 wk. (P=0.03)
9wk.
11 wk.
15wk.

Swallowillf( Score
3 -+1
3 -+1e
3.0 -+ 1.0
2.9 -+OS
3 -+ 2
3 -+1
3 -+ 1e
85%
85%r
+ 2.3 ± 1.1
+ 1. ± 1.0
+ 1.4 ± 0.58
(not recorded )
(Semi- olid)
(Semi-solid)
(not recorded)

Comp lications
43%*
0%**
22.2 %*
0 %**
11%*
5%*
9%*
20 %*
5%*
50%*
100%*
0%*
100 %b
(not recorded )
70%*
(not recorded)
(not recorded)

(PL: Procter-Living tone plastic stent; RT: radiation therapy; Cf: chemotherapy)
a expressed as mean urvival
b Doxorubicin 40 mg / m2+ Cyclophosphamide 700 mg / m2, Complications related to chemoto icity uch as alopecia, nausea, vomiting, leukopenia, thrombocytopenia,
fi tulas, weight loss, esophagitis
c 5-Auorouracil 500 mg / m2+ Ci pia tin 15 mg/ m2
d Trimetrexate 12 mg/ m2 or, ifosfamide 1.2 g / m2 + Mesna 20% or, %-Auorouracil 425 mg / m 2 + Leucovorin 20 mg / m2
e Median dy phagia score (pre- ® post-treatment)
f Swallowing scale (post-treatment): 0 (normal) - 0 (dietary modifications)
g Mean increase in swallowi ng score
• Complications include perforation, migration, aspiration pneumonia, ob truction and hemorrhage.
.. Other complications not included were tumor ingrowth and overgrowth

perforation, migration and a piration pneumonia occur
le frequently . The only major reported complications of
the metal tent were tumor in-growth and outgrowth.
DePalma et al compared the Wil on-Cook plastic stent
with the Ultraflew Ti-alloy metal tent and a! o found that
there wa no ignificant difference in median survival or
in the improvement of dy phagia. Pia tic stent were
hown to have a higher rate of complications, and a higher
mortality related to tent placement. Major complication
encountered with the plastic tent included migration,
perforation and hemorrhage. Tumor in-growth was the
only major complication to occur more often with the
metal stent. The e limited numbers of trials demonstrate
that expansile metal tent are equally effective treatment
for malignant dy phagia and a safer, more effective
alternative to pia tic tent .
Two publi hed trial comparing stent to la er therapy
are reviewed . Alder on et a/, 9 tudied the endo copic
treatment of e ophageal cancer with Cele tin or Atkinson
pia tic tube and d :YAG la er ablation. Unfortunately, it
hould be noted that thi trial wa under-powered. Both
group were found to have imilar improvement in
wa llowing function and low complication rate . The
authour make the sugge tion that Ia er ablation and stent
placement hould be con ider d a complementary rather
than mutually exclu ive treatment .
U.
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A trial by Adam et a/ 10 compared three treatment
modalities, d :YAG Ia er therapy, the Strecker cov red
metal tent, and the Wall tent or Gianturco uncovered
metal tent. o urvival advantage wa demon trated for
any of the three modalitie . Improvement of dy phagia
wa imilar for the two ty pe of tent , covered and
uncovered, and both provided uperior relief to Ia er
therapy . Patient rece iving the uncovered tent were
found to have sub tantially fewer complications than the
other two group . Covered tent were prone to reflux,
an d to migration if placed in the lower e ophagus.
Uncovered tent were prone to tumour in-growth that
was amenable to treatment with Ia er ablation, showing a
role for adjuvant laser therapy in stent placement, a a) o
sugge ted by Alder on e t al. Although the evidence in
favour of tent place ment i not unequivocal , the
improvement of tent technology, a wa u ed in the trial
by Adam, should be acco unted for a a ignificant
advancement from the Alder on trial. A pia tic tent wa
u ed in the Alder on trial wherea an expan ile metal
tent wa u ed by the Adam trial, po ibly ugge ting that
a metal tent ma y provide uperior palliation to Ia er
therapy, while a pia tic tent i comparable to Ia er.
The focu of the other trials publi s hed studying
e ophageal tent is on improving the palliation of the
tent with chemotherapy, radiotherapy or a combination
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of both. icolaou et al 11 conducted a randomized trial of
intubation u ing the C le tin tub e alone ver u
intubation with combination chemotherapy (Doxorubicin
and Cyclopho phamide). A mall increa e in medi a n
urvival wa noted in the group receiving the additional
chemotherapy. However, the results are not ignificant
becau e the tudy wa under-powered. The chemotherapy
wa well tolerated with minimal ide effect , although the
complication of the control group were not recorded.
A trial by Reed et al 12 divided the patient population
into three group , intubation with the Atkin on tube
alone, with radiation therapy, and Ia er therapy wi th
radiation therapy. It wa found that the po t-treatment
wallowing core were imilar for all three group . The
addition of irradiation offered no urvival advantage over
intubation alone and had the added complication of
radiation toxici ty.
A trial by Alberts et a/ 13 had significant negative
finding . The addition of combination chemothera py
(with 5-Fluorouracil and Ci platin) and radiation therapy
to a Cele tin tube re ulted in evere to lethal toxicity and a
decrease in the median urvival as compared to intuba tion
alone. Thi trial wa terminated early.
A trial by chmid et a/14 al o found that there wa no
difference in urvi val or degree of palliation of dy phagia
between the group of intubation with Cele tin tube alone,
with adjuvant chemotherap y and with adjuv a nt
radiotherapy. either of the adjuvant treatment regimen
were found to alter the natural cour e of the di ea e and
are not justified b cau e of additional toxicity.
CO eLUSION
The curre nt tate of re earch into th e treatmen t of
inoperable e ophageal cancer i in ufficient to upport a
meta-analy i and an Evidence-Ba ed Recommendation.
There are impl y not enough homogeneou trial to
provide ignilicant tati tical power.
The management of malignant dy phagia ha een the
emergence of expansile metal tent . The lirruted number
of trials how that they are a clinkally effective a the
previou generation of pia tic s tent in the relie f of
malignant d y phagia . The ad vantag are in an ea ier
deploy ment, and ignificantl y fewer functional a nd
technkal complications.
tudie have hown that Ia er a blation of the
ob tructi ve tumor can be clinically effective . One
di advantage i the multiple e ions reqwred to maintain
patency. An increa ed morbidity and a prolonged ho pita)
ta y rna not be ju tified in a patient who e median
urv ival is le than one year and receive no urvival
benefit from the treatment. One ugge tion made by two
of the inve tigator [9, 10] merit orne attention: A role of
Ia er ablation a an adjuvant treatment of expan ile metal
tent that e perience complications of tumour in-grow th
and overgrowth, with Ia er ablating cancerou ti ue
e tending into the lumen of the tent. Thi complementary
role require further re earch to clarify the clin ica l
effectivene of Ia er u ed in the pre ence of tent .
The literature al o hows t h at other adju ant
treatment such a radioth rapy and chemotherapy do not
improve the efficacy of stents. They in fact may negati vely
affect morbidity and mortality becau e of the a ociated
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toxicity re ulting in more complications.
De pite many treatment options being available, none
of them ignificantly improve upon the di mal median
survival of e ophageal cancer patient . A the incidence of
thi type of cancer increa e , re earch hould encompa s
extending urvival time , effective palliation and
improving diagno i at an early tage.
ACKNOWLEDGEME TS
The authour would like to acknowledge the guidance
and supervision of Dr. R. A . Malthaner, Assistant
Profe or of Surgery.
REFER£ CES:
1. Cancer Care Ontario, Amwal Publication, 1997.
2. Lislrmarr AH, Dellipiarri AW, Devlin HB. Tire insertion of esoplragogastric
tubes irr malignant esoplmgeal trictures: errdo copy or surgery? British
Jounral of Surgery 1980;80:257-259.
3. Watson A . A study of tl1e quality arrd duration of survival following
re ection, endoscopic intubation and urgica/ intubation in e oplragea/
carcinoma. British Journal of Surgery 1982;69:585-588.
4. Tytgat G f. Endoscopic tl1erapy of oe oplragea/ cancer: possibilities and
limitations. Endoscopy 1990;22:263-267.
5. Den Hartog Jager FCA , Bartel marr JFW , Tytgat G f . Palliative
treatment of obstructing e oplragogastric malignancy by endoscopic
positioning of a plastic prosthesis. Gastroenterology 1979;77:1008-1014.
6. Gasparri G, Casaleg~1o PA, Camandona Met a/. Endoscopic insertion of248
prostheses in inoperable carcinoma of tire esophagus and cardia: short-term
and long-term results. Gastrointestinal Endoscopy 1987;33:354-356.
7. Knyrim K, Wag~1er Hj, Bethge , Keymling M and Vakil . A Controlled
Trial of an Expansile Metal Stent for Palliation of Esoplmgea/ Obstruction
due to Inoperable Cancer. Tire ew England journal of Medicine; 329(18):
1302-1307, 1993.
8. De Palma GD, di Matteo E, Romano G, Fimmano A , Rondinone G and
Catanzarro C. Plastic prosthesis versus expandable metal stents for palliation
of inoperable esophageal thoracic carcinoma: a controlled prospective study.
Gastrointest Endosc;43: 478-482, 1996.
9. Alder 011 D and Wright PD . Laser recanalization versus endoscopic
intubation in the palliation of malignant dysphagia . Br . f. Surg .;
77: 1151-1153, 1990.
10. Adam A , Ellul j, Watkinson AF, Tan B , Morgan RA, Saunders M and
Mason RC. Palliation of Inoperable Esoplmgeat Carcinoma: A Prospective
Randomized Trial of Laser Therapy and Stenl Placement . Radiology;
202: 344-348, 1997.
11 . icolaou
and Conlan AA. Cyclophosphamide, Doxorubicin and Celestin
intubation for inoperable oesophageal ca rcinoma. S. Afr. M ed. j .;61:
428-431 , 1982.
12. Reed CE, Mar l1 WH, Carlson LS, Seymore CH and Kratz JM . Prospective,
Randomized Trial of Palliative Treatment for Unresectable Cancer of tire
Esophagus. Ann Tlrorac Surg;51: 552-556, 1991 .
13. Albert AS, Burger W, Greeff F, Sclroeman L, Friediger D, el j, Steyn E,
Schmid EU and Falkson G. Severe Complications of 5-F/uorouraci/ and
Ci platin witlr Concomitant Radiotl1erapy in Inoperable on-metastatic
Squamous Cell Oesoplmgea/ Cancer After Intubation - Early Termination of
a Prospective Randomised Trial. Eur j Cancer; 28A(4/5):1006-1007, 1992.
14. Schmid EU, Alberts AS, Greeff F, Terblanclre PS, Sclroemand L, Burger W,
Shiel A , Friediger D, Van der Hoven A and Falkson G. Tl1e value of
radiotl1erapy or clremotlrerapy after intubation for advanced esophageal
carcinoma - A prospective randomized trial. Radiotl1erapy and Oncology; 28:
27-30, 1993.
15. Adam A , Clretty , Roddie M et a/. Self-expandable stainless s teel
endoprostlrese for treatmen t of malignant bile duct obstnrction. American
journal of Roentgenology 1991;156:321-325.
16. Cwikie/ W, Stridbeck H, Tranberg K eta/. Malig11an t oesophageal trictures:
treatment with a self-expanding nitinol stents. Radiology 1993;187:661-665.
17. iclro/son AA, Roy ton CMS, Wedgewood K eta/. Palliation of malignant
eosplmgeal perforation and proximal oesoplmgeal malignant dy plragia witlr
covered metal tent . Clinical Radiology 1995;50:11-14.

n

- - - - - - - - - - - - - - - - - - - - - - - - U. W.O. Medical Journal 69 (2) 1999

Feature

Art i cles

MALIGNANCY AND THE ANEMIA
OF CHRONIC DISEASE
By Gary Kny, MEDS 2001

nemia, defined as a decrea e in red cell mas , i
often associated with cancer and cancer treatrnent. 1
Indeed, anemia i the mo t common hematological
aberration occurring in cancer patients, ranging in everity
from a ymptomatic to life-endangering, and can re ult in
a decrea e in the patient' overall quality of life. 1 All of this
occur at a time when the patient, along with hi or h r
family and loved one are trying their be t to cope with
thi utterly deva tating di ea e. Many cau es for anemia
have been postulated, including: blood lo (acute or
chronic); bone marrow involvement by the cancer;
chemotherapy or radiation therapy re ulting in marrow
upfres ion; red c~ll apia _ia; he~oly ~ includi~~
autotmmune hemolysts and mtcroangwpathic hemoly t -;
hyper pleni m; folate or 812 deficiency; and a di ea e
entity known a the anemia of chronic di ea e. 1
Anemia of chronic di ea e (ACD), al o named the
anemia of cancer, refers to a pecific type of anemia mo t
commonly een in patient with malignant condition .
Current e timate reveal that over half of all patient with
orne form of neoplastic di ea e are anemic during the
cour e of their illne , either a the re ult of ACD or iron
deficiency, and almo t all patients under oing
chemotherapy or radiation therapy become anemic. 1 Like
myelophthi ic anemia, iron deficiency econdary to blood
lo , and megalobla tic anemia, ACD i a form of
hypoproliferative anemia re ulting from decrea ed red
blood cell (RBC) production . 2 However, with it
characteri tic change in erythrocyte urvival time and
iiOn metaboli m, ACD is quite different from the e other
form of anemia. Specifically, ACD mo t likely involves
the accelerated destruction of erythiOcyte , suppre ion of
erythropoie i , and dimini hed iron utilization by the
erythron, leading to hypoferremia de pite adequate or
even increa ed iron tore . 1 The exact pathogene i of
ACD i not completely understood although ugge ted
mechani m include decrea ed RBC life pan, impaired
reutilization of hemoglobin iron, erythropoietin
deficiency, impaired re pon ivene , and ineffective
erythropoie is. ~ Intere tingl y, ACD ha many clinical
imilarities to anemia pre ent in patient with chronic
inflammation or infection, including chronic renal ,
hepatic, and endocrine di ea e .5 ACD i a! o one of the
mo t common anemia pre nting in general practice},
and i the mo t prevalent form of anemia in the
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ho pitalized patient population. 2 Thus, a clear
under tanding of the mechani m underlying ACD, along
with treatment
uch a
human recombinant
erythiopoietin, i crucial not only to the phy icians caring
for cancer patient , but tho e in a more general etting a
well.

CLI ICAL FEATURES
U ually mild and nonprogre ive, ACD i often a
diagno is of exclu ion, developing in idiously within the
fir t 1 or 2 month from the on et of the illne .1 Due to it
mild nature, ACD i commonly overlooked in the clinical
evaluation 2, and many patient , even those with
hematocrits a low a 30%, are often asymptomatic.1 It i
believed that the patient' inactivity, as well a the body'
natural ability to increa e oxygen delivery to the ti ue ,
re ult in this lack of ymptom . 2 In the etting of
advanced malignancy, weakne , pallor, and fatigue are
often een, and can be the result of ACD or the cancer
it elf. 2 More evere manife tation of ACD include
d y pnea, peripheral edema, angina, palpita tion , and
other igns of cardiova cular insufficiency, but are rarely
en in patients with packed cell volume (PCV) below
25%.2 Skin temperatur i often reduced, and the kin,
mucou membrane and conjunctivae, are pale. 6

LABORATORY FEATURES
ACD i u ually a normocytic, normochromic anemia,
microcytic, hypochromic red blood cell can be
n.2. In fact, up to on third of patient may have slight
to moderate microcyto i . 1 Unlike iron deficient anemia,
however, hypochromia develop before microcyto i in
ACD. 2 When the physician i contemplating the diagno i
of ACD, the other common cau e of normocytic and
microcytic anemias mu t be ruled out, including: blood
lo ; nutritional deficiencie ; infection; renal in ufficiency;
and malab orption . 2 In term of pecific laboratory
characteri tic of ACD, hemoglobin i u ually between
and 12 g/ dL, and the PCV i u ually between 26% to
3 %?· ·9 Studie have al o hown a reduction in the Mean
Cell Hemoglobin Concentration (MCHC) of 44-64%.5•10
The ab olute reticulocyte count i normally not increased,
and the white blood cell (WBC) and platelet count are
normal or even lightly increa ed. - Bone marrow is
normocellular or hypocellular, and the erythroid/myeloid
ratio is often normal or lightly decrea ed.u ,n Alth ough
body iron tore are normal or increa ed in patient with
ACD, erum iron level are often ub tantially decrea ed,
along with transferrin.25•7· 12 Indeed, tran ferrin aturation
in ACD normally falls b tween 5% and 16%, compared to
value of 20% or higher een in healthy individual .w A
erum ferritin concentration i u ually increa d in ACD,
thi provide an ea way to help di tingui h it from iron
deficient anemia . 5' 1 ~' 1 ' 16
althou~h
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PATHOPHYSIOLOGY
ACD i thought to be the re ult of a number of fact r ,
including accelerated erythrocyte de truction, and an
inadequate bone marrow re ponse to thi lo s of RB in
the form of deficient erythropoei is .' ormally, the
life pan of a red blood cell i approximately 120 day . In
ACD, however, eryt hrocy te urvi va l time i greatly
reduced, ranging from only 60 to 90 day .1• 17•1 Although
the exact mechani m behind the increa ed erythrocyte
de truction remains unclear, hyperactivity of the reticular
endothelial y tern (RES) has b en propo ed as the likely
cau e for the hortened RBC urvival time. 2 It is thought
that red cell rna be damaged , perhap by tumour
va culature or inflammatory cell , re ulting in their rapid
de truction b an activated RES. ' Interestingly, red cells
from ACD patient have been found to urvive normally
when transfused into normal ubject , ugge ting that the
ultimate cau of the increa ed erythrocyte de truction
mu t be a property of the cell' environment and not the
cell it elf. '
ormal bone marro w can increa e
erythropoie i at lea t three time the ba al rate, however,
o the increa ed lo of RBC alone hould not lead to
anemia. 2 Thu , a key factor in the pathophy iology of
ACD i a n inappropriate or la ck of increa e in RBC
production to compensate for the increa ed lo of
erythroc te .2
Many theorie have been hyp the i ed to explain the
in ufficient bone marrow re pon e: decreased iron
availability to the marrow; dimini hed erythropoietin
level ; and immune uppre ion or erythropoiesi .1 Recent
tudie , however, have hown that red cell turnove r is
normal in ACD patients, and that the idea of blockade of
iron to the erythron i not upported,'·' 2 1 making the fir t
theory an unlikely explanation. Furthermore, neither oral
nor intravenou iron given to alleviate h.)'poferremia in
ACD patient help to correct the problem.In term of erythropoietin production in ACD, recent
radioirnmunoa ay tudie for erythropoietin have found
relativel y normal level in ACD patients. 1•22•23 Alexia n
imilarl)' reported normal erythropoietin level in ACD
pati nt .2. 10 Thu , the notion of in ufficient erythropoietin
production al o i an unlikely rea on for the impaired
bone marrow re ponse in ACD. In tead, re earch now
reveal that inadequate or deficient erythropoie i may
pla y an integral role in the pathophy iology of thi
di ea e.'
Thi concept wa fir t propo ed by Zucker et al in 1974
who found that erythropoietin induced a significantly
lower amount of erythropoie i in patient with cancer
compared to normal patient with anemia re ulting from
infection or inflammation .9 They concluded that the
functioning of cell re pon ive to erythropoietin and
re pon ible for increa ed red cell production mu t
omehow be dimini hed by a humoral and/or cellular
immune interaction with malignant cell .2 In upport of
thi theory, immune cytokine uch a interferons alpha,
beta, and gamma, along with Tumour ecro i Factor
(T F), are known to be produced in the ettin g of
malignancy and have been demon trated to decrea e
erythropoei i .1.2us Furthermore, an anemia very irnilar
to ACD ha been hown to develop in mice following
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chronic exposure to TNF. t.26 A a result, it would appear
that the impaired marrow re pon e in ACD is there ult of
an activated immune y tern leading to a decrea ed
re pon e to erythropoeitin. 1 Thi , combined with an
inability to compen ate for increa e red cell destruction,
ultimatel y culminate in a nonprogressive, mild ,
a ymptomatic anemia.'
CO CLUS ION
In the pa t, treatment of ACD has focu ed on the
underlying malignanc(' with little attention being focused
on the anemia itself. However, exciting new therapies
provide hope for the future, including epoetin alpha, a
form of human recombinant erythropoietin which may be
beneficial in improving the patient's symptom and
quality of life .27 In tho e patient resi tant to epoetin
therapy, blood tran fu ion provide another treatment
option.6 Clearly, until we have a better under tanding of
the etiology and pathogene i of ACD, it will remain one
of a plethora of unpleasant and potentially life-threatening
effect of cancer and it treatment.
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ONCOLOGIC EMERGENCIES:
FEBRILE NEUTROPENIA
By Ian MacDonald, MEDS 2000

INTRODUCTION
nfectiou complications in the neutropenic host are a
major medical i ue. Cancer patient receiv ing
chemotherap are at ri k of neutropenia due to the
toxi.c eff~ct antineopla tic agent e xert on rapidly
proliferating bone marrow cell . The neutropenic pa tient
who develop a fever i at ri k of developing rapid and
fatal ep i . Prompt admini tration of empiric antibiotic
therapy is, therefore, tandard practice in the management
of the e epi odes. A variety of regimens have been shown
to be effective, including a multidrug approach a well a
monotherapy. Controver y exi t a to which method i
uperior.

patient are cia ically the endogenous Gram-negative
bacilli ari ing from the GI tract, primarily P. aerugino a, E.
coli, and Klebsiella. Mortality in neutropenic patient with
Gram-negative bacteremia can approach 40%due to the
tendency toward y temic di emination. 4 Empirical
antibiotic therapy i tailored to providing broad pectrum
coverage again t the e pathogen . However, Grampo itive organi m have emerged in the past decade as a
co~mon cau e of infection in the febrile neutropenic
patient. In particular are 5 . ep idermidis, 5. aureus, and
Strep tococcus specie . Recent tudie have hown that at
pre ent Gram-positive organisms account for 60% of
bacter mia .5

THE EUTROPE IC HOST
The neutropenic patient who become febrile h as a
60% or greater chance of being infected.2 However, f ver
often pre ent without clinical signs of localized infection
in the e patients. The dimini hed whit count preclude
ign of inflammation uch as edema, erythema, a nd
purulent di charge . In a tudy of over 1000 febrile
epi ode in neutropenic patient with cancer, the phy ical
exam was unable to reveal any ign of infection in 55% of
patient with known bacteremia. 3 The febrile tate i
defined a a core temperature > 3 .5 C or an axillary
temperature > 3 .0 C. Se ere neutro~enia, defined a an
ab olute neutrophil count < 500 I mrn , i the single mo t
important ri k factor for developing infection . The
duration and rapidity of on et of neutrop nia are al o risk
factor . eutropenic epi ode of < 7 day have been
hown to confer a better progno i than tho e with longer
duration?
The ri k of infection i al o increa ed in the pre ence
of other predi posing factor . The e include mucou
membrane damage econdary to cytotoxic chemotherapy,
kin le ions pre ent at intravenou injection ite , th u
of indwelling central venou catheter , and neopl a tic
ob truction complicated by secondary infection of
colonizing organi m . The ri k of infection i al o higher
in patient with hematological malignancie than in tho e
with olid tumour . Po t-mortem tudie e timate that
infection i the direct cau e of death in up to 50- 0% of
patient with acute leukemia and up to 50% of tho e dying
with malignant lymphoma . In patient with olid
tumour , infection is the primary or an a ociated cau e of
death in about 50% of ca e .
The infecting organi m involved in the neutropenic

INVESTIGATIO
The phy ical exam of the febrile patient i often
unremarkable in light of the ab ence of localized finding .
However, it i important to consider the common ite of
infection in febrile neutropenic : mouth and pharyn
(25 % ), the lower re piratory tract (25 % ), kin and
intrava cular catheter (15%), and the ga trointe tina! tract
(15%). 3 The remaining proportion is made up of the
perineal region, the urinary tract, and the nose and
inu . Oropharyngeal infections can occur in the patient
being treated with chemotherapy a bacterial flora
colonize muco al ulceration . Local invasion in the e
patient are at ri k of becoming y temic rapidly. The
phy ical e am hould al o a e for the pre ence of any
long- tanding intrava cular catheter which can be the
ource of catheter-related infections.
Inve tigation in the febrile neutropenic patient
should include a CBC and differential, BU I Cr, and
electrolyte . Before tarting antibiotic , blood culture
hould be drawn on ample taken from both the
indwelling catheter and a peripheral vein. The threat of
catheter-related bacteremia is increa ed when the catheter
i heavily colonized . Culture from a pre umed ite of
infection include a urine culture and ensitivity. Sputum
~ultu~e ~ay be included if produced and pulmonary
infection 1 u pected. However, che t x-ray in the early
tage of fever or in very neutropenic patient may not
reveal ignificant lung finding .

I
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TREATME T
The concept of tarting antibiotic therapy before
knowing the re ult of blood culture is based on the high
mortality a ociated with Gram-negative bacteremia .
Therefore, empiric therapy i directed at providing broad
spectrum coverage against the e organisms. In particular,
any empiric regimen hould provide antip eudomonal
activity in light of the ignificant morbidity and mortality
a ociated with thi organi m. Antimicrobial therapy
hould
imultaneou ly produce high
erum
concen_trations of bactericidal agent , while di playing
good h ue perfu ion and po e minimal toxicity to the
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patient. In terms of approach, there is still much debate
about optimal empiric treatment with re pect to
combination versus single-agent therapy.
Combination therapy is a widely adopted approach
in the management of the febrile neutropenic patient. The
traditional combinations involve an antip eudomonal
~-lactam plu an aminoglyco ide. The e include either an
extended-spectrum penicillin, uch a piperacillin, or a
third generation cephalo porin, uch a ceftazadime, plu
gentamicin or tobramycin. The main argument in favour
of combination therapy i that it provide broad pectrum
coverage, limiting the potential for econdary
uperinfections and the emergence of re i tant organi m .
Combination therapy al o provide a ynergi tic effect
that i greater than either agent alone. The major
drawback a ociated with thi therapy is the increa ed
likelihood of toxicity at therapeutic levels, specifically
nephrotoxicity and ototoxicity a ociated with
aminoglyco ide admini tration. At thi point, the
compari on of clinical trials ha failed to demonstrate any
ignificant difference in respon e rate between the
different combination regimens.
The concept of empiric monotherapy i relatively new
in the treatment of febrile neutropenia. The e agent
include the third-generation cephalo porins and the
carbapenems, which offer coverage against gram-po itive
and gram-negative organism , including Pseudomonas
pecie . The theoretical advantage of monotherapy over
combined therapy include reduced toxicity and improved
ea e of admini tration . Among the third generation
agent , ceftazadime i employed for monotherapy due to
it ignificant antipseudomonal activity and low toxicity.
Several tudie have indicated it effecti ene s in the
empirical treatment of fever in neutropenics ba ed on
re pon e rate . A recent concern with ceftazadime
monotherapy i the potential for the emergence of
re i tant organi m . The carbapenem , a new cia of
potent beta-lactam antibiotics, offer a broader spectrum of
activity than the third-generation cephalo porin .
Randomized trials have demon trated that empirical
monotherapy with imipenem i a effective a ceftazadime
alone. 1 The primary concern with imipenem therapy i its
a ociation with seizure in patients with C S di ease
and / or renal failure.
The controver y between monotherapy ver u
combined therapy continue . Pre ent evidence ugge ts
that at the end of the neutropenic period there i little
difference in term of urvival between febrile neutropenic
patient given empiric monotherapy and tho e who
received combination therapy . The European
Organization for Re earch on Treatment of Cancer
(EORTC) Trial XI wa de igned to answer the que tion of
the efficacy of monotherapy ver u combination therapy.
The re ult publi hed in 1996 demonstra ted that among
the 95 randomized patients, treatment ucce rate were
similar in both arms of the tudy. 5 A recent international
trial howed that ceftazadime was as effective but a! o
safer than the combination of piperacillin and
tobramycin. 4 Available data ugge ts that mono therapy
appear to be a uitable option at lea tin low-risk patient
(neutropenia> 500 / mm3 with expected duration< 7 day ).

M ODIFICATIO OF THERAPY
Given the increasing prevalence of gram-positive
bacteremias in the febrile neutropenic ho t, the addition of
the glycopeptide vancomycin to the empirical regimen
may be indicated. Thi trategy may be beneficial in light
of the increa ing incidence of MRSA in certain institutions,
the election for gram-po itive up rinfection a ociated
with ceftazadime monotherapy, and in neutropenic
patients at high ri k for gram-po itive ep i , uch a tho e
with indwelling central venou catheter . However,
EORTC Trial V showed that in neutropenic patient with
gram-po itive infections the u e of vancomycin from the
onset of fever did not re ult in a more rapid
deferve cence . Thu , it ha been ugge ted that the
inclusion of vancom y cin in empirical regimens i a
rea onable approach for individual patient , patient with
ign of infection at the va cular catheter ite, and upon
documentation of infection with MRSA.
The optimal duration of therapy in febrile neutropenic
patient i controver ial, although the ab olute neutrophil
count i con idered the mo t important mea ure . The
afebrile patient with a negative blood culture and
neutrophils ~ 500 I m.m3 may discontinue antibiotic after 5
to 7 day of therapy. 2 However, orne author sugge t that
antibiotic can a! o be topped in the presence of
persi tent neutropenia (< 500 / mm3) if the patient i
afebrile and blood culture are negative. In the ca e of
fever per i tence or recurrence even day after
commencement of antibiotic , there i a general agreement
r garding additional treatrn nt with empirical antifungal
therapy uch a amphotericin B, even in the ab ence of
ymptom or ign of y temic myco i . Sy temic fungal
infections have been found in up to 33 % of febrile
neutropenic patient who remain unre pon ive after 1
week of therapy and thi approach ha been shown to
decrea e the incidence and mortality of the e epi od 2
CON CLUSIO
Significant progre ha been made in the treatment of
febrile neutropenia in the past 20 year . Recognizing the
value of initiating empirical therapy in the neutropenic
patient with a fever and the availability of new
antimicrobial agent ha had a ignificant impact on
urvival rate in thi population, reducing mortality
figure by infection to a low a 6%.6 However, infection
remains the principal cau e of morbidity and mortality in
febrile n utropenic patient . The management of the e
epi ode has been complicated by the changing pectrum
of pathogen from gram-negative to gram-po itive and
concern for the emergence of re i tant pecie , fuelling the
debate over combination therapy ver u monotherapy.
Con equently, the approach to empirical therapy i
determined by the circum tance
urrounding the
individual patient and knowledge of local pattern of
infection and re istance.
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RISK FOR BREAST CANCER: THE
UPS AND DOWNS OF GENETIC
BREAST CANCER TESTING
By Glenna Cuccarolo, MEDS 2001

The following information regarding genetic tes ting fo r
individuals at high risk was obtained through an interview with
Dr. Peter Ainsworth, Director of Molecular Genetics, Victoria
Ho pita/ Campus, LHSC.
ith recent advance in genetic technology, we are
reaching a point where individual ma y
determine their ri k for developing a di ease one,
ten or fifty years in the future . The field of oncology i no
exception. Individual with a strong family history of
brea t cancer can be creened to determine if they carry a
mutation in one of two brea t cancer susceptibility gene ,
BRCAl or BRCA2 . If found to carry uch a mutation,
female may have a high as a 50-85% lifetime risk of
developing breast cancer, about half this ri k of ovarian
cancer and, for both males and female , a mall but
definite increa e in the ri k of colon and other cancers.
As always, with advancement come risk. We are
facing a ituation in which otherwise healthy individuals
can be told, with orne degree of certainty, that they may
have up to an 85% chance of developing breast cancer in
their lifetime. As future phy icians, we need to be aware
of the whole picture urrounding this type of revelation,
and what may be ahead for these individual .

W

Who should be screened?
A with all medical te ts, the cost, effectivene s and
predictive value of a test i related to the level of risk of
the group being te ted. Family medical hi tory guideline
exi t to determine which individual are at high ri k, and
thu uitable for creening. However, many individuals
may wi h to be screened even if they are not at high ri k,
to put their mind at ea e. This type of creening may not
be covered and would only be performed at the patient' s
expense. It is al o important that screening of lower risk
individual should not interfere with creening of tho e at
high risk.
Individual
hould be referred according to the
following guideline (adapted from Ontario Cancer
Genetics etwork):
3 or more do ely rela ted individual on the arne ide
of the family
Early age at diagno is (<50 year )

ABOUT THE AUTHOR
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Multiple generations affected
Multiple primary tumour (e.g. bilateral brea t cancer,
or both breast and ovarian cancer)
One or more ca
of ovarian cancer
Men with brea t cancer (BRCA2)
Jewi h ethnic background (approximately 1:50 carry a
mutation compared to 1:400 in the general
population).
What are the medical and non-medical considerations of
d etecting a BRCA mutation?
Genetic te ting of member of a family known to have
a BRCAl or BRCA2 gene mutation that has been
characterized, would divide them into two group : tho e
that carry the familial mutation and tho e found to be
non-carrier . For the latter group, genetic creening would
erve a a rea urance that they are not plagued by the
arne genetic fate a their relative who may or may not be
already affected b y cancer. For mutation carriers,
screening erve to allow for increa ed urveillance and
hopefully early detection and treatment. For each family
member there would be a 50% chance of falling into either
group, by virtue of genetic inheritance.
Increa ed urveillance involve early mammography,
starting in the late twentie or early thirtie and thi hould
be combined with regular clinical and self-examination of
the brea t . The value of ovarian urveillance technique i
more controver ial and proph y lactic surgery may be
considered in the peri- and po t-menopau al period, while
pre-menopau al women may be placed on birth control
medication to decrea e the ri k of ovarian cancer. ewer
treatment uch as prophylactic tamoxifen may be u ed to
reduce brea t cancer ri k in the future, and for some
women, there may al o be the po ibility of prophylactic
rna tectomy. The increased ri k of colon cancer in mutation
carrier hould be addressed by colono copy which ideally
would begin at age 45.
However, what eem to be an obvious and imple
management plan for early detection and urveillance
carrie the additional burden of the extent of prophylactic
or preventive treatment which a patient hould or could
undertake. Oophorectomy i recommended to postmenopau al women, but i not an option for women of
childbearing years intending to extend their family . Birth
control can be pre cribed to decrea e the incidence of
ovarian cancer in pre-menopau al women but cannot be
u ed while a women i attempting to conceive. There i
al o the controver ial que tion of prophylactic
rna tectomy: will a women feel compelled to remove her
brea t without which her ri k of cancer i nearly
decrea ed to that of the general population? Will he
blame herself for not accepting a more radical prophylaxi
if he i later diagno ed with brea t cancer? Will he feel
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aliena ted from the part of h er body which make her
uniquely fe male? The e qu estions, which may arise upon
determining one' genetic risk, cannot be answered and (je
out ide the realm of medicine to addre .
In addition to the medical controver y urrounding
genetic creening, a patient' potential ri k for brea t
cancer can be u ed out ide the medical realm a a ource
of di crimination. Although current law forbid medical
information to be di do ed to employment center , bank ,
or life in urance companie without the patient' consent,
it doe not forbid the qu tioning urrounding the e area .
Thu , once an individual ' genetic statu ha been
determined, tho e individual applying for life or h alth
insurance may be di criminated again t for rate or even
accep t ance to the policy. An individual' ability to
immigrate may be denied. Bank loans or mortgage may
be refu ed if the client is high ri k. Fu rthermore, the
children of high-ri k patient rna be denied acce to
education loans and fund on the ba i that the e fund
may not be repaid if the individual develop the di ea e.
On another per pective, early detection of a high
genetic ri k may make an individual he itant to marry and
have children, for fear that their life pan may b hort ned
and that their family will be burdened with the di a e.
Other may fear pa ing on the mutation to their children
and feel that it i morally irre ponsible to have children
w hen there i a 50% chance that they will be ubject d to
the arne fa te a them lve . In addition, ince this type of
te ting is till relativel y new, there i little evid nee
regarding the long term effect of pre- y mptomatic
te ting, in which an individual can find out potentially
year in advance, their ri k for developing a disea e in the
future. A minority become more su ceptible to depre ion
and may require a i tance from a social worker.
Currently all individual who are referred for
coun eling regarding genetic creening are allowed ample
time and everal visit before making a decision to be
screened. In general mo t individual do choo e to
und ergo the screening, but the informa tion they are
provided with, and the amount of time allotted, protect
again t making a ha ty deci ion on the part of the patient.
Patient found to be at high ri k h ave everal re ource
available to them to guide them through their plan of
action. Mo t patient take a pro-active role in their health
care and tend to improve their lifestyle, w hen found to be
at high ri k for cancer.
In the next few year , we will all be faced with advance
in genetic technology which will allow individual to know
years in advance their potential for developing a terrifying
di ase uch as cancer. There are several known, and Hkely
many more unknown, consequ ences to de(jvering thi type
of information to the patient. Howe ver, the va lue of
increa ed urveillance and early detection ca nn ot be
undere timated in relation to it potentially life- aving
ability. As a society, we need to ensure that there will be a
y tern in place to deal with the non-medical consequ nee
of determining one' gen tic tatu .

We're on your team ...

Personal
Lifestyle

Practice
Finance &
Management

Advisor to Health Care Profe ional r -

EAL, PALLETI & TOWNSEND LLP
CHARTERED ACCOUNTANTS

289 Du ffe rin Avenue, London , Ontario N6B IZI
(519) 432-5534
Fax (5 19) 432-6544

IQ!Hih§d
Glenn Hardman ghardman@nptca.com
Barrie Neal
bneal@nptca.com
David Pallett dpallett@nptca.com

John Prueter
jprueter @nptca.com
Jonathan Townsend jtownsend@nptca.com
Sandy Wetstein
swetstein@nptca.com

London Regional Cancer Centre
Centre Rigtonal de Cancirologte d.e London
790 Commluloners Road East
London, Ontario N6A 4L6
Te l: (519} 685·8615
Fax: (519} 685·8611

The

fVERSITY ofWESTERN 0
(519) 6 5- 600

Dr. J. Gregor Cairncros MD FR CP(C)
Chief Exec uti e Officer
London regional ancer Centre
Professor and Chair, Department of Oncology
The London Regional Cancer Centre is a modem, well equipped,
ambulatory treatment facility. The opportunity exi t
to participate in clinical and ba ic research program .
The Department of Oncology offer po tgraduate training
in Medical and Radiation Oncology.

For detail , contact:

ACKNO~EDGEMENTS

Dr. Walter Kocha. MD. FRCP
Residency Program Director.
Department of M"edical Oncology

This article wa reviewed by Dr. Peter Ain worth,
Director of Molecular Genetic , Victoria Ho pital Campu ,
LHSC.
Q

Dr. Barbara Fi her. MD, FR P
Re idency Program Director.
Department of Medical Oncology

62

TARIO

Faculty of Medicine • Department of Oncology
790 Commi ioners Road Ea t,
London , Ontario 6A 4L6

(519) 6 5- 63

(519) 6 5- 650

- - - - - - - - - - - - - - - - - - - - - - - - U. W .O. Medical Journal 69 (2)1999

Feature

Art i cles

THE FREE FIBULA FLAP FOR
OROMANDIBULAR RECONSTRUCTION
By joe A. Mni, MEDS 2001, Dr. Jonathon Trites, Dr. john Yoo, LHSC

INTRODUCTIO
he mandible i e ential for oral function and facial
ae thetic . Partial or complete los of the mandible
may have severe phy ical and emotional
con equence . The management of patient with
oromandibular malignancies ha evolved with advances
in s urgical technique . Mandibular resection po e a
formidable recon tructive challenge. While many tumour
of the oral cavity can be removed leaving the mandible
intact, egmental mandibular re ection is often required
for advanced stage tumour 1 (Fig ure 1). Previou ly,
re ection of the mandible for cane r commonly re ulted in
ignificant di ability with regard to rna tic ation,
swa llowing, peech and co me i . 2 Micro urgical
technique ha revolutionized the current approach to the
management of patients undergoing mandibul ar
resection. Mandibular reconstr uction u ing free
va cularized bone transfer at the time of oncologic
re ection i now the treatm ent of choice for th e e
patient Y It ha minimized many of the wound healing
problems a socia ted with previou method s of
recon truction that u ed pro the es, non-va cularized
bone graft or pedicled o teomyocutaneou flap . With
immediate wound problem largely overcome, attention
has shifted to improving functional and ae thetic results
for the patient. 3

T

OPTIONS FOR RECONSTRUCT! G THE MANDIBLE
Initially, oromandibular defect were addres ed with
no bony recon truction. Soft ti ue was repaired either
primarily or with a skin graft or local flap (e.g. tongue,
buccal muco a). Large anterior mandibular defects
managed in thi fa hion were referred to a "Andy
Gump" deformities. Free bone gra ft s and allopla tic
prosthe e we re later attempted in order to improve
functional ou tcome. However, these procedure were
a ociated with poor wound healing, high rate of
infection, extru ion of plate and crew , and con iderable
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oft ti ue contraction, e pecially when performed as
econdary procedures5 (Figure 2). The jaw often required
prolonged period of immobilization. For the e rea ons,
bone graft currently enjoy only limited u e.
Continued improvement in cure rate following
abla ti ve cancer surgery provid d a timulus for a
reconstructive era beginning in the 1960s. In addition to
metal plate and free bone graft , tray devices which
hou ed particulate bone graft were u ed in order to
restore jaw integrity. The advent of the pedicled
myocutaneou flap in the 1970 provided wellva cularized oft ti ue coverage for the e bony bridge .
Regional flap uch as the pectorali major, lati imu
dar i and trapezius con i t of mu cle and overlying kin
rotated about their constituent arterial and venou supply.
The e flap permitted ing le s tage recon truction of
virtually any head and neck defect. 5
In the late 1970 , autogenou bone such a rib and
clavicle b gan to be incorporated into myocutaneou flap
and became the predominant method used in mandibular
recon truction. Autogenou bone wa recognized a the
material least likely to be extruded, and its u e became
more widespread . Rea onable s ucce s rate co uld be
expected in limited ca e , uch a hart defects in nonirradiated patient . However, their di sa dvantage
included limite d pedicle length and arc of rotation,
exce ive oft ti ue bulk and donor ite morbidity.
Furthermore, the inability to provide bone of u fficient
length with a reliable blood upply timulated a earch for
alterna tive technique .1
•
The establi hment of a reliable blood uppl y via
microva cular anastomo i wa made po ible by the
adven t of microva cular urgery in 1973. Con equently,
ti sues di tant from the defect and ba ed on an
appro priate axial blood uppl y could be ucce fully
tran £erred for recon truction. Such "free flap " emerged
a a new approach for mandibular recon truction. The
rna t important advantage of the free tis ue transfer i it
uperior va cularity and improved ti ue urvival. The e
flap are free from a di tinct limitation of myocu taneou
flap , namely their va cular pedicle length and arc of
rotation. Moreover, the wide va riety and ver atil ity of
donor tis ue allow customization of the reconstruction to
the pecific requirement of the defect. The e refinement
in ~rimary reconstruction provide the cancer ~anent with
optimal functional and co metic rehabilitation.
FREE FLAP DONOR SITE SELECTION
The requirement for optimal recon truction of the
mandible includ adequate bone length, con i tent hape
along the length of the bone, and a vigorou and
predictable blood upply. There is u ually al o a
requirement for the bone to have adjacent muscle and kin
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of the proper volume and in etting flexibilit to allow
reconstruction of a ociated oft ti ue defects. Common
donor ite for this application include the iliac ere t,
radiu , capula, and more recently, the fibula flap .4 There
is no ingle donor ite that can be u ed for all ituation .
Donor ite election hould be determined by the pecific
bone and oft tis ue requirement of the defect.
The length of bone supplied by the radius usually
doe not exceed 10 em and i of poor quality. Donor ite
morbidity from radial fracture i a major di advantage.
The capula pro v ide up to 14 em of bone an d an
abundant kin flap which lend it elf to three dimensional
contouring. The bone is wider and longer but thinner than
the radiu . However, flap harve t require repo itioning
the patient intraoperati vely, precluding a imultan ou
two-team approach. The iliac ere t supplie an abundant
Figure 1.

Oromand ibular
defect following
urgical resection
for cancer.

Figure 2.

Patient with e truded plate following reconstruction of egmental
mandibuJectomy.
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amount of quality bone which do ely approximate the
height of the native mandible. However, contouring the
bone may be le preci e than with other flap . A major
di advantage of thi flap i the a ociated oft ti ue,
which ha exce sive bulk and an unreliable blood suppl y.3
The fibular free flap ha b come the flap of choice for
mandibular recon truction. The flap i ba ed on the the
peroneal artery, a terminal branch of the posterior tibial
artery, and its venae comitante . The caliber of the ve els
and length of the pedicle allow for reliable microva cular
ana tomo i . The ver atility of this bone flap re t on it
dependable feeding perio teal blood supply. Thi allow
multiple o teotomie , which are required to reproduce the
thre -dimensional hape of the re ected mandible. It i the
only free ti ue tran fer that provide a bone tock up to
24 cm.6 This allow near-total mandibular defect to be
Figure4.

Reconstructed
oromandibular
defect u ing free
fibula flap.

Figure 3.

Harvested fibula fl ap with adjoined oft ti ue paddle.
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repaired u ing a ingle flap. It has a consi tent hape
throughout it entire length, and ufficient bone tock to
upport o teointegrated implants for dental
rehabilitation. 3 The fibular flap can incorporate a kin
paddle from the lateral a pect of the leg that mea ure up
to 25 em in length and 5 em in width 6 (Figure 3). The flexor
halluci longu mu de lie adjacent to the fibula and thu
can be harve ted for oft ti ue recon truction . Other
advantage include minimal donor it morbidity and it
di tant location which facilitate a two-team approach .
The e di tinct advantages have made the free fibular
o teocutaneou flap the raw material of choice for
egmental mandibular recon truction.7
OUTCOME
Free tis ue transfer i a highly reliable method of head
and n ck recon truction. Shpitzer et a! recently reviewed
their erie of mandibular recon truction u ing fibular
free flaps in 47 patient . Succe ful flap tran fer wa
achieved in 95% of patients. There were no perioperative
death however nine patient had perioperative
complication that required medical or urg ical
intervention.2
Accurate long-term a e ment of diet, oral
con tin ence, peech and co me is wa po ible in 39
patient . Dietary habit were normal in 5 %, 32% tolerated
a oft diet only and 10% were dependent on a fe ding
tube. Oral continence wa normal or almo t normal in
55%. Thirty-five percent had moderate drooling and tho e
who remained dependent on a feeding tube had evere
drooling (10%). peech wa easily intelligible in 90% and
under tandable with effort in 10%. Co m tic re ults were
evaluated by both the patient and the treating urgeon.
Sixty-two percent were categorized a having excellent
re ult , 33%, acceptable, and 5%, poor.
The fibular donor ite healed adequately with minimal
morbidity in 46 of the 47 patient . 1 Immediate
po toperative donor site infection occurred in one noncompliant patient becau e of in istence on early
ambulation and discharge. Patient were able to ambulate
b twe n 2-10 week with 5 week being the average. On
follow-up, all patient were able to engage fully in daily
recreational activitie . Eight patient (17%) had mild lower
e tremity mu cle and joint weaknes , tiffne , or
in tability. One patient reported donor ite pain. It wa
concluded that long-term morbidity wa minimal and
their life tyle wa not altered.9
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quality of life for many patient undergoing re ection for
head and neck cancer. Although no one flap i ideally
uited to repair all def ct , the fibular flap is arguably the
be t method for r constructing anterior or large defect of
the mandible.
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CO CLUSIO N
Head and neck urgeon mu t addre two ba ic
i ue when planning the urgical treatrn nt of advanced
oromandibular carcinoma. The fir t i ue i the extent of
re ection required for oncologic clearance. The econd
i ue concern the optimal method of functional and
ae thetic re toration. The resection can be performed more
confidently ba ed on the ability to recon truct complex
defect involving bone and oft ti ue. In particular, the
ability to recon truct large mandibular defect ha
improved the functional and aesthetic outcome for
patient with advanced di ea e (Figure 4).
Free ti ue tran fer ha dramatically enhanced the
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WHILE MERLIN SLEEPS: CAMELOT YIELDS
A rev•• ew of the biology of
neurofibromatosis type 2 and the role of
merlin as a tumour suppressor
By David Skidmore, MEDS 2000, & Gregon1 M. Kelly, Assistant Professor, Department of Zoology; UWO

INTRODUCT IO
eurofibromata i ty pe 2 ( F2) i a r a re,
dominant! inherited genetic di ea e which ha
become the ubject of con iderable intere t;
po ibl di proportionate to the medical ignificance of
the di ea e it elf. Excitement over F2 i due in part to the
di covery that the di ea e i cau ed by the lo of
expre ion of a tumor uppre or gene dubbed mer lin.
Merlin, a widely e pre ed protein, i al o at the centre of
evera1 type of poradic malignancie . The tudy of the
genetic and molecular biology of NF2 provide u w ith
the opportunity to arrive at an improved under tanding of
the role tumour uppre or play in cell homeo ta i and
how thi control break down in leading to the
development of a malignant tate.
The F2 gene wa di covered independently by two
group .2 3 The gene at chromo om 22q12 encode m rlin,
a protein with ignificant homology to member of the
Protein 4.1 up rfamil , e pecially Ezrin, Radixin, Moe in
(the ERM ubfamily). The homology to Protein 4.1, the
prototype in a up rfamily of protein as ociated with the
cyto k leton-pla rna membrane interface, wa a urpri e
ince mo t other tumour u ppre or gene were known to
be nuclear protein . Since merlin ' di covery, other
cytopla mic tumour uppre or protein ha ve been
identified . How merlin a nd the e pro tein act in the
cytopla m to directly and I or indirect! regulate gene
transcription and cell cycl ha b en given a great deal of
attention. In ight from thi re earch will undoubtedly
increa e our comprehen ion of both
F2 and the
mechani rns by which tumour uppre or act.

N

Neurofibromatosis Type 2
S mptom of F2 which manife t them elve during
middle age con titute the le
evere Gardner ub pe,
wherea patient with the di ea e in their mid-twentie
(the evere Wi hart ubtyp ) u ually do not urvi ve pa t
40 year of age4. NF2 i the mo t commonly mutated gene
in benign tumour of the human nervou y tem. 5 Of the e
ca e , approximately half occur in familie w ith no prior
hi tory of the di ea e. Due to the high p netrance of thi
di ease, it i held that poradic ca es are due to de novo
mutations, and uggest that thi region (a hotspot) of the
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genome ha a relatively high rate of pontaneous
mutation. The hallmark of F2 i the development of
bilateral acou tic chwannomas (al o called acou s tic
neuroma ). The e tumours are benign and low growing,
but due to their location can be very difficult to treat
urgicall y. Affected indi v idual are al o at ri k of
developing multiple tumour of other ti ue of ectoderm
lineage, e pecially pinal chwannoma , meningioma and
l
common ependymoma . A high incidence of po terior
len opacitie ha also been reported. 6 Pathological
examination of afflicted individual ha demonstrated that
pinal n e rve root are studded with a y mptomatic
tumourlets. The e tumourlet are e pansile le ions which
are imilar to chwannoma , yet hi tologically di tinct.
Whether the e tumourlets, which are unique to the F2
y ndrom e, repre ent de velo pmental le ion or are a
precur or tage in the development of full- cale
chwannoma i a point of orne debate.7 It hould be
noted that while
F2 tumour are benign, th e
compre ion the cau e can lead to ignificant functional
impairment, regardle
of the indi idual' age. In
reference to F2, Gu ella et al. ta ted that the resulting
morbidi ty i of uch ignificant magnitude to re ult in a
mea urably reduced life pan.
TUMOUR SUPPRESSOR GENES
A n opla m develop when a tumor suppre or gene
lo e it function. The e gene play a role both in familial
cancer and also in many poradic neopla ms. At least 25
tumour uppre or gene have been cloned in the ten
hort year ince the di covery of the fir t tumour
uppre or, RBI (a ociated with familial retinobla toma ).
Familial cancer a ociated with tumour uppre or gene
are, a a rule, inherited dominantly. Intere tingly though,
tudie have revealed that the pre ence of a ingle copy of
a tumou r uppre or gene in a cell i enough to in ure
normal, wi ld typ function . Thi ob ervation contradicts
the Mendelian theory which tate that for domina nt
inheritance, the expre ion (or lack of expre ion) of any
mutant allele hould re ult in the di ea phenotype.
To explain the di crepancy and al o the eemingly
random nature of tumour development, Knud on
propo ed hi famou "two hit" theory. It hold that for a
neoplasm to develop there is an inactivated copy of a
tumour uppre or gene in the germ line, the "second hit"
inactivate the other copy in omatic cell leading to
tumourg ne i . Therefore, in familial cancer the "first hit"
would occur via germ line inheritance of one nonfunctional copy of a tumour uppres or and ometime
during the individual' lifetime a cell will lo thi
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heterozygo it , e ither through non-disjunction during
mito i or a random mutation, which inactivate the wildtype allele; "th econd hit".
Since the likelihood of a ingle omatic cell having two
inactive copie of a pecific gen i low, tumour would be
very unlikely to occur with any regularit unle there
wa an inherit d "hit" already pr ent. Since the timing
and the frequency with which the econd hit occur i
random, thi imple but eloquent "two hit" model would
account for the variance in everity (expre ivity) and time
of on et een among family member who inherit one
copy of a mutated gene. Data fr m m any y ndrome
upport the theory that there i a change from
heterozygosity in non-neopla tic tissue to homozygou
lo of expre ion in actual neopla tic ti ue .9
To fru trat matter , evidence exist to indicate that a
mutated tumor uppre or gene, who e inherited lo
cau e a familial y ndrom with it well-defined
ymptom , may be re pon ible for generating multiple
poradic neopla m in ti ue unaffected in the familial
y ndrome. For example me oth lioma , in which th e
homozygou lo of F2 i reJ'orted, do not occur with an
increa d frequency in F2. 1 Thi inconsi tency i like!
explained by the exi tence of oth r factor which play a
permi ive role in tumourigen i . Th e factor may be
con titutively pre ent in ti ue characteri tically affected
by the inherited yndrome, and ab ent in other without a
econd timulu to induce them. In a me othelioma, it i
propo ed that the inflammatory re pon e to a be to
alter gene expre ion of one or everal unknown proteins
which interact with merlin. In th e ca e me othelioma
develop when F2 e pre ion i homozygou ly lo t (it i
al o believed that a besto incr a
the rate of mutation) .11
Study of other tumour upp re ors in F2 will help
delineate the perrni ive factor and may highlight orne
that are amenable to prevention.
MERLI AND NEOPLASM
The neoplasm s mo t commonly a ociated with
merlin' ab ence are chwannoma . The tumour are
benign nerve heath tumour compo ed of Schwann cell
w hich can form along any peripheral or cranial nerve.
Schwannoma form with particular frequ ncy in dor al
nerve root and in the eighth cranial nerve . Multiple
tumour of thi kind are e pecially common in individual
with F2 . In an immunocytochemical tudy StemmerRa chamimov et a!., 12 creen d pathological pecimen
(both poradic and from NF2 proband ) of chwannoma
and found merlin wa completely ab nt. In a follow up
tudy the author reported that merlin' ab enc in the
tumourlet , charac teri tic of F2, might not only be
ab olute, but an early re9uirement in the progre ion to
chwannoma formation. 3 It i intere ting to note that
independent tudie have hown that merlin i ab ent in
only 7 % of chwannoma . 14 Thu , while the evidence
clearly indicate that merlin expre ion i alt red in
chwannoma , more re earch i needed to determine the
ab olute frequency.
Di crepancie in the tudie de cribed above are
trouble orne for tho e u ing genetic te t to identify
patient with F2; a lo of merlin mRNA in only 50-60%
of chwannomas i in marked contra t to Stemmer-
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Rachamimo and colleague ' ab olute (100%) lo . 15 In
orne ca e , wild type m rlin mRNA wa d monstrat db
rever e transcription polym ra e chain reaction analy i . 6
This di crepancy ugge t that orne form of a genetically
undetectable tran la tional or po ttran Jation a l
modification to merlin rna pia a r Je in up to 40% of the
chwannoma . In contra t, Gutmann found that while
merlin was pre ent in orne chwannoma , that the
ab ence of merlin mRNA correlat d with the ab ence of
the protein . In thi ca e one would ha e to agree that
current t t are adequat , but obviou ly further tudy i
needed . 17 Meanwhile, the conflict in the frequency of
merlin lo between variou tudie pre nt u from
determining the en itivity of g netic te t for F2.
Therefore, unle the pecific Je ion a ociated with a
family inheritanc ha been identified, current method of
genetic t ting for F2, while e tr mely p cific, ar not
e1 itive in up to 40% of all case .
The ab ence of merlin ha b n noted in other typ of
tumour . Merlin e pre ion i often ab ent in
meningioma in a ubty pe pecific pattern . ormal
e pre ion, how ver, wa ob erved in 0% of poradic
mening thelia) meningioma , indicating that merlin ha
no role in the gene i of thi typ of tumour. Conver ely,
merlin ' ab ence in poradic fibrou and anapla tic
meningioma , ugg t an involvem nt of m rlin in the
tumour ubtyp . In upport, Hitot umat u et al. reported
that mo t meningioma in F2 pati nt are of the fibrou
ubtype. 17 In contra t, d pite th occa ional occurrence of
ependymoma and oth r a trocy toma in F2 patient ,
merlin expre ion in poradic tumour of the fibrou
ubtype wa normal in the vast maj rity of. The author
ugge t that oth r tumor uppr or are re pon ibl for
the e condition . In thi regard, orne have noted that in
many ca
of color ctal ca ncer, deletion have occurred
on chromo orne 22q in th r gion wh r
F2 i located.19
In the majority of ca e , however, merlin e pre ion wa
unaffect d thereby ugge ting a minimal role in colorectal
cancer.20
De pite the ab ence of me othelioma in the pectrurn
of tumours ob erved in F2 patient , it appear that
merlin i ignificantl ab ent in malignant me othelioma .
Although it role in the lung ti ue i not known the data
would ugge t a pecific role for merlin in preventing
uncontrolled hy perpla ia of lung pleura .21 Determining
w hat fraction of th e tumour are due pecifically to
merlin' ab enc i an urgent re earch objective. Once
e tabli hed we can then ad quatel u e genetic t t to
creen for NF2, but if the current di crepancy betwe n the
pre ence of merlin mRN and the ab ence of the merlin
protein can be hown, then we will have to earch for
po ttran criptional event that influence tumourigene i .
If the di crepancy lie in the inability to det ct the protein
u ing currently availabl antisera then diagno tic re arch
may depend on generating a battery of antibodie to
detect everal epitope in th protein it 1£. In any event,
the e area warrant furth r investigation.
MERLIN A D ERM FAMILY PROTEINS
Merlin and the ERM subfamily of the Protein 4 .1
uperfamily are a group of evolutionary con erved
protein that di pla y considerable equence homolog
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aero the animal kingdorn. 22 All of the e proteins po e
two di tinct component . The domain located at the H3terminu form a globular region which is known to
interact with integral proteins of the pla rna membrane. In
particular, the ERM protein and merlin bind the
hyaluronic acid receptor, CD44.23• 24 Variou i oform of
CD44 exi t, orne of which are a ociated with a p oor
prognosi in malignancy, a they indicate an e a rly
meta tatic cour e. Of note, immunohi tochernical tudie
have hown that aberrant expre ion of merlin re ult in
an alteration of CD44 i oform
expres ed in
chwannorna .25 Thi information ugge t that merlin and
perhap the other ERM proteins may not only bind CD44,
but may regulate its function and ultimately its ability to
bind to thee tracellular matrix.
The econd component hared by ERM protein i the
COOH-doma in which bind
to cortical a ctin
microfilament of the cy to keleton. 26 The ability of ERM
protein to bind two fundamentally different target has
led to the propo al that ERM protein erve a d ynamic
bridge , connecting the cyto keleton with integral pia rna
membrane protein . Irn.rnunolocalization tudie reinforce
thi notion ince the ERM proteins locali ze to regi on
under the pia rna membrane, particularly to tho e regions
rich in actin.27 Merlin also localize to region just under
the pia rna membrane and in orne studie to perinuclear
regions. By proxy, merlin probably act like the other ERM
proteins albeit the ERM ubfarnily ha not been granted
tumour suppr or tatu .
How merlin behave in vivo i till poorly under tood,
but the e interaction are likely influenced by e era)
other protein . At lea t two member of the Protein 4.1
uperfarnil bind calmodulin in a calcium-dependent
manner.2 All member of the Protein 4.1 uperfamily
consensu equence for both tyro ine and erine
kina e _'l!J The epidermal growth factor (EGF) receptor can
pho phory late ezrin and when this occurs, both zrin
localization and cell morphology are altered .30 Merlin
po e e consen u pho phorylation ite , how ver,
unlike the ca e with ezrin, ti ue culture cell expre ing
merlin are not affected by EGF stimulation.31 These re ult
indicate that merlin i likel y controlled b y other
heterophilic interaction . Recently, the ERM-rn rlin
ubfamil y of protein wa
hown to participate in
homophilic interaction .32 Intramolecular bond w o uld
allow two molecule to bind in a head to tail fa hion
thereby rna king the ite for actin and I or integral pla rna
membrane protein like CD44 . Sub equent po ttranslational modification by growth factor-induced
pho phor y lation w ould induce an a llo teric h ift,
interrupting the horno-dirnerization and expo ing the
binding site to other proteins.33 Much work in this area is
needed to full y comprehend how merlin behave w ith
it elf and with other putative binding partner .
Studie with tis ue cultured cells expre ing merlin
transgenes have revealed orne intere ting features of the
protein's ability to act a a tumour suppre or. Merlin i
known to affect cell cycle and re v er e malignant
phenotype . An increase in levels of both phosphorylated
and depho phorylated merlin in cell confluency tudie
can be correlated to the decrea e in mitotic rate indue d by
the e condition . On the other hand, overexpre sion of the
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carboxy-terminal half of merlin induces cell death in
IH3T3 cell .34 Lutchrnan and Rouleau reported that
merlin e xpres ion can decrease rnitosi in a do e dependent rnanner. 35 In the arne cell line, but no w
transformed with the Ra oncogene, merlin has the ability
to re cue the Ra phenotype of anchorage independent
growth.36 Thi anchorage independent growth, erving a
a model for rnetasta is, is the epitome of what happens
when a tumour uppre or protein is lo t. It hould be
noted that in the tis ue culture tudie the phenotype w a
dependent on the expre ion of both domains of merlin,
either in ci or in tran , again upporting the notion that
the function of thi protein i affected by hornophili c
interactions.37
CON CLUSION
Several studie uggest that the careful regulation of
merlin play an important role in controlling cell cycle.
Given merlin's tructural homology to ERM proteins it is
tempting to peculate that lo of merlin expre ion alter
the link between the cy to keleton and th e pia rn a
membrane-ex tracellular m a tri x. The lo s of tructura l
integrity ha dramatic consequence on cell hape, due in
part to the inability of merlin-deficient cell to adhere to
each other or to a ub trate. The lo in a cell' ability to
adhere to a target ma y be the fir t step in tumour
progre ion, but many que tions remain. In any event,
what on needs to find i an Excalibur to watch over our
cells whil t Merlin leeps in Camelot!
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ENDOCRINE THERAPIES
ADVANCED BREAST CANCER
POSTMENOPAUSAL WOMEN
By Micllelle Suga, MEDS 2000

ine the initial therapeutic u e of ovarian ablation b
Beat on in 1 96, hormonal manipulation ha been the
mainsta of the palliative management of meta tatic
brea t cancer, 1 and i the olde t form of
temic brea t
cancer treatment. 2 Since e tr gen pia an important role
in the development and promotion of human brea t
carcinoma , the inhibition of e trogen in e trogen
dependent brea t carcinoma (e trogen ablation ) ha
become an important form of therapy. Treating brea t
cancer by decrea ing e trogen upport ha fewer ideeffect than cytotoxic drug , and i more effective in mo t
ituation .3 E trogen ablation con i t of either (a) blocking
the ynthe i of e trogen , or (b) b locking e trogen
receptor in the tumour. Blocking the synthe i of
e trogen i accompli hed through oophorectom (via
radiation or urgery) or the u e of compound that inhlbit
aromata e, the enzyme involved in the conver ion of the
adrenal androgen , andro tenedione and te to terone, to
e trone and e tradiol, re pectively, the major ource of
e trogen in po trnenopau al women. The other major form
of therapy, antie trogen , are compound which bind to
e trogen receptor and competitive! exclude e trogen.
Other endocrin therapie that are le frequently u ed
include e trogen , androgen , proge tin
and
antiproge tin , and gonadatropin-r lea ing hormone
(GnRH) agoru t .

S

A TIESTROGE S
Antie trogen act through the e trogen receptor to
regulate gene transcription. When an antie trogen bind to
the e trogen receptor, the receptor i no longer available to
bind e trogen, and thu fail to effective! timulate gene
expre i n and D A ynthe i . The antie trogen-receptor
complex doe , however, enhance production of orne
growth inhibitory factor , including tran forming growth
factor ~ (TGF-~), thereb preventing brea t cancer growth
and meta ta i .4 Becau e antie trogen act via binding to
th e trogen receptor, the pre ence of e trogen receptor in
the brea t cancer cell ha proven to b very important in
pr dieting re ponse to antie trogen therap .
Tamo ifen, a non- teroidal competitive e trogen
antagoru t, ha b en in u e for over 20 y ar , and i the
mo t common! pre crib d drug for the treatment of
brea t cane r. 45 It i con id red th 'gold tandard' for
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antie trogen treatment of meta tatic brea t cancer in
po tmenopau al women6. Approximately 40% of brea t
cancer patient benefit ub tantially from tamoxifen
treatment, and treatment ha b en hown to reduce the
ri k of development of contralateral brea t cancer by
alma t one-half. v Tamo ifen binding to the e trogen
receptor inhlbit cell proliferation by a mechani m part!
due to the antagoni tic effect on e tradiol regulated
proteins with growth regulatory function . Studie have
hown the following effect of tamoxifen: increa ed ex
hormone-binding globulin, increa ed number of natural
killer cell , decrea ed level of tumour- timulating
autocrine growth factor (tran forming growth factor-a
and in ulin-derived growth factor), and increa ed TGF-~
(a tumour- uppre ive growth factor). 7
De pite the effectivene of tamoxifen, many women
eventually suffer relap e, becau e some brea t cancer
tumour invariably develop re i tance to tamo ifen/ 5·q
which leads to tumour progre ion and death. Although
tamo ifen is predominantly an e trogen antagoni t in
brea t cancer cell , acquisition of i.ncrea ingly dominant
agoru t activity over time may re ult in clinical re i tance
becau e of the acquired ability of the drug to timulate,
rather than inhibit, tumour growth. In addition, although
tamo ifen i mo tly inhibitory in its function a an
e trogen antagoni t in brea t cancer cells, it ha orne
e trogen-like activity in other cell of the bod .
Stimulatory effect of the agent on the uteru and liver
may underlie the increa ed incidence of endometrial
hyperpla ia, and alteration in liver function een in
women on prolonged therapy.7 Tamoxifen u e ha al o
been a ociated with di comfort uch a hot fla he ,
vaginal di charge, thinning of the hair, brittlene of the
nail , dryne of the kin, dizzine , nau ea, depre ion,
and thromboembolic phenomena.' On the other hand, the
e trogen-like activity of tamoxifen i beneficial in term of
enhanced bone mineral den ity in postmenopau al
women, enhanced bone maintenance, and reduction in
erum chole terol level, with an a ociated decrea ed ri k
of coronary problem . 1•7
A new antie trogen, toremifene, wa recently
approved for the treatment of po tmenopau al women
with m ta tatic brea t cancer. 10 Toremifene i a chlorinated
tructural analogue of tamo ifen and pharmacologically
related to it. Toremifene cau es growth inhibition in breast
cancer cell by uppre ing mito is and inducing
apopto i , po ibly via induction of TGF-~ and inhibition
of in ulin-like growth factor-111. Although primarily an
antiestrogen, it al o ha orne e trogen agoru t prop rtie
in po tmenopau al women. Mo t of the adver e effect of
toremifene are related to thi e trogeruc effect, and include
hot fla he , vaginal di charge, and nau ea. 11 In pha e III
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clinical trial , toremifene ha demon trated an efficacy
against metastatic breast cancer that i comparable to that
of tamoxifen. 10 However, torernifene is potentially afer
than tamoxifen, in relation to carcinogenic effect . In
contrast to tamoxifen, in pre-clinical trial s, high-dose
torernifene wa not found to be hepatocarcinogenic in rat
and, thu far, no carcinoRenic effect of torernifene have
been noted in human .1• 10•
More recently, newly developed "pure" teroidal
anne trogen , uch a ICI 164,3 4 and ICI 1 2,7 0, have
been found to be complete e trogen antagoni t , by
binding and inactivating the e trogen receptor, and
exhibiting no e trogen agoni tic activityY · It ha been
uggested that "pure [steroidal] antie trogen may have a
therapeutic advantage over tamoxifen in reducing the
probability of treatment failure due to regrowth of
tumour from resi tant cell ". The pure an tie trogenic
activity and the high potency of steroidal antie trogen
ugge t that the e compounds are uperior to tamoxifen
both with re pect to complete initial re pon e and longla ting re pon e .9 However, they are not effective in
preventing bone lo and may have detrimental effect on
the cardiova cular y tem. 7
ICI 1 2,7 0 i a 7a-alkyl ulfinyl analogue of e tradiol
that po e ses a greater ability to uppre e trogenensitive gene expre ion and greater anti-tumour activity
than the partial e trogen antagonist tamoxifen. 5 However,
a with tamoxifen, mo t tumour eventually became
re i tant to ICI 1 2,7 0 and grew independently of
e trogen. 5• ICI 164,384 i more effective than tamoxifen in
inhibiting e trogen becau e tamoxifen bind to the
e trogen receptor with an affinity of le s than 5% of the
binding affinity of ICI 164,384.
AROMATASE INHIBITORS
In premenopausal women, the main source of
e trogen i the ovary, where it i ynthe ized from
androgen under pituitary control. In po trnenopau al
women, estrogen is produced mainly by peripheral
aromatization of andro tenedione and te to terone, and i
mediated by the enzyme aromatase.12• 13 About two-third
of human brea t carcinoma contain detectable level of
aromata e. 14 Since aromata e catalyze the final, ratelimiting tep in trogen production, it therefore has been
the principle target of inhibition of e trogen ynthe i . 15 In
po trnenopausal women, the aromata e enzyme complex
i not regulated by a feedback mechani m, and o it
inhibition ultimately cau e an appreciable decrea e in
ti ue e trogen level , which ha therapeutic effect. 1
Therefore, estrogen deprivation through aromatase
inhibition provide effective therapeutic treatment of
advanced, hormone-dependent brea t cancer in
po trnenopausal women.
There are two main group of aromata e inhibitor :
uicide inhibitor (exclu ively teroidal) and competitive
inhibitor (either teroidal or non teroidal). 13 Suicide
inhibitor eem to be a better choice than competitive
inhibitor , ince they ar highly pecific, and the
continued pre ence of the drug i unnece ary to maintain
inhibition. With both types of inhibitor the inactivation of
aromata e can be prevented by the pre ence of high
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concentrations of ub trate relative to the inhibitor during
the reaction. 3
Aminoglutethimide wa the fir t aromata e inhibitor
to be u ed in brea t cancer therapy. It i a competitive nonteroidal aromata e inhibitor. Unfortunately,
aminoglutethimide lack pecificity, and al o inhibit
adrenal corti ol production and interact with ynthetic
glucocorticoid , accelerating their metabolic clearance.15
Thi
therefore
nece itate
hydrocorti one
suppleme ntation .
Important
ide-effect
of
aminoglu tethim ide appear at the level of the central
nervou y tern, the major ymptoms being lethargy,
vertigo, ataxia, mental depre ion, and in omnia. 15
Forme tane (4-Hydroxyandro tenedione) i the fir t
teroidal compound to be tructurally de igned a an
aromata e inhibitor. It i an analogue of andro tenedione,
and it i a teroidal, irrever ible inhibitor of aromata e. It
ha been hown to be 30- to 60-fold more potent than
aminoglutethimide, and to ignificantly reduce pia rna
level of e trogen . 16• 17 Forme tane i very pecific and
require no glucocorticoid replacement. It mu t be
admi ni tered via intramu cular injection, and i well
tolerated in patient , the major complaint being local pain
at the injection ite. 1
Ana trozole and letrozole are the fir t elective, oral,
non- teroidal competitive aromata e inhibitor . 19
Ana trozole reduce circulating e trogen level by more
than 0%, letrozole by 79%. 20 Ana trozole ha a low ideeffect profile (low occurrence of hypertension,
thromboembolic event , weight gain, dy pnea, vaginal
hemorrhage, weating and diarrhea). 21 It i currently u ed
to treat women a econd-line treatment after tamoxifen
and as fir t-line treatment after tamoxifen ha b n u ed
a an adjuvant therapy . It may al o be used when
tamoxifen is not tolerated. 22 Letrozole i a potent, highly
elective competitive inhibitor of aromata e. The high
electivity ha been demon trated by the lack of
compromi e of glucocorticoid and mineralocorticoid
production or thyroid function. 23 Letrozole is able to
achie e total e trogen deprivation in animal , imilar to
that produced by urgical oophorectomy. 23 While it ha a
imilar ide-effect profil to anastrozole, it i le likely to
cau e thromboembolic event . Both ana trozole and
letrozole are contraindicated in women who are pregnant,
brea t-feeding or premenopau al, and in patient with
evere liver di ea e. Ana trozole i al o contraindicated in
patient with moderate liver di ea e or severe renal
im pairrnen t. 20
OTHER E DOCRINE THERAPIES

Surgical attd Radiation-Induced Endocrine Ablation
Therapies
The main therapy in thi category i oophorectomy.
Beat on fir t u ed urgical oophorectom in 1 96, and
described dramatic po t-surgical tumour hrinkage in
three women with locally advanced brea t di ea e . 1
Radiation-induced ovarian ablation wa introduced in
1922. Oophorectom work b eliminating the ovarian
e trogens, the main ource of e trogen in premenopau al
women, and i therefore of therapeutic value mainly in
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premenopau al w omen w ith e troge n- en itive brea t
tumour , with les benefit reported for po tmenopausal
patient . Two other urgic a l therapie u ed are
adrenalectom y and h poph y ecto m . Adrenalecto m y
eliminate adrenal timulation of the o arie , but require
upplementation with corti one after urgery to maintain
the other non- trogenic e ffect of adrenal hormone .
H y poph y e ctom y re ult
in a reduction of
adrenocorticotropic h o rm o ne, LH a nd FSH (and thu
adrenal androgens a nd o va rian e teroid ), but a l o
require uppl ementati on of hormone replacemen t for
glucocorticoid, mineralocorticoid and thyroid defici ncy.
Wherea urgical adrenalectomy and hypophy ect m y
have been alma t compl tel abandoned sine the
di cover of pharmacological mean to achieve imilar
effect on target ti ue, urgi cal oophorectomy i curr ntly
u ed to treat premenopau al women with advanced brea t
di ea e}
Estrogens
E trogen were introduced in the earl y 1940 a an
effective treatment for ad va nced brea t cane r in
po tmenop a u a l w om e n . The y appear to wor k b y
occupying e trogen rec ptor and thu reducing e tr gen
effect ; the are probabl y al o cy toto ic. 1 The mo t
common e troge n u ed wa DES (dieth y l tilbe trol).
Prolonged u e of estrogen , howev e r, ha potential
harmful effec t , including increa ed ri k of
thromboembolic complication , fluid retention, t res
incontinence, and withdrawal bleeding. U e of th e e
compound i generall y re erved for a Ia t attempt at
hormonal therapy in po trnenopau al women!

Androgen
Although androgen have been u d ince the 1940s,
their mechan i m of action is till unclear. 24 In
po tmenopau al women, androgen appear to suppre
LH and FSH (thu reducing e trogen l vel ), and occupy
androgen rece ptor w ith a ub equent reduction in
e trogen receptor, limiting the effect of e trogen _l In
recent year , the most widel y u ed androgen ha been
fluoxyme t ron acetate. The ad ver e effect of androgen ,
which include virilization, nau ea, hepatotoxicity w ith
chole ta i , increa ed libido, acn , and, in orne in tance ,
h y percalcemi a, a nd the decrea ed ffectivene
of
androgen compared to e trogen , have limited their u e
to third- or fourth-line therapy. 1•24
Progestins and Antip rogestins
Proge tins ccupy proge terone receptor and reduce
e trogen receptor and e trogen action . They may al o
produce direct inhibition of brea t cancer c ll _I
M droxyproge terone acetate (MPA), mege trot acetate
(MGA), and norethine terone ( ES) have all been te ted
in ad vanced di ea e. The u e of ES ha been aband ned
in recent year , but MPA and MGA are currentl y u ed,
with MGA being the more wide! pre cribed.24 Alth ugh
generall y well tolerated, orne patient receiving thi
therapy have e perienced h perten ion, fluid retention,
thromb emoli m, weight gain, withdrawal bleeding, and
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dy pnea?·24
Antiproge tin al o occupy progesterone receptor
and bring about reduced proge terone action .
Mifepri tone (R 4 6) i a potent proge terone-receptor
blocker currently in clinical trial . In addition to binding
proge terone receptor , it al o bind to glucocorticoid and
androgen receptors, bringing about more compte ide
effect , uch a fatigue, hot fla he , nau ea, anorexia, and
brea t tend erne .24
GnRH Analogues
GnRH i relea ed from the hypothalamus in a
pul atile fa hion, and stimulate ecretion of LH and FSH
from the pituitary gland. A continuou level of tirnulation
of the pituitary gland by a GnRH analogue lead to an
initial elevation in LH and FSH level , followed by their
uppre ion, which ultimately lead to a lack of gonadal
endocrine timulation and to level of e trogen irnilar to
tho e een after oophorectomy .• GnRH analogues are
con idered the medical
urrogate to
urgic al
oophorectomy.7 Four uch drug te ted in the etting of
meta tatic breast cancer a re bu serelin, leuprolide,
go erelin, and triptorelin, admini tered via intramu cular
or ubcutaneou injection . Toxic effect of the e
compound include hot flashe and other effect o f
menopau e, a well a discomfort at the ite of injection.
The e drug have been u ed ucce fully in the treatment
of premenopau al women with breast cancer, but less
optirni tic re ult have been reported in po trnenopausal
brea t cancer patient .25
CONCLUSION
It i currently recommended that the majority of
patient with advanced brea t cancer receive endocrine
therapy a their fir t mode of treatment, although it i
po trnenopausal patient with e trogen receptor po itive
tumour who are likely to gain the mo t benefit from thi
approach .25 Although numerou endocrine treatment
have be n hown to be ucce ful in treating ad vanced
brea t ca ncer in po tmenopau al women, it mu t be
mention d that brea t cancer i a highly meta tatic di ease
and it ha been found that different meta tatic ite vary in
their re ponse to endocrine treatrnent. 17
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DYSPLASTIC NEVI-A CLUE
TO INCREASED CUTANEOUS
MELANOMA RISK
By Noreen Galaria, George F. Murphy, M.D.

he characterization of the clinical and pathologic
feature of dy pla tic nevi (heritable melanocytic
le ions) by Wallace Clcuk et. al in 197 allowed the
recognition of the e le ion a mcuker of melanoma ri k
in a pecific ub et of patient .1 Dyspla tic nevi cue now
known to occur in two major epidemiological conte t .
The were fir t de cribed in the setting of melanoma
prone fainilie where the pre ence of a ingle dy pla tic
n vu wa hown to be a n itive phenotypic rncuker of a
trong gen tic tendency to develop melanorna. 2 It wa
later di co ered that even out ide of thi familial etting,
the e nevi were important mcuker of a mailer and a yet
incompletely defined ri k for developing melanorna. 1 The
dramatic ri e in the incidence of melanoma, coupled w ith
the clu tering of other ri k factor that i often e n in thi
population, irnplie that there cue enormou public health
benefit to the eculy recognition of dy pia tic nevi.

T

CLINICAL FEATURES OF DYSPLASTIC EVI
Dy pla tic nevi (D ) are clinically atypical nevi that
maybe important marker for the development of
malignant melanoma. 3 Clinically, they may have a
maculcu compon nt, irregular and indi tinct border that
fade into the urrounding kin, variable color (tan, brown,
pink), and a diameter greater than 5 rom and often greater
than 10mrn. 1 Dy pia tic n vi occur more typically on une po ed area (e.g. the back and che t) but the can
appear on normally protected area uch a , t~e calp:
buttocks, groin, and brea t , where common acqwred n VI
occur le often . Patient with the d pla tic ne us
yndrome will often have from twenty to over ~ hundred
I ion , which are often larger than u . ual nevt ~d may
occur ingly or clu tered together In group . . Al ?,
typically, the d pia tic ne i are not pre ~nt at b1rth ~n
tho e with the yndrome. In tead, they begm to app cum
mid-childhood year when they rna re emble common
mole . The e patient u ually develop melanoma at a
younger ag and tumor may be multiple and cue often of
the uperficial preading type. 5
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HISTOPATHOLOGIC FEATURES O F DYSPLASTIC
NEVI
Benign ne vi are divided into three subtypes junctional, compound and dermal nevi. This cia ification
i ba ed on the location of nevu cells in the epidermal
and dermal layer of the skin. The three type repre ent
seq uenti a l developmental stages in the life cycle of a
nevu . Flat junctional nevi, with nevu cell located at the
dermal-epidermal junction, cue the fir t to be een. The e
evolve into cornpund nevi when orne of the nevu cell
begin to percolate into the papillary dermis. Continued
migration of all of the nevu cell into the dermi w ith
di app cuance of the intraepiderrnal component re ults in
the dermal nevus.
The majority of D , clo e to 0%, are compound in
nature. There cue many lightly vcuying criteria in u e for
the hi tologic characterization of a D . Generally
speaking, the epidermis show elongated rete ridge that
cue often club- haped, with increa ed melanocyte at the
ba al layer. Spindle haped and epi thelioid melanocyte
often form horizontal bridge between ne t at the dermalepidermal junction and nests may al o form in the interrete pace or at the edge of the rete ridge in tead of
from the rete tip , a is normally een in benign nevi. The
ne t , in cornpari on to tho e een in typical nevi, will
often vary in ize, hape and pacing (they are not at
equidi tant interval ). At the edge of the le ion, a houJder
of e clu ively intraepidermal growth often how more
pronounced cuchitectural atypia and thi lateral exten
can b u eful in identifying D particularly at cannmg
magrtification. In the papillary dermi , both lamellar and
concentric eo inophillic fibroplasia can be een. 6 There
ma y a l o be an increa ed number of blood ve el !
pigment incontinence, and a potty lymphocytic infiltrate.'
At high r rnagrtification, cytologic dy pla ia i
en when
the indi v idual nevu cells randomly di pla y enlarged
nuclei, hy perchroma ia, and contour angulation, forming
rectangular or rhomboidal hape . Cell w ith th e e
charact ri tic will often how coar ely granulated
(muddy) cytopla mic melanization. 7 Histologicall y,
everely dyspla tic nevi may be difficult to di tingui h
from in- itu or even inva ive melanoma, unle detailed
hi tologi c criteria cu rigorously applied.

!on

GE ETICS AND EPIDEMIOLOGY
The full development of malignant melanoma eem
to re ult from multiple genetic al terations, occurring in
equence, in the neopla tic cell . Many of the e alterations
cue recognizable as chromo ornal alterations.
In the context of acquired rnelanocytic nevi, a focal
proWeration of tructurally normal cell may progre ses
to a D , with abnormal hyperpla ia of melanocyte and
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atypia. Alternatively, D may appear de novo a in the
dy pia tic nevus syndrome. Following this tep come
primary melanoma, first as the radial growth pha e,
which pread centrifugally within the epidermal layer
and doe not have the capacity to meta ta ize, and then as
the vertical growth pha e, which invades perpendicular to
the epidermal surface and i capable of progre ing to
meta tatic di ea e. 7 Dyspla tic nevi in the setting of the
d y pia tic nevu yndrome and melanoma appear to be
pleotropic effect of a ingle auto omal dominant gene
wi th high penetrance, that may be situated on
chromosome band 1 p36 . 1 However, non -random
karyotypic change involving chromo orne 6, 7, 9, and 10
have al o been identified by everal group .9 Interestingly,
the well-known oncogenes p53 and K-ras have also been
identified b y molecular tudie to be involved in
melanocytic tran formation . There i evidence that RAS
gene mutation may be important in the progre sion of
the radial growth pha e melanoma to the vertical growth
pha e melanoma. 9
In addition to genetic tudie , the ri k of melanoma in
tho e with dyspla tic nevi ha been evaluated. I olated
d y plastic nevi are found in 2-5% of the population,
wherea the incidence of the dy plastic nevus syndrome is
probably le than 1%.3 The lifetime ri k of developing
cutaneous melanoma among the Cauca ian population in
the United States is about 0.6% (1 in 150). Persons who
have a D and no family hi tory have a 6% ri k of
developing melanoma. Persons who have D and a
hi tory of melanoma have a 10% risk of developing a
econd melanoma; per on who have D and a family
member with melanoma have a 15% ri k. The lifetime risk
of melanoma approache 100% for individual with D
from familie with two or more first-degree relati ve
having cutaneou melanoma. 5
Halpern et. al found that tho e with dy plastic nevi
often had a clustering of other risk factors as well.
Con idering a number of risk factor (ie. freckling, greater
than 50 nevi, blond or red hair, a tendenc y to burn
everely, little ability to tan, and a hi tory of multiple
painful or blistering sunburns) their group found that 46%
of tho e with dy pla tic nevi had at lea t three or more of
the e additional ri k factor .2 Thi finding ugge t that
" the identification of people with D tran late into the
iden tification of people likely to po es multiple
independent risk factor for melanoma." 2

MANAGEMENT
There i
till orne controver y regarding th e
management of dy plastic nevi . In 1983, the ational
In titue of Health recommended cla ifying the patients
into one of two group after an accurate family hi tory
and evaluation of parents, siblings, offspring, aunts and
uncle and grandparent : indi vi dual with D and a
family hi tory of melanoma or those with D and no
hi tory of melanoma.5
A thorough hi tory and physical which include
examination of the scalp, intertriginous regions, muco al
urfaces and eyes is necessary for initial detection of
melanocytic dysplasia. In patients with the dysplastic
nevus syndrome it i recommended that the phy ical be
repeated twice a year or more often depending on the

p a tient ability to monitor their own lesions and th e
s ta bility of the les ion s. 3 In the e individual , it i
advan tageous to take clinical photograph or computer
can of larger or more clinically atypical nevi to monitor
change.3 Biop y of at lea t one or more dy plastic nevi is
genera ll y performed to establish the diagnosis. evi
undergoing udden change, a well a le ion that are
otherwise s u piciou hould be removed . There i no
place for the whole ale ur gica l exci ion of all D ,
however. Prophylactic exci ion of D of the calp or other
potentially hidden area is often recommended since the e
le ion are difficult to monitor.5 It i prudent for the e
patient to avoid sun expo ure as there i evidence that
this will increa the number of nevi and their activity, a
well a the general ri k for development of melanoma
and other kin cancer .3
In the etting of i olated dy pla tic nevi (non-familial),
excisional biopsy is often performed if a) the le ion i
perceived a changing in ize, hape, or color either by the
patient or the ph ys ician; b) the le ion ha becom e
y mptomatic (ie. itching); or c) the le ion has clinical
ambiguity with early melanoma.
The incidence of malignant melanoma i rising at an
alarm ing rate, as is the mortality a ociated with thi
di ea e. The increa ed melanoma ri k in tho e patient
with dy pla tic nevi upports the need for targeted
education in thi high-ri k group. Early recognition and
urgicaJ cure are two way in which we can hope to better
con trol the morbidity and mortality as ociated with
di ea e.
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MEDICAL STUDENT STRESS,
MISTREATMENT AND WELLNESS
By Bindu Kumar, MEDS 2000

INTRODUCTION
ir William 0 ler tated that it i "in the tudent pirit
you can be t fulfil the high mis ion of our noble
calling." He goe on to define the components f the
tudent' pirit: humility, confidence, pride and hop .1 It i
thi enthu ia m and dedication that incoming m dical
tudent bring with them a they embark on their m dical
training. omewhere along this path, tudent will face
unique tre e : enormou volume of material to rna ter,
call- chedule not conducive to adequate sleep, a well a
challenging and potentially abu ive interper onal
experience with faculty , hou e taff, re ident and
patient .2• 3 Recognizing the reality of many of the e
tre e and providing trategie to promote tre s
management early in a tudent' career may translat into
better coping kill a a re ident and ultimate) a a
practicing physician.
Evidence indicate that the e tre or impact on the
attitudes of tudent toward their educational experience
and their future a phy ician .~ Furthermore, the effects
of mi treatment and abu e have been identifi d a
stre or influencing medical tudent health, both
p ychologically and emotionally. 5•6 Th re i al o evidence
that experience with mi treatment in undergraduate
training have even impacted on the wellne s of phy icians
in a po t-graduate etting.7 In fact, parallel have b n
made betw n the abu e experienced by m dical tudent
and the abu e experienced by children in dy functional
farnilie . It ha been hypothe ized that the cynicism and
lack of caring that an abu ive medical chool environment
can create translate into potentially adver e interactions
with patient later in life . Hence, the abu ed ma y
demon trate abu ive behaviour and thi may begin a
early a cl rk hip. Thi di turbing theory obviate the
need for further re earch into the area of t re ,
mi treatment and the evolution of tudent attitude
toward th ir profe ion a they progre through the
many level of training.
Ultimately, preventative mea ure mu t be tak n to
minimi ze tress and rna imize tudent wellne and
health. That i , medical chool hould aim to be a afe
learning en ironment that i conducive to tudent well
being. De cribed a a culture unto it elC educator and
curriculum developer mu t realize the unique exp rience
of the medical tudent. Many tudents enter their program
in their early 20 and require an adju tment period to
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acculturate them elve with the demand of medical
chool. By directing trategie to ensure, promote and
maintain tudent health and a po itive attitude tudents
can benefit from program and supports immediately.
Pre ented here i a brief account of the literature
concerning medical tudent stres and mi treatment.
!here wi ll be a di cu ion of potential trategie to
tmprove health and treatment of student with an
introduction to the WHIMS (Wellne
and Health
~mpairment in Medical Student ) p ilot project to be
Implemented at the Univer ity of We tern Ontario
Medical School in addition to the other medical chool in
Ontario.
MEDICAL STUD ENT STRESS AN D MISTREATM ENT
Unque tionably, medical tudent are faced with
tre e unique to their curriculum. For example, the
expectation to rna ter large volume of information,
dealirlg with the challenge that patient experience with
their illne , attempting to meet the diver e need of the
public, 10 and ultimately choosing a field to train and
practice in upon graduation 11 are all part of the medical
tudent ' realm. A Univer ity of Briti h Columbia (UBC)
appointed advi ory group determined the following
tre or that medical tudent face over the course of four
year (Table 1). By examirling the unique feature of each
year, an adequate need a e ment can be performed and
the appropriate upport offered. 12
The tre e li ted in Table 1 may be unique to UBC,
but would pre umably be reflective of the issue
concerning tudent at mo t Canadian medical chool .
However, with each chool boa ting a different cultural
flavour , thi type of as e ment would need to be
performed at each institution in order to tailor workshop
and offer appropriate upport to tudents.
Currently counselor , both academic and per onal, are
availabl to medical tudent at the Univer ity of We tern
Ontario (UWO). Students are aware that they can speak
freely with the e individuals about any per onal i sue of
concern; however no formal tudent wellne program i
in place. A well, extracurricular groups intere ted in
educating peer about attaining a balanced life tyle have
taken the initiative to give tudents a chance to a k
que tions and expre feeling of tre s
A tudy of 318 Briti h medical tudent employed a
General Health Que tionnaire to a ess medical tudent
tre level and to further identify which area of stre
tudent found to be mo t difficult. Compared to
employed individual , graduated non-medical tudent
and non-medical tudents still enrolled in chool, medical
tudent were identified to have a higher mean score
indicating a higher ranking of stressful experiences.
Relation hips with academic taff and consultant as well
a talking to termirlally ill patient were identified to be
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the mo t tre ful experiences. 10 In con trast, Lloyd et al.
determined that the mo t tressful aspect of medical
school was the volume of material students were expected
to master. Demands of academic excellence and lack of
lei ure time were also considered stre ful.
Lloyd et a/. also demonstrated the evolution of tre
throughout the four years of medical school, with women
coring higher total stress scores than men. 3 The mean
total stress score increased year to year, but decrease in the
fourth year. Stre s attributed to lack of leisure time wa
consistent throughout the four years although the volume
of material to learn became a less stre sful is ue by the
senior year. In contrast, the most prominent concern of
practicing physici~s in UBC was remaining current with
medical education. b Whereas tudents move away from a
theory based learning approach toward the end of their
undergraduate tudies, as a practicing physician, the
learning process is critical to remaining aware of the late t
trends in medicine as are essential to the practice of
medicine.
Although an a e ment of tudent tre s has not been
performed at UWO, it would be intere ting to determine
what students find particularly stre ful about the new
curriculum versus the old curriculum. Have the stres e
increased or decrea ed? Doe a more integrated approach
organize material in uch a way that the volume of
material does not seem as overwhelming? Is a patient
centred approach more conducive to successful patient
interaction sooner? If the Univer ity of We tern Ontario
Faculty of Medicine is to champion the movement toward
addressing the issue of student wellne s, an accurate
a e ment of the unique need of our students would be
important in developing stre management and health
promotion programs.
Throughout the non-Canadian literature, the
uncertainty of post-graduate training and choosing a
pecialty were no t identified a sources of stress.
However, in a recent issue of MediScan, 11 tre related to
the Canadian Re ident Matching Service (CaRMS) proce
experienced by student were identified. Seventy-eight
Table 1.

I

First Year:

gender issues
performance expectations
"keener envy"
emphasis on facts

Second Year:

emphasis on hard facts
lack of intimacy of small group
little emphasi on attitude/ human issues

Third Year:

anxiety, depression
academic anxiety
lack of academic su pport

Fourth Year:

bum out; overworked
phase of apathy;
ovenvhelmed on rotations
inadequately prepared for career decisions

Articl e s

per cent of the 2500 tudents surveyed found choosing a
future discipline in medicine to be extremely difficult. A
similar number confirmed that it was an inadequate
expo ure to the variou pecialties that made the CaRMS
experience particularly tre sful. Furthermore the lack of
opportunity to change fields of training was identified a a
flaw in the system. Sixty-eight per cent indicated that
there was a great deal of tress related to making their
career choice. The fact that thi choice i virt u ally
inflexible make the proce s all the more stressful. 11 The
new curriculum at We tern ha modified the clerk hip
program in third year to allow student more elective time
and therefore more time to gain exposure to the specialtie
of interest. Student training in the old curriculum have
applauded this modification.
Recently, student from the Manitoba Medical
Student ' As ociation re ponded to the three suicide of
medical students and re idents in the Faculty of Medicine
at the University of Manitoba. They wrote:

W1wt do third-year students know about what sort of
specialty they would be interested in? Once accepted in a
particular program, residents are locked into this field for
the rest of their lives. What if they hate it? What if they
want to change fields? Unfortunately this is impossible the
way things stand. 13
Dr. Jacyk, coordinator of the Manitoba Medical
A ociation Phy icians at Risk Program commented on the
perceptions of re idents once placed in their respective
program, stating that they "don' t want to be perceived as
being vulnerable ... [and] resident are too afraid to access
[help] for fear of reprisal." . 13 The e hindrances mu t be
explored and viable option to eek help must be provided
through an employee a istance program run through the
hospital.
It i important to understand what ervice are
available to residents and medical student . The CFMS
(Canad ian Federation of Medical Students) has made a
erie of recommendations to addre the issue of tudent
stres . A "comprehen ive mental health care plan" has
been uggested which would include multip le entry
points for student and be visible, acce sible as well as
confidential. Proactive program including tres and
career management in clerk hip wa al o sugge ted, and
that support should be available at all point in a tudent's
education, not exclusively to tho e in their fir t year. 14
It is, however, in thi first year of medical chool that a
student's attitude and health can begin to be influenced
adver ely. Wolf et a/. determined that medical tudents
reported a decrea se in elf-e teem, and increased
expre ion of cynical attitudes after their fir t year
compared to their feelings upon entry in to medical
chool. By employing a number of psychological
as e ment cale , thi group looked at lifestyle,
nutritional, physical, and emotional changes among fir tyear students before chool began and then at the end of
their fir t year. In an anaJy i of the adjustment of students
to a medical chool environment, it was found that
psycho ocial functioning and self-esteem decrea ed while
depre ion and ho tility, a a-called negative mood,
increa ed. Under tandably, a tudent' ability to cope
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within medical chool is influenced by their prior level of
function, but knowledge of the deterioration in attitude
and feeling of the medical chool can have implications for
prevention. Wolf suggests that stre management and the
establishment of realistic expectations in medical chool
are po ible way of promoting health in the medical
student. Improving mentoring programs with more
empha is on role modeling and life tyle management may
also be beneficial.
Wolf et al. al o determined that mistreatment wa
positively a sociated with an increa e in cynici m and
hence a negative evolution of tudent attitudes. In fact, a
number of studie identified abu e (verbal, physi cal or
exual) to be a ignificant ource of s tre . The tudy
reported that of 87 graduating medical tudents, 98.9%
experienced some type of mistreatment during their four
year as a medical tudent. inety-two per cent of the e
tudent were y elled at with the greate t ource of
mistreatment coming from residents and interns. In this
particular tudy, the term mi treatment wa defined to
include: shouting, belittling, being assigned punitive task ,
physical harm, sexual haras mentor exploitation. 5
Similar re ult w ere found by Baldwin et al. who
surveyed third and fourth year tudents across the nited
States and determined that mi treatment was most
commonly manifested in the form of humiliation. Sixtyfive per cent reported having received negati v e or
disparaging comments about their choice of m dical
career or the practice of medicine. The majority of students
implicated re ident in these cases. Seventy percent of
tudent felt the e comment were bothersome . In
determining the degree of effect that such mistreatment
had, being threatened with an unfair grade was the most
concerning form of abu e with humiliation being econd.16
WHIMS
The Wellne s, Health and Impairment in Me dical
Students (WHIMS) project was created to addre s the
issue of "loneline and helple ne s which can facilitate
the de v elopment of dy functional behaviour" .9 By
recognizing the unique demands of medical school and
the various opportunitie to offer prevention trategies, it
is felt that cultivating po itive attitude early in medica]
chool can steer s tudent away from ubstance abuse,
depression and despair. The learning module designed to
be implemented into the curricula aero all five Ontario
medical schools focu es on s ubstance misu e amongst
phy ician . The overall goal , however, include increasing
awarene of illne e in medical tudent , the importance
of maintaining wellne p r onally and professionally and
offering education about the resources available to
students in need of support. By incorporating addiction
medicine i ue into the LMCC exam, medical school will
be compelled to educate students about impairment i sues
The evidence pre ented by Richman et al. provide an
example of how mi treatment can lead to depres ion and
sub tance abu se. Informing tudents about the warning
signs of the impaired colleague and how to inform the
appropriate authoritie is part of ensuring quality of care
and maintaining the integrity of the profession, a
re pon ibility belonging to all health care professionals.
Taking advantage of certain teachable moment : entry to
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medical chool, preclerkship and during clerkship,
students are empowered with the knowledge and
resources that will hopefully lead to a heightened
awareness of addiction that will extend into the pos tgraduate years.
When considering ways to addre student stress and
mi treatment, it i important to think of trategies that
implement measure for prevention versus rescue.
Enhancing student wellne s and offering an outlet for
tudent ' tresses and concerns can be both therapeutic
and beneficial to the maturation of a medical student.
Mo t schools have a mentor program where students are
paired or grouped with a community physician, usuaJly
for ocial interaction. Having an academic faculty advisor
allows s tudent to address i sues of cholastic nature, be it
exams, career choice or CaRMS. A predominantly ocially
oriented mentor group ma y not be conducive to
di cu ing a student' concerns. Perhap if tudent have
an option to address concerns early, faculty advisors can
discover where they falter and offer upport. Finally,
mentor hould ideally be role models. Physicians that
reach out to students, sharing their per onal experiences
and coping mechanisms further enforce the reality of
juggling personal stresses in a highly demanding
professional environment. Positive role models that
demonstrate enthusiasm for the profession as well as
balanced life tyles may influence medical students to seek
and maintain similar goals.
Clinical vignette have already been designed to
address boundary is ues in medicine between patients,
medical students, and clinicians. Demonstrating typical
medical tudent stres or and boundaries may be equally
beneficial. Because the stresses medical students
experience are dynamic, different cenarios for each year
can be u ed to generate discussion and help introduce
support programs available to tudents at each phase of
their career. It is important that any strategies to improve
student wellness be met with enthusiasm from faculty.
Strong, weU-e tablished programs that allow for student
involvement will create an environment where students'
needs are met.
Medical chool can be a challenging and rewarding
experience. The learning environment must be a safe and
healthy one in order to preserve positive attitudes about
elf and others. Furthermore, maintaining respect for the
profe sion and the value tudent will take with them
into their professional careers should be considered an
essential element of the medical school experience. Ideally
medical schools should boast a zero-tolerance policy
regarding tudent intimidation and mistreatment.
However, with the complexities of interpersonal
communication, thi i clearly impractical. It is important
for all schools to have a code of conduct, which should be
included in student handbooks as well as resident training
/ teaching manuals. Educating tudent and faculty about
the exi tence of policy on mistreatment, its enforcement
and the available re ource , however informal, that
students can use should be a priority if progress in this
field is to be made.
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E..,... SIJMiies
The AEs reported by at least 2'/o of p ems ., any trea~ group are cEsplayed
by COSTART body system and term arod by treatment group lor controled long·
term E~KGpean Studies ., Table 5.
TABL£5
Treatmeiii-Emergent AEs Reported by ~ 2'!1. of Patients
Trooted with H,-RAs or laMOpruole ito Long-Tena.
Phase 11/ 111 H1-RA Controlled European Studies
Treotmelll Groap
Body Systenv'COSTART Tenn
Total Pa ems
Any bent
Body as a Whole
Abdornonal Pam
Back Pall
AcCICientallnJUry
lnfecnon
CardiOVascular System
Hypenenston

Digestrve System
Diarrhea
GastntJs
Consnpanon
Vornttmg
Dyspepsla
Musculos eletal System
Arthralg10
ervous System
01lllf1tSS

27(4.21
7(11)

ned to those

TABL£4 (coot'~ l

Treatmeiii-Emergeot AEs Reported by ~ 2'!1. of the Placebo
ud Laosopnzofe Potieats to the Ti011 ol first Rec:orreoce
of Disease• i• tbe Maiwte1ance Treabltent Studies

ResporatllfY System
Resptratory OISoofer
Cough Increased

Lansopnzole
(N=263)

H,-RAs
IN= 161)

"In)

"'fnl

49.8(1311

46 61751

3.0(8)
2.3161
15(41
11 (3)

17(6)
0.6(1)
2.5(41
11(51

19(5)

2.5(4)

9.1(24)
5.3(14)

4.3(7)

19(5)
1.1 (3)

1.2(2)
2.5(41
11151
31 (5)

1.9(5)

2.5(41

1.9 (5)

2.5(4)

2.3161
1 1131

1 1(5)
2.5 (4)

2.1m

The AEs reported by It ast 1" of pauents receMng lood-tn opeo-labellansoprazole trea ent'" long-term Et.upean Studies are diarrhea (S.~l esQjlhagtlos
12.5"'. abdonwlllp.. l21"',gastnbSI21"',fla nee(!~~ adache(U"~
coostJpatlOII(l 0'11.1. arod nausea (I 0'11.~ The 11Codence of AEs reported ll the lead·
., opeo-label penod of e European studies W11S
ar tD that seen., controlled
studies, however, the overall mCidence was ~er fCH' the lead~m open-label
studies than lor the H1-RA conuolled studies (275" versus 49.8'1.. respectively~
Add' onal1dverse e enences occurnng 10 < 1\ of pa ents or subtetts m
dornesnc anol'or e"'"""""lu..ls.oroccumng sooc:e the drugwasmarte:ed,arl!
shown below
each body syst
Body as 1 Whol.-aslhen11. candtdiaSIS, chest plln (not otherw~se specified),
edema, tev.r. syndrome, halitosiS. eCOOII(not otherwose spedied~ malaise,
carc1100111, general pa
C~rdrovascul~r Syste : angma, cerebrovascular acc•dent. hypertenseo~
hypotensiOn, ntyoeanhl1nfarctton, palprtanons. shock (c~rculatory l11lurel.
vasodilatJOO;
D~esrm System:
lena. c
ISIS, abnonnal stoolsi.,.lena, bezoar,
consnpotlOII, dry 110uth/tlltst. flaudence, gasuoe errus, go
snnal
hemorrhage, hema e SIS, anore a, Wlcreased appe e. incrused saivaoon.
rectal hemorrhage. canfiospa dyspepsil. dysphag11. erurunon. OSOilhageal
stenosiS. 1!$01lhageal Lker. esophagms. stoma ns.lecal distolonnon. tenesmus.
Lkeranve colins, gastnc notiiAes/fundic glarod polyps. c•cllOIIf;
Endocnne System: diabetes me
goner, hyperglyce~enia;
Hematll/ogt< •nd L~atJC System ' agraiMocytDSIS, a
oplaSIIC ane a,
hemolySis, hemolync a
a. leuiope0111, neuuopenoa, pancytope01a, tlvornbocytopenoa, arod tlvorrbotJc thrombocytopenoc purpura,
Merabolic and NutrrtJOnJI DISOrrJtrs·gout. weight g01rl'loss. edema:
Musculoskeletal Srste<n: arthnns!arthralg11, musculoskeletal p11n. myalgia:
NeiYOUS Srstem: agltl
amniSII, apathy, confusion. duzmtss, syncope, ha~
luCJ\anoros. hostity aggravated, ibodo decreased. depressloo.~tem~Pe9ia. insmt101. sormolenc:e.
alnirmaity, IOlllety, nervousness. paresthesia:
/ltiiWatory System-a
bronchitis. cough 11<reased. tlyspneo, hemoplysos,
llccup, upper respontory
ectJon. pneumonoo, epostaJOS;
Sbn and Appendlges: acne, prunrus. nsh. urtJcona, alopec11,
Speclll Senses: amblyopia, eye pall. YISIJI!Iield defect ll1nllUS, ophthalnoologoc
disorders. ear disorder, deafness, ootos medio. taste pen.....n;
Uruge
SystBDra
menses..........,., breiS! enlargement! gynec_omasna. breast tenderness. glycosuna. potence, itdney colc,.,s. hematuna.
LmOryurgency
t The ma}Onty of hema iog1c cases recetved were fOfttgn·sourced and thetr
relationshop to lansopruole was unclear.
CotJIIIi....., Tlltnpywith C/~udAno>xici/fir.lnclincaltrialsusmg
combmanon therapy
PREVACID plus elanthromycm and amo c·lil. arod
PREVACID plus amo ciftin, no adverse reactJOns related to these drug
c
na ns were observed. Adverse reacbOns that have occurred have been

at have been preVIously reported Wlth PREVACID, clar-

romycm. or amoXJcilhn. For more mformanon on adverse reac ons wrth

clanthrornycll or llliOJIIcilin. rl!ferto their respective Product Monograplos, uroder
the ADVERSE REACTIONS secTriple ruro,y; PlfVACID/cl•ritll""'fCill/,_ncillio: The most frequently
reported odverse M
for pa ms wflo received tnple rapy were diarrhea
1~1.
eadacht (6"1. and taste perverSIOn 15"1. No trea ntlll:lergent adversa events were obserwd at Slgnifica
higher rates with tnple
therapy than wrth any dual lherapy r
n.
D11l Tlleropy; PRfVAC/D/omuicillil< The r~ost frequently reported adverse
events for panents who received PREYACID ti.d. plus
ti.d. dual therapy
were diarrhea(I'JI.)and headache 17"~ No ~ea~-finlfgent admse MntS
were observedatSJg a logherra eswrth PREVACID ti.d. plus a
ilm
tid dual therapy than wrth PREVACID alone.
laboratory nlues: In addinon. theloflow10g changes 10 laboratory parameters
were reported as adverse events. Abnormal liver luncoon tests, ooc:reased SGOT
IASn. 1ncreased SGPT IALn. 10crnsed creatinine, r~creased alkaline phosphatase, 10creased gamma globulins. mcreased GGTP, Wlcrnsedl decreased/
abnonnal WBC. abnormal AG rano, aboonnal RBC, biirubone1111a, eoSioophiha,
hyperlipe a, 1ncrease decreased electrotytes, increased/ decreased

cholesterol. llcreosed glucocorncords. U1Creased LDH. 11<reasedl decreased/
abnonnal platelets, ond r~creased gastnn levels. Addibonal ISOla ed laboratory
abnormalities were reported.
In lhe placebo-cootroled studies. when SGDT (AST] arod SGPT !Alnwere evaluated, 0.4-. fl/2501 piacebo pa ents and m 1217951 lansopmole pa ems had
enzyme elevations greater than H
s UPIM!r
of normal range at lhe
!treatment YISil None of lhese pa nts reported sa:mdice at any
dlmg
lhe study
For more ormanon on laboratory value changes wtth clanthromyc1n or
amo cilin, refer to thev respec e Product Mooognphs, uroder the ADVERSE
REACTIONS secnon
Postmarbting bperiuce: HypersensrtMty reacbons have been reponed,

IIIClutMg onaphytaJCS.
DOSAGE AND ADMINISTRATION
Daodeaol Ulcor: The recoovneroded adult oral dose is 15 mg ddy before breakfast
fortwotofotK-ks (See! DICATIONSANDCUNICALUSE.I
A small percent1ge of patients that 1re H. pylori-negatrve will expenence a
disease recurrence and wil requlfe rm1menance treaur.ent With an annsecreuwy
agent PREVACID 15 mg dady before breakfast may be used up to one year for
lhe ma nancnn n ol recurre duodenal Lkers.
HelicobiCler "Iori Erodicotioo tt Redoce the /lislr of DHdtoal Ukor
~

Tn,lo TNra,y; Pf/EVAQ~ The recOIMIIIIded adult
oraldoseiS30mg PREVACID, SOOmg clarr.fvornyt11,and 1gamo iln.algwen
twice dally for 14 days.(Seel DICATID SAND CUNICAl USE.) 011ly doses
shcMcl be taktn before meals.
(For additioul iofonaatioo 01 triple therapy for the trealllleat ol
H. ,rori iofectioo eed actite doodeoal olcer recorreoce, mer to the Hp-PAC
Prvdact MoMgnplll
Deal Tllerapy; PREVACID/omoxiciflirL The recommeroded adu~ oral dose IS
30 g PREVACID arod 1g amo cinin. eoch giVen three umes d11ly lor 14 days
(See INDICATIONS AND CUNICAL USE. I D11 doses should be taken before
meals.
Opumal therapewc reg1mens conSisting of a shorter treatment duratton for
lhe eradicanon of Hllicobocter pylon are currently under IOYI50gatJon. For the
eradiconon of H pylon. 1
cillln and clanthromyc1n should not be admmiS·
ttted to panents wrth renal enpa~nnentsooc:e the appropriate dosage., this pa nt
populo non has oot ~~been estabished.
Gastric Ulcer: The recommeroded adult oral dose is 15 mg daily before breakfast
for tot. to light weeb.
ltr1Cy
dosage
o dosage adjusunent IS necessary ll patJents wrth renal·
a ustme IS necessary r1 1he
PREVACID dosing reganen., older pa nts
and ll panents wrth lllild to moderate hepa rnpUme Dosong rec
aIIOOS described ll tho labelilg shcMd be adhered to for older panents arod hepat·
ICaly rnpued pa Ots.
PREVACID IS oot lncf•:a ed for ma~ntenancelherapy Wllhe ~ea nt of panems
wrth gastnc Lker
Rella Esopbgitis or Poorly~ Reflu &o,Ugitis loclodill!l Patieats
witlt Barrell's Esoplilglls: The rec
roded edub oral dose IS Jl mg daily before
breH!ast for fotK 1D eoght weeb.(See INDICA nO S MD CU !CAl USE.!
Mli1teuace TreJtmelt of Huled Reflu Esop 1gitis: For the long-term
manageroem of pauems wrth healed reflux esophagitis, 15 mg PfiEVACID grttn
once daily before breakfast has been found to be effective "' controled cinocal
Ullb of 12 months' duranon.
The recommended adu~ oral dose of PREVACI Ofor maintenance treatment
of pa ems wrth healed reflUllesop/llg IS 15 mg daily before breakfast (See
I DICATIONSANDCUNICAlUSE.I
Trutme1t 11d M1i1t!IIICI of PJD:ological Hypersecretory C01ditioas
loclodiog Zollitover-EIIisoo Syedromo: The dosage of PREVACID ll pa nts wrth
pathologoc ltypersecrl!tory condinofls varies with lhe indivodual panent. The recoovneroded adu~ oral startl\g dose IS liD mg once a day. Doses shcMcl be adjusted to 1ndmdual pawn needs and s.twuJd continue for as long u c ~l'll caly
Indicated. Doseges up to 90 mg b.td. have been
red. Daiy dosages of
grea than 120 mg shcMcl be admnstered ll d'Yided doses. Some panents With
Zofnger-Eiison syndrome have been ea ed connnuouslywrth PfiEVACID lor
IT10ft than tot. years.
Pllieats with Hepotic lmplirmeot The daily dose shcMcl not exceed Jl mg. (See
WAR INGS.)
Pllieats with Reullmpairmeot o dosage modificanon of PfiEVACID IS necessary. (See PRECAUTIONS.)
Eldofly Pllieots: The ddy dose shcMcl not exceed Jl mg. ISee PRECAliTIDNS.I
CoocOIOitaot Aotocicl Use: Simultaneous ad nistra on ol PREVACID wrth
Mn (alu111111um and mognewm hydroXIde) or · pa (magaldra e) resuhs
10 lower peak plasma levels, bill does not Significantly reduce b10availabilll'(
Antacids may be used concomnantly d rl!qtilred. ff sucralfate IS to be giVen concomitantly, !'REVACID shcMcl be admii1Slered at leastllmintJtes poor to sucralfate. In cline a! tna1s, antacids were a
red coocll!Mantly wrth PREVACID
de!oyed-release capsules; this did na1 rtere with Its e'fecl
AVAJLABIUTY OF DOSAGE FORM: PREVACID flansoprazole delayed-release
capsulesiiS available as 15 mg. opaque, hard gela n. pml: orod green coloured
capsules ., bottles of 30 and 100 The 30-mg capsules are opaque, hard gela n.
ponkarod black coloured, avo able'" boules of 30 and 100.
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